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Abstract 
 
The work in this thesis involves the development of a protected transesterification 
route for the production of novel cyanoacrylate monomers. As well as the 
modification of iodinated contrast agents to increase their solubility in cyanoacrylate, 
to enable monitoring of the adhesive within the body for possible use in the 
treatment of brain aneurysms. Chapter 1 provides an introduction to biological 
adhesives, in particular alky 2-cyanoacrylates and how they degrade to release 
formaldehyde. Details into iodinated X-ray contrast agents, their structure, uses and 
synthesis, as well as the current treatments for brain aneurysms.  
 
Chapter 2 focuses on the modification of several iodinated contrast agents in order to 
increase solubility in ethyl cyanoacrylate. Three existing contrast agents were 
protected using a variety of different protecting groups and tested for solubility in 
ethyl cyanoacrylate. Partition coefficients were calculated for the successfully 
modified compounds. Chapter 3 outlines the development of the anthracene 
protected route for the synthesis of cyanoacrylate monomers, utilising the Diels-
Alder and retro-Diels-Alder reactions of anthracene. This route was subsequently 
used to synthesis a range of cyanoacrylate monomers. Polymerisation of these 
monomers gave a range of polymers which were tested to determine their rate of 
degradation through formaldehyde detection. Chapter 4 further details the first and 
final step of the anthracene protected route developed in chapter 3. It involved 
1
H 
NMR experiments to determine how substitution at the 9 and 10 position of 
anthracene affects the rate of reaction of the forward and retro-Diels-Alder reaction. 
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1.0 Introduction 
 
1.1 Biological adhesives 
 
Biological adhesives have been around in some form since the introduction of 
bandages. The earliest material used in hospitals were natural rubber based, these 
have since been superseded by synthetic alternatives. The first commercial example 
was the use of medical bandages consisting of a pressure-sensitive adhesive and a 
backing, which is a carrier for the adhesive, first marketed to hospitals by Johnson & 
Johnson in 1899.
1
 There are case reports in the literature for some patients 
experiencing an allergic contact dermatitis (ACD) to the chemicals in either the 
adhesive or the backing in these medical bandages. These reports do not adequately 
correspond to the frequency that patients report having an "allergy" to medical 
adhesive bandages.
2
  
A   B  
Figure 1.1: A) Adhesive bandage, B) Allergic reaction experienced by some patients 
 
The chemicals in medical bandages include adhesives such as hydroabietic acid (an 
industrial derivative of colophony),
3
 glycerol esters of hydrogenated abietic acid
4
 
wood rosin derivatives
5
 and p-tert-butylphenol formaldehyde resin, an acrylate 
polymer used as a contact adhesive owing to its flexibility, strength, and rapid onset 
of action.
6,7
 Other agents added include dodecyl maleamic acid, octadecyl maleamic 
acid,
8
 and tetrahydrofuryl acrylate.
9
  Plasticisers such as tricresyl phosphate found in 
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the vinyl backing
10
 are added and used to increase the stretch potential of some 
adhesive tapes.
11
  A  range of initators (benzoyl peroxide) and/ or antioxidants and 
preservatives (2,5-di(tertiary-amyl)hydroquinone or diethyldithiocarbamate)
12
 are 
added to initiate adhesion or increase stability depending upon the formulation. 
Epoxy resins have also been used as adhesives for contact bandages.
13
  
 
Many other bio-adhesives have been developed since the introduction of medical 
bandages, these include synthetic polymeric materials, such as poly(methyl 
methacrylate)s, epoxy resins, polyurethanes and cyanoacrylates. These can be used 
directly in wound closure, as well as in dentistry and even in some surgical 
procedures.
14
 All biological adhesives, whether light wound liquid adhesives such as 
poly-vinylpyrrolidone or deep wound cyanoacrylate glues, have the same objectives; 
a) fixture of the structures and surfaces to be bonded; b) microbial protection of the 
wound to avoid sepsis; c) filling of cavities; d) regulation of the moisture content; e)  
promote the natural healing process.
15
   
 
1.1.1 Poly(methyl methacrylate) resin 
 
Poly(methyl methacrylate) (PMMA) 1 is the synthetic polymer of methyl 
methacrylate 2 (Scheme 1.1) and has been used as a bone cement in orthopaedic 
procedures such as hip replacements.
16
  
  
Scheme 1.1: Synthesis of poly(methyl methacrylate) PMMA 1 
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Methyl methacrylate monomers used in adhesive systems are conventionally cured 
by radical polymerisation initiated either by the addition of radical initiators or 
irradiation with light. For in-situ curing of methyl methacrylate monomers an 
initiator that works at body temperature is added, such as N,N-dimethyl-p-toluidine, 
this gives a curing time of 2-10 mins.
15
 PMMA bone cement is more like a grout 
than glue, although sticky it does not bond to the bone or implant, it fills the space 
between the prosthesis and the bone preventing motion.
17
 PPMA has revolutionised 
orthopaedic procedures, especially for large joint replacements but there are draw 
backs to its use. Although PMMA is biologically compatible it breaks down to 
methyl methacrylate which is an irritant and possible carcinogen. It is the release and 
subsequent absorption of the monomer and/ or additives (such as N,N-dimethyl-p-
toluidine) that is thought to lead to side effects such as hypotension.
18
  
 
1.1.2 Polyurethane composites 
 
Polyurethane polymers 3 are formed by reaction of an isocyanate 4 with a diol 5 
(Scheme 1.2). 
 
Scheme 1.2: Synthesis of polyurethane 3 from 4,4’-methylene diphenyl isocyanate 4 and 1,4-
butanediol 5 
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Polyurethanes have played a major role in the development of many medical devices 
such as cardiovascular devices, artificial organs and tissue replacements.
19
 The 
mechanical properties of polyurethanes have shown them to be well suited for usage 
in a number of bio-medical devices; they have been shown to be durable, have good 
elasticity and are tolerated in the body during healing.
20–23
 Polyurethanes have also 
been successfully modified; for example the hydrolytically unstable polyester 
polyurethane has been replaced by the more resistant oxidation-sensitive polyether 
based polyurethanes 6 (Figure 1.2), biologically active species such as anticoagulants 
have also been added.  
 
Figure 1.2: Poly(propylene oxide) polyether based polyurethane 6 
 
These modifications are designed to enhance the acceptance of the polyurethane 
composites within the body and promote healing, aiming to mimic natural tissue as 
closely as possible.
24
 However in-vivo instability has been observed for prolonged 
implantation, causing major limitations for bio-medical applications by limiting the 
time such devices can be left in the body. Over time the polymer degrades via a 
depolymerisation mechanism (Scheme 1.3) to give the starting materials; one of 
which is an isocyanate, a known irritant that has been observed to give adverse 
effects.
25
   
 
Scheme 1.3: Degradation of the polyurethane linker via a depolymerisation mechanism 
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1.1.3 Fibrin sealants 
 
Fibrin sealants are biological adhesives derived from blood. Fibrinogen is the main 
structural protein in blood, and is responsible for forming blood clots (Figure 1.3).
26
  
A  B  
Figure 1.3: A) Ribbon model of human fibrinogen, B) Fibrinogen clot examined by scanning 
electron microscopy (SEM) 
 
Fibrinogen is converted to strands of fibrin, in the presence of calcium ions, by 
thrombin, a serine protease. The fibrin monomers assemble in fibrils, forming a three 
dimensional network of fibres; a blood clot (Figure 1.3)
27
. Fibrin sealants are a 
formulation made up of fibrinogen and thrombin, used to create a fibrin clot.
28
 The 
components may be applied sequentially or simultaneously to the site of repair by 
either syringe or spray. Prior to polymerisation fibrin sealants act as a spray-able 
“sticky” liquid that can readily adhere to wet surfaces. After the addition of 
thrombin, the fibrin glue polymerises in-situ, and becomes a semi-rigid, fluid tight 
adhesive capable of holding tissue or materials in place. Applications of fibrin 
sealants include repairing dura tears or bronchial fistulas, as well as in ‘no suture’ 
corneal transplantation. The first recorded use of fibrinogen as a tissue adhesive was 
in 1942, when it used for peripheral nerve repair in animal models.
29
 In recent times 
fibrin glues have been used in successfully cardiovascular surgery for bypass 
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surgery, vascular graft, sinus rupture and repair of septal defects.
30–33
 Fibrin glue has 
many advantages that make it a good bioadhesives; for example fast curing times 
(10-60 secs) and biodegradability. However it has a relatively poor adhesion and 
tensile strength, wounds closed in-vivo by a fibrin sealant are normally coupled with 
a few sutures to reinforce the repair. Use of fibrin glues also involves the risk of 
blood–borne disease transmission and potential for allergic reactions in patients.34  
 
1.1.4 Polyethylene glycol (PEG) glues 
 
In recent years PEG-based hydrogels have been investigated for the sealing of 
sutured wounds, in particular, as a safe watertight closure, used in addition to sutures 
for dural repair during cranial surgery. The hydrogel is applied to the tissue as a two-
component system; eosin based primer and polymer sealant. The sealant consists of 
water soluble polyethylene glycol, a biodegradable polyacetic acid, trimethylene 
carbonate and a polymerisible acrylic ester. The eosin based primer penetrates the 
tissue, cross-links with itself and provides a mechanical interlink to the sealant; the 
two component work together to provide tissue penetration (primer) and the desired 
elastic properties (sealant) resulting in a cross-linked gel which degrades in the body 
after 8 weeks. PEG hydrogels can be synthesised using ‘click’ chemistry to give 
highly cross linked structures (Scheme 1.4). PEG-based sealants have been shown to 
stop cerebral spinal fluid leakage after neurosurgical dural repair.
35
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Scheme 1.4: PEG hydrogel construction 15a-d based on ‘click chemistry’36 
 
1.1.5 Cyanoacrylate adhesives  
 
The most commonly used bio-adhesive for direct wound closure on the market today 
is Alkyl 2-cyanoacrylate 16 (Figure 1.4). Widely used in the closure of  superficial 
wounds,
37
 they have superseded the used of sutures for external wound closure. 
 
Figure 1.4: Alkyl 2-cyanoacrylate monomer 16 
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1.2 Alkyl 2-cyanoacrylates as biological adhesives 
 
Alkyl 2-cyanoacrylates 16 (Figure 1.4) are liquid monomers that rapidly polymerise 
in the presence of a basic catalyst (pH 7 or above) such as water or alcohol.
38
 The 
adhesive properties of the alkyl 2-cyanoacrylates 16 were discovered in the 1950s by 
the Tennessee Eastman Company.
39
 Cyanoacrylate monomers can polymerise via 
two different mechanisms; free-radical (Scheme 1.5) or anionic (Scheme 1.6).
40
 For 
free-radical polymerisation there are two different modes of termination; coupling 
and disproportionation, which give way to three different end groups. 
 
Scheme 1.5: Free-radical polymerisation of cyanoacrylate
40 
 
In practice the anionic route is favoured because it is rapidly initiated at ambient 
temperature; polymerisation occurs in the presence of even a weak base such as 
water or alcohol, due to the electron withdrawing CN and COOR groups.
41
 Thus 
polymerisation can be initiated quickly by contact with the surface of hydrophilic 
substrates, avoiding the need for catalysts or heating.
42
 It is because of its excellent 
wetting properties and ability to bind to a number of substrates that have resulted in 
the successful application and marketing of alkyl-cyanoacrylates as “superglue”.43 
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Cyanoacrylate monomers have been shown to be highly susceptible to anionic 
polymerisation.
44,45
 Polymerisation proceeds by initial addition of an anion (amides, 
alkoxides, hydroxides, cyanides, phosphines, amines etc.) to the strongly activated 
carbon, carbon double bond. This is followed by linear chain elongation as further 
cyanoacrylate monomers are added with eventual termination of the growing chains 
by uptake of a proton.
46
  
 
Scheme 1.6: Anionic polymerisation mechanism of cyanoacrylate
46
 
 
Polymerisation is rapid and can be difficult to control; studies have determined 
temperature has a limited affect on the average molecular weight (MW) of the 
resulting polymer. However pH and the R group of the ester have been shown to 
influence the average MW. This is demonstrated by the differences between ethyl and 
octyl cyanoacrylate at pH 2, 7 and 11 (Table 1.1).
47
 Poly(ethyl cyanoacrylate) 
showed the highest average MW at pH 11; however the opposite was true for 
poly(octyl cyanoacrylate), the highest average MW was achieved at pH 2.  
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pH Average MW (Da) 
ECA 
Average MW (Da) 
OCA 
2 2.21 x 10
5
 4.15 x 10
5
 
7 2.94 x 10
5
 3.42 x 10
5
 
11 3.05 x 10
5
 3.30 x 10
5
 
Table 1.1: Average Molecular Weight of ECA and OCA polymers at 25 
o
C at pH 2, 7 and 11, 
measured by GPC 
 
Due to its ready ability to polymerise at room temperature,  methyl-2-cyanoacrylate 
16 (R=Me) was introduced as a rapid setting adhesive across a number of industries, 
(metal, glass, electronics and medicine).
48
 Cyanoacrylates are desirable to the 
medical industry because they are liquid monomers (easy to apply) and polymerise 
in protic or moist environments (living tissues).
49
 Cyanoacrylate adhesives cure on 
the skin surface within 5-60 seconds, sealing the wound instantly and forming a 
waterproof barrier.
50
 Cyanoacrylates can be used on various parts of the body, from 
the mouth to the foot.
51
 They have also been investigated for use in dental fields for 
pit and fissure sealants, exposed dental pulp and direct bonding of orthodontic 
brackets. Despite rapid setting of cyanoacrylate the major disadvantages were 
polymerisation shrinkage, brittleness, and erratic polymerisation set times.
52
  
 
1.2.1 Skin adhesive vs. stitches 
 
Each year in the US between 26 and 90 million lacerations occur, and over 7 million 
surgical incisions require closure.
53
 There are several methods for wound closure; 
stitches, staples, surgical tape and skin adhesives such as alkyl cyanoacrylate. 
Cyanoacrylates continue to retain their adhesive qualities even in the presence of 
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moisture.
50
 This is important for medical applications as human skin presents a huge 
variation of presentable substrates, for example wet, dry, oily, wrinkly, hairy.
54
 
Cyanoacrylates adhesives are currently the standard wound closure method for the 
repair of superficial lacerations
55
 (Figure 1.5).  
 
 
Figure 1.5: Head closure using cyanoacrylate adhesive 
 
Tissue adhesives have several benefits over traditional sutures; they are more cost 
effective as they require less instrumentation, no suture kits, dressings or removal 
kits.
56,57
 They also have cosmetic advantages as they prevent the formation of suture 
marks on either side of the wound and therefore reduce scarring.
58,59
 There is no 
need for removal,
60
 and there are no foreign bodies such as stitches or staples within 
the wound that may increase risk of infection.
61
 Biological adhesives remove the risk 
of injuries from suture needles and therefore the risk of transmission of infectious 
diseases.
50
 Due to the lack of instrumentation required skin adhesive is a much faster 
closure method, it is also less painful than sutures.
58,62,63
  
 
Skin adhesives are a popular wound closure method, with most patients preferring 
them to stitches or staples.
64
 There are several advantages to the patient; no 
anaesthesia is required, the procedure is non-invasive and painless and there is no 
need for follow up care.
65
The simplicity and speed of this application is especially 
useful in military conditions, or in remote locations where general practitioners are 
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not always ready available.
66
 When cyanoacrylate skin glues were first introduced it 
was thought there was a high risk of allergic reactions occurring in patients. Studies 
into the potential for allergic reaction were conducted. One such study monitored 43 
patients over a three month period after the closure of surgical incisions.
67
 The 
patients, representing a cross section of gender, age and health status, were divided 
into two groups; wounds closed with either sutures or ethyl cyanoacrylate adhesive. 
No patient experienced any allergic reaction, this result agreed with other results
68,69
 
and thus it was determined that the risk of allergic reaction was low and was 
outweighed by the advantages of cyanoacrylate adhesive over sutures.      
 
Surgical tape, containing zinc oxide, offers many of the same advantages as skin 
adhesives: easy to use, rapid, painless, comfortable, does not require removal and 
cost effective. However, because of low bursting strength and tendency to fall off, 
the use of surgical tapes is limited to simple very low tension wounds.
70
 It can 
however be used in conjunction with cyanoacrylate adhesive for the closure of long 
wounds. The tape holds the edges of the wound in place while the adhesive is 
applied (Figure 1.6). 
 
Figure 1.6: Use of surgical tape to aid closure of long wound
71
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1.2.2 Degradation of poly(cyanoacrylate)s 
 
The main drawback of using poly(cyanoacrylate)s as biological adhesives is that 
upon biodegradation they liberate formaldehyde.
72
 The degradation process is 
initialised by the random addition of water molecules into the polymer chain 24, 
which further degrades into a polymer fraction 21 and formaldehyde 28. The process 
is accelerated by alkaline conditions, and is started by the initial attack of the 
hydroxyl ion, leading to a reverse Knoevenagel reaction
73
 (Scheme 1.7). 
 
Scheme 1.7: Degradation of poly(alkyl cyanoacrylate) 24 
 
The production of formaldehyde is an undesirable effect of a biological sealant as it 
leads to irritation and inflammation of adjacent tissues. Methyl cyanoacrylate was 
shown to cause tissue inflammation and cell necrosis in experimental animals.
74,75
 
Due to its rapid degradation methyl cyanoacrylate is no longer used as a skin 
adhesive.
76
 Both butyl and octyl cyanoacrylates show a decrease in the inflammatory 
response and a slower degradation rate than methyl cyanoacrylate. This is thought to 
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be due to steric reasons.
77
 Both butyl 29 and octyl cyanoacrylates 30 are licensed for 
use as skin adhesives, trade names Liquiband and Dermabond.  
 
1.2.3 Octyl cyanoacrylate 
 
Octyl cyanoacrylate 30 has many advantages over butyl cyanoacrylate 29 (Figure 
1.7), including higher breaking strength, flexibility and resistance to splintering after 
drying. The wound busting strength (WBS) was measured for octyl and butyl 
cyanoacrylate, as well as surgical tape. The mean WBS of octyl-cyanoacrylate (298 
mm Hg) was significantly higher than that of butyl-cyanoacrylate (199 mm Hg) or 
the surgical tape (129 mm Hg). In context of the strain that is likely to be exerted on 
these wound closures during normal daily routine compare to intra-abdominal 
pressures of the following activities; standing (13 mm Hg), pain (44 mm Hg), 
pressing (59 mmHg), vomiting (110 mm Hg), cough (150 mm Hg), and jumping 
(252 mm Hg).
78
 
 
Figure 1.7: Butyl cyanoacrylate 29 and octyl cyanoacrylate 30 
 
Although both are licensed it is octyl cyanoacrylate 30 that is now used as standard 
for wound closure as it forms strong bonds across wound edges.
79
 This bond 
provides a flexible water resistant coating as octyl chains are hydrophobic, creating a 
barrier to microbial penetration
69
 thus providing a natural healing environment.
80
 
Cyanoacrylates have also been shown to have anti-microbial properties both in vitro 
and in vivo in animal models,
81
 in particular against Gram-Positive organisms that 
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are responsible for most wound infections. This anti-microbial barrier may be 
particularly important in the treatment of surgical incisions where a trend towards 
decreased wound infection rates were found in comparison with sutures.
82
 In general, 
there have been many examples of both butyl 29 and octyl cyanoacrylates 30 being 
used in a wide variety of clinical settings.
65,68,83,84
 For example, general plastic and 
paediatric surgery, neurosurgery, gynaecology, ophthalmology etc. Alternative 
applications of cyanoacrylates are under investigation including use internally in the 
vascular system and for the treatment of gastric varices (dilated submuscosal veins in 
the stomach which can led to gastrointestinal hemorrhage).
85
 
 
1.3 Properties of cyanoacrylate polymers 
 
There are a number of qualities required of an adhesive in its final cured state in 
order for it to be serviceable. It must have good tensile strength in order to withstand 
the stresses upon it without being brittle. Adhesive strength is important and can be 
measured by three different components; peel adhesion, tack strength and sheer 
strength.
54
 Peel adhesion is the force needed to remove the adhesive material from a 
substrate. The peel strength of methyl, ethyl and propyl cyanoacrylate at room 
temperature is 183, 159, 95 psi respectively. The peel strength decreases as the chain 
length increases; this may be due to the increased flexibility of the longer chained 
monomers. Tack strength is used to gauge the strength and ease of formulation of the 
adhesive bond. Shear strength is a measurement of the cohesive strength of an 
adhesive; cyanoacrylates have been shown to form strong bonds at room 
temperature, methyl and ethyl cyanoacrylate give valves of 710-720 psi.
86
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The thermal properties of poly(ethyl cyanoacrylate) have been studied previously in 
order to determine the thermal behaviour of the cured adhesive. Thermal degradation 
of poly(ethyl cyanoacrylate) has been measured by thermal gravimetric analysis 
(TGA), which measures the % weight loss of the polymer with increasing 
temperature. The polymer starts to lose weight at approx. 160 
o
C and is at its 
maximum rate between 225 and 250 
o
C, it is completely degraded by 300 
o
C (Figure 
1.8). 
 
Figure 1.8: TGA of poly(ethylcyanoacrylate)
43
 
 
The TGA clearly shows one mechanism for degradation; as the polymer is heated it 
degrades via an ‘unzipping’ mechanism, releasing cyanoacrylate monomer from the 
polymer backbone (Scheme 1.8). 
 
Scheme 1.8: Thermal degradation of cyanoacrylate via an ‘unzipping’ mechanism 
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TG curves for the thermo destruction of poly(ethyl cyanoacrylate) under isothermal 
conditions at 140 
o
C have also been recorded (Figure 1.9). Isothermal conditions are 
used as a model for the aging process of an adhesive bonded joint. The degradation 
of poly(ethyl cyanoacrylate) proceeds vigorously and in an almost exponential 
course, reaching 45% weight loss within the experimental time of 3 h. This shows 
that the polymer degrades at a steady ready rate over time. 
 
Figure 1.9: TG Curve of poly(ethyl cyanoacrylate); conditions: isothermal mode (3 h/ 140 
o
C)
87
 
 
Differential scanning calorimetry (DSC) is a measure of amount of heat required to 
increase the temperature of a sample. DSC can be used to determine thermal 
transitions of polymers; such as melting point and glass transition temperature. The 
glass transition (Tg) is the temperature that a material undergoes a reversible 
transition from brittle state into a molten or rubber-like state. DSC of poly(ethyl 
cyanoacrylate) gives a Tg of approximately 140 
o
C, hugely above room and body 
temperature (Figure 1.10). Up until the Tg, in this case 140 
o
C, the polymer is brittle; 
it is possible to lower the Tg by adding plasticisers, or by making the alkyl chain 
longer resulting in a more flexible polymer. The Tg of poly-butyl and -octyl 
cyanoacrylate are lower; 86 
o
C and 40 
o
C respectively (Figure 1.11).
49
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Figure 1.10: DSC curve of poly(ethylcyanoacrylate); conditions: 10 
o
C/min
49
 
 
 
Figure 1.11: DSC thermograph of poly-butyl and –octyl cyanoacrylate; conditions: 10 oC/min 
 
Poly(cyanoacrylate)s have been used extensively as adhesives across a number of 
industries, however they have a number of other applications.  
 
1.3.1 Alternative uses of cyanoacrylate polymers 
 
An alternative use of cyanoacrylates is for the detection of latent fingerprints on non-
porous surfaces.
88
 This was first demonstrated by the Japanese Criminal 
identification Division in 1978.
89
 Since then the cyanoacrylate fuming method has 
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gained wide popularity and is used for development of prints on surfaces such as 
metals, electrical tape, glass, leather and plastics.
80,90–92
 The cyanoacrylate fuming 
method involves exposure of the evidential object to cyanoacrylate fumes in an 
enclosed cabinet. The cyanoacrylate monomer vapours polymerise on the ridges of 
the fingerprints, producing a white deposit. A number of improvements have been 
made to this technique in order to accelerate the fuming process and minimise 
background development.
93–95
 Traditionally detection of fingerprints on bank notes 
is extremely difficult. Figure 1.12 shows a white light image of a successfully 
imaged fingerprint on an Australian $5 note treated with ethyl 2-cyanoacrylate.
96
 
 
Figure 1.12 Fingerprint treated with ethyl 2-cyanoacrylate on banknote 
 
For the past 30 years there has been interest in poly(alkyl cyanoacrylate)s for drug 
delivery systems; the polymers are biocompatible and approved for human use.
63,97
 
Since the first attempt in 1979
98
 emulsion polymerisation has been applied for 
entrapment of various drugs in poly(alkyl cyanoacrylate)s nanoparticles under 
various different conditions
99–104
 (Figure 1.13).  
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Figure 1.13: Poly(alkyl cyanoacrylate) nanoparticles 
 
Over the years there has been an increase in the number of reports using mini-
emulsion polymerisation for the engineering of poly(alkyl cyanoacrylate) 
nanoparticles
105–109
 and nanocapsules.
110–112
 Functionalisation of particle surface and 
adjustment of particle size can be accomplished by this technique.
113
 Today 
poly(alkyl cyanoacrylate) nanoparticles are considered one of the most promising 
polymer colloidal drug carriers, in particular for use in cancer therapy.
114
 However 
there are a number of limitations; molar masses of the formed polymer and 
nanoparticles size are strongly affected by the conditions of polymerisation, and can 
sometimes be difficult to control.
115–117
  
 
Initial studies into mini-emulsion polymerisation of poly(alkyl cyanoacrylate)s 
focused on anionic polymerisation. This resulted in quite low molar masses, usually 
below 8 000 gmol
-1
, which were dependent upon pH and concentration. 
Investigations have compared both radical and anionic mini-emulsion polymerisation 
in the formation of nanoparticles of poly(n-butyl cyanoacrylate).
40
 Particle sizes 
were measured as a function of the pH, temperature and method of polymerisation, 
the final molar mass and the degradability of the polymer were recorded. The two 
different methods of polymerisation displayed differences in the rate of complete 
monomer conversion (radical: 20 min, anionic: 1 h) at pH 2. This effect is more 
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pronounced at pH 1, when it takes about 7 h for anionic polymerisation to fully 
convert monomer to polymer. Thus anionic polymerisation could be effectively 
slowed by changing the acid concentration.
46
  In the case of anionic polymerisation 
the molar mass of poly(n-butyl cyanoacrylate) was observed to vary even after the 
monomer has been used up. This phenomenon is observed because the anionic 
polymerisation of butyl cyanoacrylate is a reversible process. On the other hand 
radical polymerisation gives a constant distribution of molar masses once the 
monomer has been used up, and this distribution has been shown to be stable for at 
least 5 days at pH 2.
118
  Complete degradation of both materials occurred between 
24-48 h, making these systems suitable for in vivo applications, but those derived 
anionically degraded faster.  
 
Poly(i-butyl cyanoacrylate) nanoparticles have been prepared by anionic 
polymerisation under acidic conditions  in the presence of cyclodextrin
119
 (Figure 
1.14). The size of the nanoparticles depended on the type of cyclodextrin used. 
Smaller particles were obtained with hydroxypropyl-β- 34 or hydroxypropyl-γ-
cyclodextrin 35, 103 and 87 nm respectively.  
 
Figure 1.14: Hydroxypropyl-β-cyclodextrin 34 
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IR and 
1
H NMR of nanoparticles prepared in the presence of hydroxypropyl-β-
cyclodextrin 34 suggests the products are associated by weak bonds, not covalent 
coupling. Poly(i-butyl cyanoacrylate) nanoparticles including hydroxypropyl-β-
cyclodextrin 34 and those without cyclodextrin were loaded with a series of steroids. 
The nanoparticles including cyclodextrin were between 100 – 200 nm smaller than 
those made solely from i-butyl cyanoacrylate. Despite this the nanoparticles that 
included hydroxypropyl-β-cyclodextrin 34 showed a significant increase in loading 
capacity; 7 times more for spironolactone up to 130 times more for prednisolone. 
DSC analysis of the combined nanoparticles loaded with progesterone showed the 
loss of the endothermic peak at 130 
o
C that is characteristic of progesterone melting. 
It was replaced by a broad endothermic transition in the region of 130-170 
o
C, 
suggesting progesterone is molecularly dispersed in the nanoparticles.  
 
1.4 Synthesis of cyanoacrylate monomers 
 
Alkyl 2-cyanoacrylates 16 were first synthesised by the pyrolysis of alkyl-3-alkoxy-
2-cyanopropionates 36
120
 (Scheme 1.9).  
 
Scheme 1.9: Pyrolysis of alkyl-3-alkoxy-2-cyanopropionates 36 
 
Thermolysis of ethyl cyanoacrylate 37 was later achieved to give free 2-cyanoacrylic 
acid 38. This allowed preparation of some cyanoacrylates via the acid chloride 39 
(Scheme 1.10).
121
 This is a simple route for the production of cyanoacrylate, 
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however it has been shown to have limited applications as only a small number of 
monomers have been successfully synthesised this way.   
 
Scheme 1.10: Synthesis of alkyl 2-cyanoacrylate 16 from 2-cyanoacrylic acid 38 
 
Cyanoacrylates have also been synthesised by condensation of cyanoacetate 40 and 
formaldehyde 28 in the presence of heat and vacuum.
122
 This method first requires 
the synthesis of the necessary cyanoacetate; this can be achieved in two steps from 
mono-chloroacetic acid 41 (Scheme 1.11). 
 
Scheme 1.11: Synthesis of ethyl cyanoacetate 40 from mono-chloroacetic acid 41 
 
The cyanoacetate 40 can then be condensed together with formaldehyde 28 to form 
the cyanoacrylate oligomer. This is then depolymerised, or ‘cracked’ at high 
temperatures and reduced pressure, to give the cyanoacrylate monomer 37 (Scheme 
1.12). 
 
Scheme 1.12: Synthesis of ethyl cyanoacrylate 37 from cyanoacetate 40 and formaldehyde 28 
 
Several improvements have been made to this reaction, including: a) using non-
aqueous solvent during the condensation stage to enable quick and easy removal of 
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water from the reaction media,
123
 b) closely regulating the pH of the first step as it is 
base catalysed
124
 and then neutralising any remaining base before moving onto the 
depolymerisation stage,
125
 c) regulating the mole ratio of formaldehyde and 
cyanoacetate to provide a readily polymerising cyanoacrylate oligomer,
126
 d) 
providing a dry atmosphere
127
  and using phosphoric acid as a heat transfer media for 
the final step.
128
 The optimisation of this reaction has made this process industrially 
viable for the production of a range of simple cyanoacrylate monomers with low 
boiling point. However due to these monomers undergoing rapid polymerisation in 
the presence of moisture, stabilisers are needed during the synthesis and in the 
storing of the monomers in order to prevent premature polymerisation.  
 
The above condensation method has also been used to synthesise alkyl 2-cyano-2,4-
pentadienoates 43a-c from the corresponding cyanoacetate 40 and acrolein 44 in the 
presence of a zinc chloride catalyst (Scheme 1.13). 
 
 
Scheme 1.13: Synthes/is of alkyl 2-cyano-2,4-pentadienoates 43a-c 
 
The resulting alkyl 2-cyano-2,4-pentadienoates 43a-c all polymerised in the presence 
of water. Addition of the alkyl 2-cyano-2,4-pentadienoates 43a-c to cyanoacrylate 
increased the adhesive strength compared to cyanoacrylate alone. Addition of ethyl 
2-cyano-2,4-pentadienoate 43b increased the bond strength between stainless steel 
surfaces considerably to 22.8 and 25.0 MPa at 100 and 125 
o
C, respectively 
compared to 8.00 and 6.42 MPa. Cyanoacrylate adhesives modified with alkyl 2-
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cyano-2,4-pentadienoates can be used to join together surfaces that are exposed to 
temperatures in the range of 100 to 150 
o
C.   
 
Previous studies of the synthesis of cyanoacrylate monomers have also investigated 
the possibility of protecting the reactive double bond. It has been previously reported 
that anthracene adducts 45 can be used for the synthesis of cyanoacrylates.
129
 The 
Knoevenagel condensation of formaldehyde 28 and alkyl cyanoacetate 40 was 
carried out in the presence of anthracene 46a. The resulting cyanoacrylate monomer 
was trapped by 16 in situ to give a stable anthracene adduct 45. This when heated in 
the presence of maleic anhydride 47 undergoes a retro-Diels-Alder reaction and 
collapses to give the cyanoacrylate monomer 16 (Scheme 1.14). This approach has 
only been used to prepare a small palette of monomers. 
 
Scheme 1.14: Synthesis of cyanoacrylates 16 using anthracene 46a 
 
An alternative approach is to use anthracene 46a to react with cyanoacrylates 
directly to give a stable anthracene adduct 45 to which modification of the ester 
moiety can be undertaken without polymerisation occurring. Anthracene 46a, which 
has been acting as a protecting group can then be removed via a retro-Diels-alder 
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reaction yielding a new cyanoacrylate monomer. Previous work in this area includes 
the development of a multi-step synthesis for bis(2-cyanoacrylate) monomers 52 
from the Diels-Alder adducts of alkyl 2-cyanoacrylate and anthracene,
130–133
 
(Scheme 1.15). Anthracene adduct 45 was prepared by Diels-Alder reaction of 
anthracene 46a with alkyl cyanoacrylate 16.
134
 This was then hydrolysed with NaOH 
to the corresponding carboxylic acid 49, before conversion to the acid chloride 50. 
Two equivalents of the acid chloride were then reacted with the appropriate diol 
furnishing bis-anthracene adducts 51. A retro-Diels-Alder reaction using maleic 
anhydride to trap the freed anthracene 46a was then required to complete the 
synthesis and yield the bis-cyanoacrylate monomer 52.  
 
Scheme 1.15: Synthesis of bis(2-cyanoacrylate) 52 
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In principle, this chemistry can be adapted for the synthesis of a range of novel 2-
alkyl cyanoacrylates 16; due to the anthracene starting material being regenerated it 
may be possible to apply continuous flow techniques to this route. This will be re-
visited in Chapter 3, (Scheme 1.16). 
 
Scheme 1.16: Proposed anthracene protected synthesis of cyanoacrylates 
 
1.5 X-ray contrast agents 
 
A contrast agent is a substance used in medical imaging to enhance structures or 
fluids within the body. X-rays provide good visualisation of bone structure because 
there is a natural contrast between electron dense bones and the surrounding soft 
tissue. However, contrast between the different soft tissues in the body is so small 
that unenhanced X-ray images cannot differentiate between them.
135
 To differentiate 
soft tissue areas such as the cardiovascular system, X-ray contrast agents are used. 
Iodine and barium are the most common types of contrast medium for enhancing X-
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ray-based imaging methods. Barium sulphate is an insoluble white powder and has 
been used for radiographic imaging of the GI tract since 1910. It is still widely used 
for detection of conditions such as ulcers, inflammatory bowel disease and gastric 
cancer.
136
 Barium sulphate is mixed with water, thickeners and de-clumping agents, 
to make the contrast agent. It is usually swallowed or administered as an enema, after 
examination the contrast agent leaves the body with the faeces. Iodinated contrast 
agents are water soluble compounds that are administered intravenously as a 
solution. They can be used anywhere in the body and are the most commonly used 
contrast media in medical imaging, an example of an iodinated contrast agent is 
iohexol 55 (Figure 1.15). 
 
Figure 1.15: X-ray contrast agent iohexol 55 
 
Contrast agents work by absorbing X-rays and creating contrast between substrates. 
Different tissues within the body affect the X-ray beam to different degrees. The 
degree to which the X-ray beam is affected by an element is complex. One of the 
many variables is the number of electrons in the path of the beam with which it can 
interact with. This is dependent upon three factors; i) the thickness of the substance 
being studied, ii) the density of the substance, iii) the number of electrons per atom 
of the element i.e. atomic number.
137
 If two organs have similar densities and similar 
average atomic numbers, then it is not possible to distinguish between them on an X-
ray because no natural contrast exists.  
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The average atomic number of a structure can be artificially altered by adding a 
medium with a much higher average atomic number, e.g. a contrast agent. The 
purpose of a contrast agent is to absorb X-rays and thus create a distinction between 
the vessel of interest and the surrounding tissue,
138
 (Figure 1.16). 
 
Figure 1.16: Angiogram of the celiac trunk and portal system with contrast
135
 
 
Contrast agents are used in diagnostic tests in order to visualise organs or blood 
vessels. Heavy metals such as barium and iodine are used as they allow significant 
contrast between blood vessels and organs due to high atomic number. Although 
there are many compounds with higher atomic numbers than iodine, none provide as 
good a compromise between contrasting power, safety due to reduced toxicity and 
cost.
137,139
 
 
1.5.1 Iodinated contrast agents 
 
Iodinated contrast agents are among the most widely used intravascular 
pharmaceuticals. Worldwide over 600 million X-ray examinations are carried out 
annually, and approximately 75 million of those will require use of iodinated 
contrast media.
138
 There are several types of iodinated contrast agents, however all 
are metabolically stable in the body and are rapidly eliminated via urine or faeces. 
All contain several iodine molecules as they are responsible for absorption of X-
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rays.
140
 Modern iodinated agents are based around a 1,3,5-triiodinated benzene ring 
which first appeared in diatrizoic acid 56 in 1954.
135
 There are four different class of 
iodinated contrast media based on this ring (Figure 1.17).  
 
Figure 1.17: Iodinated contrast agents: diatrizoate acid 56 (ionic monomer), ioxaglate 57 (ionic 
dimer), iohexol 55 (non-ionic monomer), iodixanol 58 (non-ionic dimer) 
 
The first generation were ‘ionic’ monomers such as diatrizoic acid 56, which possess 
low toxicity and high water solubility. However these compounds can dissociate to 
give free iodide ions and can lead to cardiovascular, allergic and painful side effects 
and so have since been replaced.
141
 The second generation of contrast agents are 
‘non-ionic’ monomers, for example iohexol 55, this class of compound is still one of 
the most commonly used in X-ray imaging. Non-ionic compounds are preferred as 
the iodine remains covalently bound and hence biologically unavailable; they have 
lower osmolality and greatly reduced pain upon injection.
142
 The third and fourth 
class are both dimers; ionic e.g. ioxaglate
143
 57 and non-ionic e.g. iodixanol
144
 58. 
All four classes include the tri-iodinated ring 59 with different side chains attached, 
the aim of the side chains are to give the contrast agent high water solubility and low 
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toxicity. Non-ionic monomers such as iohexol 55, consists of long side chains rich in 
hydroxyl groups evenly distributed around the benzene core. Two of these side 
chains are usually identical, giving the compound a divalent structure.
138
  
 
1.5.2 Synthesis of iodinated contrast agents 
 
Diatrizoic acid 56 was the first commercially available iodinated contrast agent. 
After its introduction in 1955 investigations into other tri-iodo-3,5-diaminobenzoic 
acid derivatives as potential radiopaques were undertaken.
145
 Two different synthetic 
approaches were employed for the preparation of these iodinated compounds. The 
first approach required one N-acyl group in place prior to iodination. Initial attempts 
to iodinate the starting material 60 using iodine chloride in dilute HCl resulted only 
in the di-iodo derivative 61. Despite longer reaction times and increasing the amount 
of iodine chloride the tri-iodo compound 62 was not isolated. In order to successfully 
synthesise the tri-iodo derivative 62 it was necessary to reduce the acidity of the 
reaction by taking the amine salt of the starting material and reacting it with 
potassium iododichloride. The tri-iodo compound 62 was then successfully acylated 
to give a range of tri-iodo-3,5-diaminobenzoic acid derivatives 63 (Scheme 1.17).  
 
Scheme 1.17: Preparation of 3,5-diacylamino-2,4,6-tri-iodobenzoic acid 63 
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The second approach involves iodination of 3,5-diaminobenzoic acid 65 using 
potassium iododichloride, followed by acylation of the tri-iodo derivative 66, 
(Scheme 1.18).  
Scheme 1.18: Preparation of 3,5-diacylamino-2,4,6-tri-iodobenzoic acid 63 from 3,5-
dinitrobenzoic acid 65 
 
Diatrizoic acid 56 gave a toxicity of 13.4 g/kg when injected as an aqueous solution 
of the sodium salt in mice. Over the years there has been a move away from these 
first generation agents, e.g. diatrizoic acid 56 towards second and third generation 
agents such as iohexol 55 and iodixanol 58. These agents are larger and more 
complex and require linear multistep procedures where different side chains 
(containing groups such as carboxylic acids, carboxamides, alcohols, and ethers) are 
successively introduced to the tri-iodinated benzene core. More nucleophilic sites are 
introduced to the molecule as the synthesis progresses, making promoting the 
desired alkylation over competing side reactions more challenging. Under the 
conditions needed for N-alkylation of the amide group, competing O-alkylation of 
the primary and secondary hydroxyl groups present on the side chains can occur. 
One way to prevent this is the use of protecting groups; however this strategy is not 
desirable to an industrial process as it involves two additional steps; application and 
removal of the protecting group. However exceptions can be made where a 
concatenated process may be established when the protection, the desired synthetic 
transformation, and the de-protection can all be performed in a one-pot procedure 
with cheap reagents and simple work-up. Scheme 1.19
146
 illustrates one such method 
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using temporary protection of the 1,2-diol groups by boric acid, to allow selective N-
alkylation in the synthesis of three known contrast agents iohexol 55, iopentol 67 
and iodixanol 58. When the protection strategy was used the N/O-alkylation ratios 
were substantially improved resulting in increased yields of the target compounds 
55, 58 and 67.  
 
Scheme 1.19: Boric acid as a temporary 1,2-diol protecting group for selective N-alkylation in 
the synthesis of iohexol 55, iopentol 67 and iodixanol 58 
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Iodixanol 58 can also be synthesised from the tetra-acid chloride 70, adding the four 
side chains to give intermediate 71. A simple procedure was developed to achieve 
selective N-alkylation by reacting acid chlorides with amines in a medium of THF 
and water. Due to the high rate of the N-alkylation reaction the competing process 
(hydrolysis of the acid chloride) to give side product 73 is only observed in low 
yields (Scheme 1.20).
147
   
 
Scheme 1.20: Preparation of iodixanol 58 from tetraacid chloride 70 
 
Iohexol 55 is a second generation contrast agent, non-ionic monomer, and is still 
used today in hospitals worldwide. Since the introduction of non-ionic monomers 
work has been conducted to improve the design of these compounds. For example 
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iohexol 55 displays hydrolytic instability of the ArN-(CO) bond leading to the 
corresponding aniline, during storage of the injectable solution. This is thought to 
arise from the anchimeric assistance to the cleavage of the amide bond by the 
neighbouring hydroxyl groups. To overcome this problem synthesis of compounds 
based on the oxazolidin-2-one moiety 80a-e were investigated as they were expected 
to provide highly stable molecules at physiological pH ranges.
148
 The starting 
materials for this synthesis were prepared from the aniline 74; this was first iodinated 
using potassium iododichloride to give 75. Diazomethane esterification of 75 gave 
77a in 98%. The synthesis of compounds 77b-e was achieved by reaction with 
thionyl chloride to give the acid chloride 76, which was reacted in-situ with the 
corresponding amino-diol. In the case of 77b and 77d this was followed by O-
acetylation with acetic anhydride in pyridine (Scheme 1.21).  
 
Scheme 1.21: Synthesis of starting materials 77a-e 
 
Chapter 1: Introduction 
 
36 
 
The starting materials synthesised above were converted to the corresponding 
isocyanate 78a-e by treatment with phosgene in dioxane. Addition of glycidol was 
achieved at room temperature in the presence of phenylmercuric acetate to give the 
glycidyl carbamate 79a-e in 81% yield. Heating the glycidyl carbamate 79a-e to 50 
o
C in pyridine for 2 h gave the desired products 80a-e (Scheme 1.22). 
 
Scheme 1.22: Synthesis of oxazolidin-2-one derivatives 80a-e 
 
The above oxazolidin-2-one derivatives 80a-e were evaluated for their potential as 
X-ray contrast agents. Although they were hydrolytically more stable in aqueous 
solution, their relatively poor water solubility (~15%) prevented further 
consideration as contrast media, an application that requires 80% w/v.    
 
In order for new contrast agents to show significant improvement in tolerability or 
performance over existing ones novel classes of agent need to be considered. For 
example tungsten clusters,
149
 metal chelates,
150
 iodinated dicarbon carborane cages
151
 
or fullerenes, the latter of which are of interest as C60-derived materials have 
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previously been utilised for biological applications. Investigations were undertaken 
to synthesise a C60-based contrast agent,
152
 first the highly-iodinated addend 87 was 
synthesised from 5-aminoisophhalic acid 65. The first step was iodination using 
potassium iododichloride, followed by treatment with thionyl chloride to give diacid 
chloride 81. The diacid chloride 81 was directly condensed with malonyl dichloride 
to give the tetrachloride 82 in 83% yield. Condensation of the tetrachloride 82 with 
5-amino-2-phenyl-1,3-dioxane 86 in DMA at r.t. proceeded in 95% yield to give the 
hexa-iodinated, O,O’-protected malondiamide addend 87 (Scheme 1.23).    
 
Scheme 1.23: Synthesis of the hexa-iodinated, O,O’-protected malondiamide addend 87 
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The reaction between the malonodiamide 87 and C60 proceeded at room temperature 
with CBr4 and DBU in toluene/ pyridine, giving a surprisingly good yield of 77%, 
considering the steric bulk of addend 88 (Scheme 1.24). 
 
Scheme 1.24: Synthesis of monoadduct 88 
 
Initial deprotection of monoadduct 88 resulted in a material that was only sparely 
soluble in water. Therefore, given the high water solubility requirements for X-ray 
contrast agents, additional functionalisation of 88 was undertaken to improve its 
water solubilisation. This was achieved by addition of the smaller malonodiamide 
group BrCH(COSer)2 89 to the monoadduct 88, followed by deprotection to give 
new contrast agent 91 (Scheme 1.25). Animal studies to determine the efficacy of the 
fullerene compound 91 as an X-ray contrast agent have not been published. 
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Scheme 1.25: Assembly and deprotection of X-ray contrast agent 91 
 
While contrast agents have been used for the imaging of blood vessels, analysis of 
bone structures has not yet been achieved. Investigators
153
 aimed to synthesise 
organic-iodine based conjugates that could ‘lock’ onto bone cracks. They proposed 
that to achieve this required structures with a receptor moiety conjugated into the 
iodine moiety with the aim of maximising the interactions with ions such as Ca(II) 
that are exposed on the surface of damaged bone. Three such first generation 
complexes to detect microcracks in bovine bones using CT imaging were 
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synthesised.
153
 The first and the simplest of these compounds contains a single 
phenyliminodiacetate unit, attached to the iodinated aromatic ring via an amide 
spacer 95. This target compound was synthesised by a coupling reaction between 
2,3,5-triiodobenzoyl chloride 92 and the phenyliminodiacetate ethyl ester 93 
(Scheme 1.26). The two starting materials were synthesised from commercially 
available substrates; 2,3,5-triiodobenzoyl chloride 92 from reaction of the carboxylic 
acid and thionyl chloride in an 85% yield. The phenyliminodiacetate ethyl ester 93 
was formed from aniline in three steps; dialkylation using ethyl bromoacetate in the 
presence of K2HPO4, followed by nitration using nitric acid and finally 
hydrogenation using 10% Pd/C. Condensation of 92 and 93 was achieved in THF 
using Et3N to give the diester 94 which was then hydroylised using NaOH to yield 
95. 
 
Scheme 1.26: Synthesis of 95 from 2,3,5-triiodobenzoyl chloride 92 
 
Compound 99 contained two phenyliminodiacetate moieties in a meta configuration 
in a bid to increase ionic interaction and stronger binding at the unsaturated lattice 
sites in damaged bone. Firstly, commercially available 5-aminoisophthalic acid was 
iodinated using potassium iododichloride to give starting material 96 which was 
converted to the acid chloride 97. The condensation of the acid chloride 97 and the 
phenyliminodiacetate ethyl ester 93, using Et3N in DMA, resulted in the ethyl ester 
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intermediate 98. This was hydrolysed using the same method as 95 to give target 99 
(Scheme 1.27). 
Scheme 1.27: Synthesis of 99 from 5-aminoisophthalic acid 96 
 
The final compound 101 is a dimer, containing six iodine atoms and four chelator 
units in a meta configuration, and was expected to have the highest binding affinity. 
Compound 101 was synthesised from the bis-acid chloride 97 which was first 
reacted with malonyl dichloride to give the dimer 100 which using the same 
procedure as the previous two compounds gave 101 (Scheme 1.28).  
 
Contrast agents 95, 99 and 101 were subsequently used to label bone scratches on 
bovine tibiae and tested by CT imaging. The scratch was visible with all three 
contrast agents, however it was difficult to differentiate between bone and contrast 
agent in order to determine features such as scratch depth. This was thought to be 
due to the beam hardening effect, which masks the imaging from the agents. 
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However the results show that agents can bind to bone cracks and are important in 
future developments for bone-targeting CT imaging agents.   
 
Scheme 1.28: Synthesis of 101 from bis-acid chloride 97 
 
1.6 Current treatment of brain aneurysms 
 
An aneurysm is an abnormality, a weakness in the wall of a blood vessel which 
causes dilation and ballooning of the arterial wall (Figure 1.18). This can occur in 
any vessel in the body. If an aneurysm in the brain ruptures it can lead to a stroke 
which can cause brain damage and death.  
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Figure 1.18: Brain aneurysm 
 
It is not known for certain the cause of intracranial aneurysms or how they form, 
grow and rupture, however there is evidence to suggest that hypertension and 
smoking induced vascular changes play a major role.
154
 Brain aneurysms are often 
discovered once they have ruptured, causing bleeding in the brain or the 
subarachnoid space. Treatment is focused on stopping the bleeding and hopefully 
preventing permanent brain damage. However it is possible to prevent brain damage 
by treating the un-ruptured aneurysm.  
 
In the past intracranial aneurysms were normally only discovered after rupture and 
subsequent subarachnoid haemorrhage. Now increasingly aneurysms are detected 
before rupture due to improved sensitivity of imaging techniques. Once detected 
there are three treatment options:
155
 firstly observation, this involves follow up 
imaging to monitor the aneurysm. The second option is surgical clipping, this is an 
open procedure and involves making an incision in the scalp, opening the bone and 
dissecting through the bone to place a clip across aneurysm where it arises from the 
blood vessel, thus preventing the blood flow from entering the aneurysm (Figure 
1.19).  
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Figure 1.19: Surgical clipping
71
 
 
The final option is endovascular “coiling” which involves inserting a catheter into a 
vessel in the groin and navigated through the blood vessels, with the aid of contrast 
media to visualise vessels, to the brain and into the aneurysm. Coils are then packed 
into the aneurysm until it arises from the blood vessel, stopping blood from 
entering,
156
 (Figure 1.20). The treatment option selected depends on several factors 
included the size of the aneurysm and the patients age, both of which effect the risk 
of rupture.
157
  
 
A          B                 C 
Figure 1.20: Coiling treatment of aneurysms A) before treatment, B) after coiling, C) X-ray image 
shows densely packed coils
154
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Previous to the availability of detachable coils, most intracranial aneurysms were 
surgically clipped to prevent rupture.
157
 In recent years there has been a move 
towards “coiling” for treatment of aneurysms as it has been shown to give better 
outcomes than neurosurgical clipping for subarachnoid haemorrhage
158
 It is also 
more popular with patients as it is less physiologically stressful and less invasive 
than clipping. Minor risks of coiling include, reaction to the contrast agent, groin 
hematomas and infection, similar risks to those of diagnostic catheter 
angiography.
159
 Several studies comparing endovascular and surgical management of 
ruptured and un-ruptured intracranial aneurysms show significantly improved 
outcomes with coiling.
71,160 
Coiling has been shown to give lower rates of patient 
mortality, shorter hospital stays and lower treatment costs.
161
   
 
Endovascular coiling has been shown to effectively prevent re-bleeding of ruptured 
aneurysms.
162
 It also shows better outcomes at 12 months and during follow ups 
extended to 7 years.
163
 However it is not feasible to perform coiling for some 
aneurysms (approximately 10 – 15% of cases) due to difficult access or if the 
contours of the aneurysm do not allow for coils to fit safety inside.
155
 Also several 
reports have shown that aneurysm recurrence or reopening is more frequent after 
coiling,
164, 165 
and so is not always more preferable to clipping. 
 
1.7 New applications of cyanoacrylate adhesives in combination with 
contrast agents 
 
New applications for cyanoacrylate adhesives are currently being explored, in 
particular the internal use of cyanoacrylates. In theory cyanoacrylates could be used 
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to treat brain aneurysms in place of coiling. As with coiling a catheter could be 
inserted into the groin and navigated into the aneurysm. Instead of packing the 
aneurysm with platinum coils, cyanoacrylate adhesive could be dispensed into the 
aneurysm, sealing it off and stopping blood from entering. This would be less 
expensive than platinum coils and the adhesive can take any shape necessary to fill 
the aneurysm. Cyanoacrylate polymerises quickly within the body and would 
therefore form a solid barrier which would prevent blood from entering the 
aneurysm. In order to monitor the glue as it is inserted in the aneurysm and to ensure 
it polymerises and therefore seals off the aneurysm it needs to be visualised within 
the body. This involves the use of contrast agents as with conventional coiling. 
However after coiling treatment, the sealed aneurysm can be visualised by X-ray as 
the platinum coils are visible, this would not be possible with cyanoacrylate glue.  
 
To overcome this problem a known contrast agent could be combined with the 
adhesive before application. This would allow the cyanoacrylate to be visualised as it 
was guided through the body to the brain. It would then be possible to check the 
position of the glue and that it had successfully sealed the aneurysm by X-ray. 
However X-ray contrast agents are water soluble, meaning that they will not dissolve 
in cyanoacrylate. The main group of X-ray contrast media are iodinated agents and 
are based around a 1,3,5-tri-iodinated benzene ring 59 (Figure 1.21).  
 
Figure 1.21: 1,3,5-tri-iodinated benzene ring 
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They have long side chains rich in hydroxyl groups evenly distributed around the 
benzene core. It is these hydroxyl groups that make the compound highly water 
soluble. If these hydroxyl groups could be protected with simple protecting groups 
the compound could be modified to be more organic soluble. Any group added to the 
contrast media needs to be small, so as to not significantly increase the molecular 
weight and therefore significantly decrease the iodine concentration. It is the iodine 
molecules that absorb the X-rays and therefore create distinction between the vessel 
of interest and the surrounding soft tissue.  
 
The following three chapters describe attempts to (a) chemically modify 
commercially available contrast agents so that they dissolve in cyanoacrylate 
adhesives, (b) the development of novel cyanoacrylates that are less susceptible to 
biodegradation and formaldehyde release and (c) the improvement and development 
of an industrial synthesis of cyanoacrylate monomers. 
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2.0 – Incorporation of Contrast Agents in Cyanoacrylate Adhesive 
 
2.1 Introduction 
 
Contrast agents are substances used to enhance the contrast of structures/fluids 
within the body during medical imaging, for example during X-ray or MRI imaging. 
Tri-iodophenyl derivatives 59 have long been established as X-ray contrast agents
166
 
(Figure 2.1).  
 
Figure 2.1: Triiodophenyl core of iodinated X-ray agents 
 
The incorporation of an X-ray contrast agent into cyanoacrylate bioadhesives would 
allow the glues to be imaged and their position in the body determined, which would 
be beneficial in the development of new applications, for example in the treatment of 
brain aneurysms. Currently brain aneurysms are treated by either surgical clipping or 
endovascular coiling.
167
 In endovascular coiling a micro catheter is inserted into the 
femoral artery in the patients leg. Fluoroscopic imaging is used to navigate through 
the vascular system into the aneurysm to deploy a series of platinum coils to densely 
pack the aneurysm and exclude it from circulation and therefore rupture
168
 (Figure 
2.2).   
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(i)                                       (ii) 
Figure 2.2: Posterior inferior cerebella artery aneurysm before (i) and after (ii) treatment
168
 
 
Cyanoacrylate adhesive would be a cheaper alternative to platinum coils; the 
monomer is flexible and would take the shape of the aneurysm, it polymerises 
quickly in the presence of moisture
42
 to form a solid barrier that would block off the 
blood flow and prevent rupture. Currently cyanoacrylate adhesives cannot be 
followed/ imaged in the body. If an X-ray contrast agent could be incorporated into 
the mixture then the flow of adhesive could be monitored in the body and this 
approach would become a viable alternative to coiling. However typical X-ray 
contrast agents, such as tri-iodophenyl derivatives 59, are highly insoluble in 
cyanoacrylates. By using simple protecting group chemistry it should be possible to 
alter the solubility of the contrast agents sufficiently that they will dissolve in the 
hydrophobic cyanoacrylates allowing for the positioning of the adhesives to be 
followed by X-ray (Scheme 2.1). 
 
Scheme 2.1: Use of protecting group chemistry to investigate effect on solubility 
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There are a number of known iodinated contrast agents commercially available. 
These can be classed into ionic or non-ionic reagents. Originally ionic reagents 56 
(in the form of the sodium salt), were used, however in recent years there has been a 
move to non-ionic agents 55 and 58 as they may be administered in higher 
concentrations and have reduced side effects.
169
 The ion charges resulting from the 
disassociation of compounds such as 56 can potentially disrupt the electrical charges 
in the brain and heart.
170
 Examples of existing contrast agents include diatrizoic 
acid
171
 56 (ionic), trade name Hypaque, iohexol
172
 55 and iodixanol
173
 58 (non-
ionic), trade names Omnipaque and Visipaque (Figure 2.3). 
 
Figure 2.3: Contrast agents diatrizoic acid 56, iohexol 55 and iodixanol 58 
 
If a particular chemical reaction needs to be carried out selectively at one site in a 
compound with multiple functional groups, other reactive sites need to be blocked, 
or protected. Over the years many different protecting groups for a range of different 
functional groups have been developed for this purpose.
174
 Protection of acidic 
functionality (such as carboxylic acids and alcohols) within the contrast agents 55, 
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56 and 58 would lead to more hydrophobic molecules which would have better 
solubilities within cyanoacrylate monomers and polymers.  The contrast agent would 
require a solubility of approximately 10-15% by weight in any cyanoacrylate 
adhesive if it is to be easily observed in the body. It follows that contrast agents with 
higher percentages of iodine atoms within their structures would require less 
solubility within adhesives than those with lower percentages to achieve the same 
contrast. Protection of functional groups within the target contrast agents 55, 56 and 
58 will increase their molecular weights lowering the effective iodine concentration. 
In order to keep the effective iodine concentration as close to the commercial 
contrast agents as possible we will restrict our study to only the use of small 
protecting groups.  
 
2.2 Chemical Protection of Contrast Agents 55, 56 and 58 
 
Aim: Protecting groups will be added to the free hydroxyl groups and the 
carboxylate group on the above X-ray contrast agents 55, 56, 58 in order to try and 
make them more hydrophobic and soluble in cyanoacrylate.  
 
2.2.1 Modification of diatrizoic acid 56 
 
Diatrizoic acid 56 is the simplest of the above examples. The obvious choice for 
protection is the carboxyl acid functional group. As it has only one CO2H group 
which was to be protected larger organic groups, i.e. long chains could be used as the 
effect on the ‘iodine concentration’ will be less than for the larger agents 55 and 58 
with multiple hydroxyl groups. However the carboxylic acid to be protected is 
sterically hindered and therefore attaching bulky groups may be difficult. A series of 
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n-alkyl groups with increasing chain length were synthesised by conversion of the 
carboxylic acid 56 to the acid chloride which was further reacted with alcohols in 
situ to give the esters 102-104 (Scheme 2.2).   
 
Scheme 2.2: Synthesis of diatrizoic acid ester series. Reagents and Conditions: i) diatrizoic acid (1 
eq.), thionyl chloride (5 eq.), reflux, 6 h ii) ROH, pyridine (1.1 eq.), reflux, 36 h, 102 2%, 103 4%, 
104 2%. 
 
The reactions were low yielding and the resulting products were still insoluble in 
most organic solvents. However mass spectroscopy of the crude reactions showed 
the relevant mass peaks (Figure 2.4, 2.5 and 2.6).  
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Figure 2.4: Crude mass spectroscopy of methyl 3,5-diacetamido-2,4,6-triiodobenzoate 102 
 
Figure 2.5: Crude mass spectroscopy of butyl 3,5-diacetamido-2,4,6-triiodobenzoate 103 
 
Figure 2.6: Crude mass spectroscopy of octyl 3,5-diacetamido-2,4,6-triiodobenzoate 104 
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Despite low yields and little solubility in organic solvents esters 102, 103 and 104 
were purified and tested for solubility in ethyl cyanoacrylate 37. They displayed no 
solubility, therefore demonstrating that increasing the chain length had little effect. 
Hence it was concluded that diatrizoic acid 56 wasn’t a suitable contrast agent to be 
incorporated into cyanoacrylates, and therefore the reactions were not optimised in 
order to improve the yields.   
 
2.2.2 Modification of iohexol 55 
 
Iohexol 55 (Figure 2.7) was considered a better candidate for incorporation into the 
adhesive as it has six hydroxyl groups, all of which can be protected to increase 
solubility in an organic medium. A range of different common alcohol protecting 
groups were studied (e.g. acetate, allyl, and acetonide.). Analysis of the reactions 
was difficult, due to the possibility of obtaining a mixture of mono-, di-, tri-, tetra-, 
penta- and hexa-protected products. In addition each product contained a mixture of 
diastereoisomers and the restricted rotation around the N-Ar and the N-CO bonds led 
to broadening of the peaks in the 
1
H NMR, making them difficult to interpret. As a 
consequence we used mass spectrometry to monitor the progress of these reactions.  
 
Figure 2.7: Contrast agent iohexol 55 
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The first issue to overcome was the limited solubility of iohexol 55 in the most 
common organic solvents. A quick investigation revealed useful solubility in 
methanol, DMF, pyridine and DMSO.   
 
2.2.2.1 Hydroxyl protecting groups 
 
Allyl: 
Allyl protection of alcohols is common in carbohydrate chemistry as allyl ethers are 
often compatible with the various methods for glycoside formation.
175
 The fact that 
hydrophilic carbohydrates often have multiple alcohol functional groups to be 
protected (like iohexol 55) suggested this was a useful protecting group to study.  
There are several methods for addition of this group, for example refluxing the 
alcohol with allyl bromide and a base
176
 (Scheme 2.3). 
 
Scheme 2.3: General method for allyl protection 
 
Iohexol 55 was reacted with allyl bromide and NaOH in DMF
177
 to give the hexa-
allyl protected product 107 (Scheme 2.4). 
 
Scheme 2.4: Attempted allyl protection of iohexol 55. Reagents and Conditions: iohexol (1 eq.), 
allyl bromide (7.5 eq.), NaOH (10 eq.), DMF, 50 
o
C, 24 h, 65% crude. 
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The crude 
1
H NMR of 107 was difficult to interpret, because of the mix of protected 
products there were a large number of broad and overlapping peaks (Figure 2.8). 
Mass spectroscopy revealed peaks for penta- (A) and hexa-allyl (B) products, 
however peaks were also observed for the hepta- (C) and octa-allyl (D) compounds. 
Suggesting the two secondary amides had also reacted with the allyl bromide under 
the reaction conditions (Figure 2.9). 
 
Figure 2.8: 
1
H NMR of attempted allyl protection of iohexol 107 
 
 
Figure 2.9: Mass spectrometry of crude allyl protection of iohexol 107 
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The penta-, hexa-, hepta- and octa-allyl peaks (A-D) give sequence with a repeating 
unit of 40 which corresponds to the addition of an allyl group. Another set of peaks 
with the same repeating unit of 40 was observed between 834 and 994 (labelled 1-5). 
However the difference between the penta-allyl peak (A) and the last peak in this 
second series (5) is 50, suggesting they are two separate sequences. The mass peaks 
correspond to a loss of the N-acetyl group as well as a single iodine atom for each of 
the penta-octa allyl compounds (A-D) (M+Na
+
 -C2H3OI). It was not possible to 
separate the mixture of allylated products by column chromatography; therefore the 
desired hexa-allyl product 107 (B) was not isolated. Despite problems with 
purification the solubility of the crude mixture as a whole was tested in ethyl 
cyanoacrylate 37. The mixture showed no solubility in ethyl cyanoacrylate 37 and 
therefore the allyl product was discounted without further optimisation.  
 
Acetate: 
The acetate protecting group seemed to be a viable candidate for the modification of 
iohexol 55 as it wouldn’t significantly increase the molecular weight and therefore 
affect the contrast (by lowering the weight % of iodine in the compound 
significantly). Also hydrolysis of the acetate group under physiological conditions 
would release iohexol 55 and acetic acid, which the body can process without 
adverse effects. One of the most common methods for acetate introduction is 
reaction of acetic anhydride under basic conditions
178
 (Scheme 2.5).  As pyridine 
was found to be a suitable solvent for the dissolution of iohexol 55 we attempted 
reaction with acetic anhydride in pyridine
179
 (Scheme 2.6). 
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Scheme 2.5: Acetate protection of cyclohexanol 
 
 
Scheme 2.6: Acetate protection of iohexol 55. Reagents and Conditions: iohexol (1 eq.), acetic 
anhydride (8 eq.), pyridine, 50 
o
C, 48 h, 61%. 
 
Following the reaction by mass spectrometry showed the fully acetate protected 
product 110 was formed (Figure 2.10). 
 
Figure 2.10: Mass spectrometry of hexa-acetate protected iohexol 110 
 
1035.9 1073.8
1095.9
+MS, 1.1-1.9min #(81-162)
0
1
2
3
4
6x10
Intens.
1025 1050 1075 1100 1125 1150 1175 m/z
[M+Na]
+
 
[M+H]
+
 
Chapter 2: Incorporation of Contrast Agents in Cyanoacrylate Adhesive 
 
59 
 
The crude product was purified by column chromatography and the resultant white 
solid was tested for solubility in ethyl cyanoacrylate 37. The product displayed 
approx. 15% solubility, however it also caused polymerisation of the ethyl 
cyanoacrylate 37 over a period of minutes. Polymerisation occurs in the presence of 
nucleophiles (e.g. water, alcohols) and nucleophilic bases (e.g. pyridine).
48
 This 
suggested that basic/nucleophilic residues were left over from the protection reaction 
despite purification. Immediate polymerisation is not suitable for this product as it 
allows no application time. The contrast agent needs to be incorporated in the 
cyanoacrylate but without changing the properties of the adhesive. Thus it was 
concluded an alternative approach to make 110 using acidic conditions instead of 
basic conditions and lower temperatures would be more appropriate. The allyl-
protected product 107 also caused the cyanoacrylate to polymerise, however since 
the product displayed no solubility in ethyl cyanoacrylate 37 it was ruled out without 
exploring alternative non-basic methods.  
 
Iohexol 55 was combined with iodine
180,181
 in acetic anhydride to form a paste, no 
solvent was added and the reaction mixture was stirred at r.t. for 5 days
182
 (Scheme 
2.7).  
 
Scheme 2.7: Acetate protection of iohexol 55. Reagents and Conditions: iohexol (1 eq.), iodine (0.1 
eq.), acetic anhydride (8 eq.), r.t., 5 days, 40%. 
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As the acetate groups start to add to the starting material it becomes more soluble 
and thus more reactive. After several days mass spectrometry showed the hexa-
acetate product 110 [I2] (Figure 2.11). 
 
Figure 2.11: Mass spectrometry of acetate protected product 110 [I2] via non-basic route 
 
The acetate protected product 110 [I2] showed 15% solubility in cyanoacrylate 
adhesive and unlike 110 [py] rapid polymerisation did not occur upon addition.  
 
2.2.2.2 Stability of 110 [I2] at  pH 4, 7 and 10 
 
In order to assess the stability of the acetate product 110 [I2] in aqueous solution and 
to determine how it decomposes the reactions were monitored by mass spectrometry 
for a number of weeks. Neutral (pH 7), acidic (pH 4) and basic (pH 10) buffer 
solutions were used to see how the different conditions affect how 110 [I2] 
hydrolyses.  
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hexa-, penta- and tetra-protected products (Figure 2.12), indicating a relative quick 
hydrolysis of the first two acetates. Interestingly, little further hydrolysis occurred 
over the next week.  
(i)  (ii)  
Figure 2.12: pH 7 buffer and acetate product 110 [I2], (i) initial conditions, (ii) 1 week 
 
The solution was monitored by mass spectroscopy for three weeks in total (Figures 
2.13 and 2.14). After three weeks the number of mass peaks significantly increased 
and with peaks for the partially de-protected products, indicating that 110 [I2] is 
broken down as expected by hydrolysis of the acetate groups particularly slowly. 
 
Figure 2.13: pH 7 buffer and acetate product 110 [I2], 2 weeks 
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Figure 2.14: pH 7 buffer and acetate product 110 [I2], 3 weeks 
 
pH 10: 
At pH 10 110 [I2] appears to be behave in a similar manner to the neutral solution. 
Comparison of the mass spectrometry shows an increase of mass peaks from initial 
conditions (Figure 2.15) to three weeks (Figure 2.16) as with pH 7. The mass 
spectrometry also shows the same peak pattern as the acetate groups are hydrolysed, 
suggesting 110 [I2] is broken down in the same way. 
 
Figure 2.15: pH 10 buffer and acetate product 110 [I2], initial conditions 
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Figure 2.16: pH 10 buffer and acetate product 110 [I2], 3 weeks 
 
pH 4: 
Under acidic conditions 110 [I2] exhibits a somewhat different pattern. The 
hydrolysis appears to be relatively slow and even after three weeks the major 
hydrolysis product is only the penta-product with further hydrolysis products being 
minor components (Figures 2.17 and 2.18).  
 
Figure 2.17: pH 4 buffer and acetate product 110 [I2], initial conditions 
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Figure 2.18: pH 4 buffer and acetate product 110 [I2], 3 weeks 
 
In conclusion the pH tests suggest that 110 [I2] will break down in the body as 
expected, releasing by-products from iohexol 55 and acetic acid. Therefore given 
this and its solubility in ethyl cyanoacrylate 37 the acetate protected product 110 [I2] 
is a viable candidate for incorporation into the adhesive for use within the body.   
 
2.2.2.3 Affect of increasing the ester chain length  
 
The incorporation of acetate groups increased the solubility of iohexol 55 in ethyl 
cyanoacrylate 37 by 15%. Would increasing the chain length increase the solubility 
further? Iohexol 55 was reacted with pentanoic anhydride under the same conditions 
to give 111 in 14% yield (Scheme 2.8). The pentanoate product 111 also shows some 
solubility in ethyl cyanoacrylate 37; however this was less than 10%. Despite the 
larger protecting groups 111 showed less solubility than the acetate product 110.  
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Scheme 2.8: Pentanoic acetate protection of iohexol 55. Reagents and Conditions: iohexol (1 eq.), 
iodine (0.1 eq.), pentanoic anhydride (8 eq.), r.t., 6 days, 14%. 
 
 
Figure 2.19: Mass spectrometry of pentanoic anhydride protected product 111 
 
Increasing the number of carbons of the protecting groups did not further increase 
the solubility in ethyl cyanoacrylate 37. Therefore despite both protected products 
110 and 111 showing solubility it is the acetate protected product 110 that is the 
most suitable.  
 
2.2.2.4 Acetonides as 1,2-diol protecting groups 
 
Due to the abundance of 1,2-diol functionality in natural products there are a number 
of 1,2- and 1,3- diol protecting groups. Acetonide protection is the most common 
form of 1,2- and 1,3-diol protection, and has been extensively used in carbohydrate 
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chemistry.
183
 Acetone can be used under acidic conditions to form the acetonide 
group
184
 (Scheme 2.9). 
 
Scheme 2.9: Acetonide protection using acetone and TsOH 
 
Dimethoxypropane can also be used under similar conditions to give the acetonide 
product,
185,186
 (Scheme 2.10).   
 
Scheme 2.10: Acetonide protection using dimethoxypropane 
 
Iohexol 55 has three 1,2-diol systems, meaning diol protecting groups could be good 
targets. The advantage to this is the reduced number of possible protection products 
compared to hydroxyl protection (mono-, di- and tri-protected verses mono- to hexa 
protected). Experience from the previous protections indicated that picking reactions 
that occur under acidic conditions was preferred. Acetonide protection was 
undertaken using acetone and CuSO4/H
+
 (scheme 2.11).
187
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Scheme 2.11: Acetonide protection of iohexol 55. Reagents and Conditions: iohexol (1 eq.), 
acetone, CuSO4.5H2O (2 eq.), TsOH (0.2 eq.), 50 
o
C, 48 h, 57%. 
 
This resulted in a crude yellow solid which by mass spectroscopy was shown to 
contain S.M. as well as mono- 116a, di- 116b and tri-protected product 117c (Figure 
2.20). 
 
Figure 2.20: Crude mass spectrometry of acetonide protected iohexol 55 
 
It was unclear how stable the protected products 116a-c would be upon 
chromatography, so initially the product was purified by rapidly flushing through a 
plug of silica eluting with EtOAc. However this only removed the remaining S.M., 
leaving the mixture of products 116a, 116b and 116c. Before effort was expended in 
finding appropriate purification protocols it was necessary to briefly explore whether 
the acetonide product 116c was a viable candidate, thus the mixture was tested for 
solubility in ethyl cyanoacrylate 37. The mixture of 116a, 116b and 116c showed 
approximately 10% solubility in the adhesive and didn’t cause rapid polymerisation. 
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This indicated that the presence of unreacted free hydroxyls are not themselves 
problematic in incorporation into cyanoacrylate and are not responsible for the 
polymerisation observed in 107.  The reaction was repeated on a larger scale (> 5 g), 
this time adding molecular sieves to the mixture in order to try and push the 
equilibrium towards product and increase the yield. In addition the CuSO4.5H2O 
used was dried in a vacuum oven for 24 hrs at 60 
o
C to render it anhydrous, and the 
acetone solvent was dried over molecular sieves. This time no peak for S.M. 55 was 
observed in the mass spectroscopy (Figure 2.21). Interestingly, very little di-
protection 116b was indicated in either of the two mass spectras Figure 2.20 and 
Figure 2.21. While mass spectrometry is not quantitative the relative low abundance 
of the molecular ion for this product was puzzling. 
 
Figure 2.21: Crude mass spectroscopy for acetonide protected iohexol 55 
 
Initial purification by flushing 116 through a silica plug suggested that 116 was 
stable to chromatography. Thus, 116 was purified by ‘normal’ flash column 
chromatography in order to attempt to isolate 116c only. The main component from 
the column was analysed by LCMS, the UV trace showed one peak, suggesting only 
one product (Figure 2.22). However the mass spectrometry shows peaks for 116a 
(mono-) and 116c (tri-) for the LC peak at 11.2-12.0 minutes.  
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Figure 2.22: LCMS of purified acetonide protected iohexol 55 
 
The purified product mixture was re-tested for solubility in ethyl cyanoacrylate 37; it 
still displayed reasonable solubility, approx. 10%. Due to the mixture of compounds 
and the inability to separate them on chromatography, alternative methods of making 
116 were investigated. An alternative route was tried using 2,2-
dimethoxypropane,
185,186
 and this gave the desired product 116 in 85% yield 
(Scheme 2.12). The reaction was run in DMF as solvent (as opposed to acetone) and 
the increased solubility of 116 under these reaction conditions furnished the reaction 
in only 24 hrs at r.t. (compared to 48 hours). 
 
Scheme 2.12: Alternate acetonide protection of iohexol 55. Reagents and Conditions: iohexol (1 
eq.), 2,2-dimethoxypropane (4 eq.), TsOH (0.1 eq.), DMF, r.t. 24 h, 85%. 
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The product was once again purified by column chromatography to give a white 
powder and as before the LCMS showed one peak on the UV trace (Figure 2.23) 
corresponding to the same peak observed from the previous reaction (Figure 2.22).  
 
 
Figure 2.23: LCMS of purified acetonide protected iohexol 55 via alternative route 
 
However once again the single peak in the UV showed molecular ions for both the 
116a (mono-) and 116c (tri-) product in the mass spectra. This suggests one of two 
things; either that 116c is breaking down to 116a in the mass spectrometer. However 
this seems unlikely as electrospray ionisation was used which should prevent 
molecule fragmentation and one might also expect to see peaks for di-protection 
116b. Thus, it would appear that the traces from 116a and 116c are coalescing, 
which is why the UV shows only one peak. However, this too is unusual as it 
suggests that’s very little di-protected compound 116b is formed. This may be due to 
the increased solubility of the di-protected compound 116b (relative to 116a) under 
the reaction conditions, meaning that it rapidly reacts to tri-protect 116c as soon as it 
is formed from the less soluble 116a. 
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As before the product 116 was tested for solubility in ethyl cyanoacrylate 37; 
however instead of 10% solubility as previously displayed for 116 (CuSO4) this 
compound 116 (TsOH) did not dissolve but formed an emulsion. This behaviour was 
unexpected. The two products 116 (CuSO4) and 116 (TsOH) were made via two 
different routes but the 
1
H and 
13
C NMR, mass spectroscopy and IR spectra appear 
identical. However because they behave very differently in ethyl cyanoacrylate there 
must be a difference-perhaps in morphology or minor contaminants. Elemental 
analysis showed both compounds to be authentic samples and equal in purity, (Table 
2.1). 
 Theory Route A Route B 
C 35.7 35.4 35.3 
H 4.1 4.0 4.0 
N 4.5 4.3 4.4 
Table 2.1: Elemental analysis of 116 from route A and B 
 
Route A uses CuSO4 in the reaction; if residual amounts of copper were still present 
in the product 116 (CuSO4) they could be responsible for the solubility difference by 
initiating differing morphology. Therefore both samples were analysed for copper by 
ICP-MS. Analysis on the samples was carried out using an Aglient 7500cx ICP-MS. 
External single element calibrants and internal standards were used during the 
analysis which determined that any copper present was below the detection limit of 
the instrument (sub-ppb) for both samples. Thus copper contaminants are unlikely to 
be the reason for differential properties of the two compounds 116 (CuSO4) and 116 
(TsOH). 
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2.2.2.5 Thermal analysis of ethyl cyanoacrylate polymers with inclusion of 116 
(CuSO4) and 116 (TsOH) at varying levels 
 
As the target protected contrast agent 116 is to be incorporated into the ethyl 
cyanoacrylate adhesive monomer it was important to determine how varying levels 
of incorporation of compound 116 would affect the properties of the polymer 
produced. If the properties were widely different to the parent ethyl cyanoacrylate 
polymer then they might not be useful for in vivo applications. We chose to 
investigate the thermal properties of the polymers, not because the polymers would 
be exposed to extreme temperature changes in the body but because analysis would 
allow differences in decomposition (and hence structural effects) to be easily 
determined. Thermal analysis is when the properties of materials are studied as they 
change with temperature. There are several different methods; in this case 
Thermogravimetric analysis (TGA) and Differential scanning calorimetry (DSC) 
were used. TGA measures the change in % mass as the material is heated to high 
temperatures, in this case 600
o
C. DSC measures the heat flow as the material 
undergoes various phase transitions, i.e. melting point and glass transition.  
 
Poly ethyl cyanoacrylate is known to decompose via depolymerisation
188
 or by 
decomposition with loss of HCN
189
 at temperatures between 180-260 ˚C. The TGA 
of poly ethyl cyanoacrylate shows this decomposition pathway as expected
43
 (Figure 
2.24). Next we compared the TGA of the two modified contrast agents 116 (CuSO4) 
and 116 (TsOH) (Figure 2.24). Both modified contrast agents exhibited the same 
decomposition pathway (within experimental error). They both have a sharp 
degradation curve at just over 300
o
C and then both slowly tail off. This shows that 
despite the differences in solubility, the thermal properties of the material are the 
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same. Initial decomposition leads to loss of about 60% weight, followed by two 
other decomposition pathways at higher temperature, the second occurring between 
300-500 ˚C (leading to a further 20% loss) and the final pathway slowly causing 
decomposition above 500 ˚C.  It is likely that loss of iodine and deprotection occurs 
first (equating to the 60% weight loss).  
 
Figure 2.24: TGA of cyanoacrylate and 116 from route A and B 
 
Despite 116 (TsOH) from route B not dissolving in ethyl cyanoacrylate 37 it did 
form a gel like emulsion which showed similar stability in the monomer to that of 
116 (CuSO4) from route A. Therefore both compounds were incorporated in the 
ethyl cyanoacrylate monomer 37 and the after polymerisation analysed by TGA. 
Two different loadings of 116 (CuSO4) and 116 (TsOH) in the adhesive (5% and 
20% w/w) were investigated (Figure 2.25). Unsurprisingly the major decomposition 
resembles that of the polymer. For the two 20% w/w samples decomposition starts 
about 10 ˚C earlier indicating higher % incorporations are affecting the materials 
properties. 
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Figure 2.25: TGA of cyanoacrylate combined with 116 from route A and B 
 
The TGA also shows that once incorporated in the cyanoacrylate adhesive whether 
the contrast agent has dissolved 116 (CuSO4) or formed an emulsion 116 (TsOH) 
makes little difference. A minor second decomposition pathway at 260 ˚C (from the 
contrast agent) can be seen. The DSC further backs this up, by displaying very 
similar results for all combinations (Figure 2.26). 
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Figure 2.26: DSC of cyanoacrylate combined with 116 from route A and B 
 
2.2.2.6 Variable temperature 
1
H NMR of 116 
 
The iohexol protected products 116 (TsOH) and 116 (CuSO4) were difficult to 
analyse by 
1
H NMR as in addition to a number of diastereomers the spectra were 
complicated by the slow rotation around the amide bonds and the potential 
atropoisomeric nature of the C-N bond in the anilide (due to the large iodine 
substituents). Variable temperature NMR is often used for similar compounds, by 
changing the temperature peaks can shift, sharpen, broaden and coalesce.
190
 Variable 
temperature is often used to calculate the barrier to rotation about a bond. High 
barriers to rotation can lead to the existence of two separate rotamers, particularly at 
low temperatures. This can then lead to two sets of peaks in the 
1
H NMR. As you 
heat up the sample you observe coalescence of these peaks to give one set of signals 
at high temperature. Using line shape analysis the rate of coalescence of the two sets 
of peaks can be measured allowing the barrier to rotation to be calculated. However 
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if the barrier is too high it can’t be calculated by this method because coalescence is 
not observed at temperatures accessible for 
1
H NMR experiments.  
 
The two acetonide products 116 (CuSO4) and 116 (TsOH) from routes A and B were 
analysed using variable temperature 
1
H NMR in d6-DMSO in an attempt to simplify 
the spectra and aid interpretation. Heating up the samples from r.t. to 100 
o
C caused 
the amide NH peaks to broaden and coalesce, and the peaks at 3.25-3.50 ppm to 
broaden, but no simplification of the spectra was observed. Both products behaved in 
the same way (only the spectra for 116 (CuSO4) are shown Figure 2.27). Attempts to 
cool down the samples dissolved in CDCl3 (r.t. to -59 
o
C) also led to unhelpful 
broadening for both samples (Figure 2.28). No useful information on barriers to 
rotation or significant simplifying of the spectra was observed.  
 
Figure 2.27: VT 
1
H NMR of 116 (CuSO4) from route A, 298 K – 373 K.  The spectra for 116 
(TsOH) were identical 
298 K 
333 K 
373 K 
Chapter 2: Incorporation of Contrast Agents in Cyanoacrylate Adhesive 
 
77 
 
 
Figure 2.28: VT 
1
H NMR of 116 (CuSO4) from route A, 214 K – 298 K. The spectra for 116 
(TsOH) were identical 
 
A recent study into the rotational barriers of iodixanol 58 calculates the rotation 
around the phenyl-N bond to be between 28-33 kcal mol
-1
.
191
 This is sufficiently 
high to give rise to non-interconvertible rotamers at r.t., as iodixanol 58 is the dimer 
form of iohexol 55, the same barrier to rotation would be expected, which is why VT 
1
H NMR didn’t yield any useful information. 
 
2.2.2.7 X-ray diffraction of 116 (CuSO4) and 116 (TsOH) 
 
The two products 116 (CuSO4) and 116 (TSOH), while appearing identical (
1
H, 
13
C 
NMR, IR, M.S, m.p., elemental analysis, TGA and DSC) were made via different 
methods (A and B) and exhibit differential solubility in ethyl cyanoacrylate 37. The 
different preparation methods (including work-up), may lead to differences in the 
crystallisation patterns of the two solids. This could explain why two seemly 
214 K 
256 K 
298 K 
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identical products have different solubility characteristics in the cyanoacrylate 
adhesive. 116 is a powder and therefore it was not possible to get a crystal structure 
of the two different products, for this reason both solids were analysed by X-ray 
diffraction (XRD). XRD is a powerful technique for studying powdered materials, as 
different materials produce distinctive diffraction patterns. By producing a 
diffraction pattern for each solid we the two samples could be compared, any 
significant differences could explain why they behave differently in the adhesive.  
 
XRD works by the detector sitting at a certain position and counting the X-rays 
scattered from the sample in that position, before moving on to the next position and 
so on and so on. However no Bragg peaks were observed for either sample 
indicating that they both were amorphous solids. A Bragg peak is a pronounced peak 
on the Bragg curve which plots the energy loss of the X-ray as it travels through 
matter. This means that the sample is amorphous (effectively structureless or 
disordered) so all the molecules are packed together randomly, rather than in an 
ordered way. The lack of Bragg peaks lead to powder diffraction patterns for both 
samples which were mainly background noise (Figure 2.29 and 2.30. The only sharp 
peaks observed were at 39
o
 and 45
o
, these are from the aluminium sample holder. 
Significant amounts of sample were analysed and so the low signal must be due to 
amorphous behaviour of both solids. 
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Figure 2.29: Powder diffraction pattern from 116 (CuSO4) via Route A 
 
 
Figure 2.30: Powder diffraction pattern from 116 (TsOH) via Route B 
 
It is still entirely possible that the differences in the properties of the two materials 
are due to a difference in the way the molecules are packed, but unfortunately 
because they are not crystalline this can’t be observed by XRD. In summary after 
extensive analysis (
1
H, 
13
C NMR, mass spectroscopy, m.p., ICP-MS, IR, TGA, DSC, 
Al holder 
Al holder 
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XRD) both samples 116 (CuSO4) and 116 (TsOH) appear identical apart from their 
solubility in ethyl cyanoacrylate 37. Despite inconclusive results from XRD it seems 
likely that the difference in solubility is due to different morphologies, although it 
wasn’t possible to prove this.  
 
2.2.2.8 Cyclic 1,3-protecting groups 
  
To probe the anomaly further, to produce more compounds for testing and to 
potentially increase solubility in ethyl cyanoacrylate 37 further cyclic protecting 
groups 117 and 118 (Figure 2.31) were investigated. 
 
Figure 2.31: Cyclic 1,3-protecting groups 
 
As before two routes of synthesis were chosen A (ketone, CuSO4/H
+
) and B (2,2-
dimethoxyalkane, TsOH). Solubility of the identical compounds (produced by the 
two different routes) in ethyl cyanoacrylate 37 will be determined. This will illustrate 
if the differences in solubility between route A and B products are exclusive to the 
acetonide product 116 or are a general observation. 
 
Six membered rings: 
Firstly Route A was attempted using cyclohexanone (Scheme 2.13) to give the tri-
cyclohexane protected protect 119. 
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Scheme 2.13: Synthesis of 119 via route A. Reagents and conditions: iohexol (1 eq.), 
cyclohexanone, CuSO4 anhydrous (2 eq.), TsOH (0.2 eq.), 85 
o
C, 6 days, 12%. 
 
The reaction was followed by mass spectroscopy and took 6 days, longer than the 
acetonide reaction (2 days). Despite the longer reaction time the tri-cyclohexane 
protected product 119 was isolated pure after chromatography (Figure 2.32).   
 
Figure 2.32: Mass spectroscopy of 119 via route A 
 
119 (CuSO4) Was tested for solubility in ethyl cyanoacrylate 37, however displayed 
none. For comparison 119 was also synthesised via route B, firstly 1,1-
dimethoxycyclohexane was synthesised from cyclohexanone
192
 (Scheme 2.14).  
 
Scheme 2.14: Synthesis of route B starting material 121. Reagents and Conditions: cyclohexanone 
(1 eq.), trimethyl orthoformate (2 eq.), ZnCl2 (0.1 eq.), methanol, reflux, 4 days, 73%. 
Tri [M+Na]
+
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The product 121 was reacted with iohexol 55 via route B to give 119 in 69% yield 
(Scheme 2.15). The reaction was complete in 24 h which is significantly faster than 
via route A. As before it was shown to be pure by mass spectroscopy of 119 (Figure 
2.33), however the product still showed no solubility in cyanoacrylate. 
 
Scheme 2.15: Synthesis of 119 via route B. Reagents and conditions: iohexol (1 eq.), TsOH (0.2 
eq.), 1,1-dimethoxycyclohexane (4 eq.) DMF, r.t., 24h, 69%. 
 
 
Figure 2.33: Mass spectroscopy of 119 via route B 
 
In this case the products from the different routes behaved similarly in their 
solubility in ethyl cyanoacrylate 37. Therefore the difference between the two 
acetonide products 116 (CuSO4) and 116 (TsOH) does not seem to be due to the 
method used to make them.  
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Five membered rings: 
In order to see whether the difference in solubility for the acetonide reaction was an 
anomaly the cyclopentane protected product 124 was also synthesised via both 
routes. However, when route A (CuSO4) was attempted using cyclopentanone none 
of the desired product 124 was produced. Several attempts with varying conditions 
were made including adding DMF to the reaction mixture to try and increase the 
solubility of the starting material 55. It was possible to prepare 124 however, using 
method B. Firstly, 1,1-dimethoxycyclopentane was synthesised from cyclopentanone 
122 using ZnCl2 as a Lewis acid catalyst
192
 (Scheme 2.16). Secondly, reaction with 
55 and catalytic TsOH in DMF gave 124 in 38% yield after purification (Scheme 
2.17). 
 
Scheme 2.16: Synthesis of route B starting material 123. Reagents and Conditions: cyclopentanone 
(1 eq.), trimethyl orthoformate (2 eq.), ZnCl2 (0.1 eq.), methanol, reflux, 4 days, 41% 
 
 
Scheme 2.17: Synthesis of 124 via route B. Reagents and conditions: iohexol (1 eq.), TsOH (0.2 eq), 
1,1-dimethoxycyclopentane (4 eq.) DMF, r.t., 30h, 38%. 
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Disappointingly product 124 displayed no solubility in ethyl cyanoacrylate 37. 
Neither of the cyclic protected products 119 and 124 were soluble in ethyl 
cyanoacrylate 37, meaning that increasing molecular weight does not increase 
solubility. Overall the best candidate for the protection of iohexol 55 is the hexa-
acetate product 110. 
 
2.2.3 Modification of iodixanol 58 
 
Iodixanol 58 trade name Visipaque (Figure 2.34), is another known contrast agent, it 
is the dimer form of iohexol 55 and has nine free hydroxyl groups. This means there 
are more sites to functionalise, which will hopefully help to increase the solubility in 
cyanoacrylate further with comparison to iohexol 55. However, the lack of solubility 
of the related cyclic compounds of iohexol (119 and 124) indicate that it is likely that 
that the amide and aryl iodide groups are also contributing to the insolubility in 
common organic solvents and that protection of the many hydroxyl groups 
themselves will not be sufficient to impart great solubility in organic solvents. 
 
Figure 2.34: Contrast agent iodixanol 58 
 
As acetate 110 and acetonide protection 116 of iohexol 55 resulted in an increase in 
solubility, both groups were added to iodixanol 58 in a bid to increase solubility 
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further. Firstly, 58 and iodine were combined in acetic anhydride at r.t. for six days 
to give 125 in 76% yield after purification (Scheme 2.18). 
 
Scheme 2.18: Acetate protection of iodixanol 58. Reagents and Conditions: iodixanol (1 eq.), 
iodine (0.1 eq.), acetic anhydride, r.t., 6 days, 76%. 
 
Mass spectroscopy (Figure 2.35) showed all nine hydroxyl groups had been 
functionalised. When tested 125 showed 5% solubility in ethyl cyanoacrylate 37 
causing no polymerisation. This is less than the iohexol equivalent 110 (15%), 
suggesting that the increase in molecular weight and number of reactive sites is 
lowering solubility. 
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 Figure 2.35: Mass spectroscopy of 125 
  
Acetonide protection of iodixanol 58 was also attempted, via route A and B. 
However as with cyclopentanone attempts, route A failed to produce any of the 
desired product 126, despite solubilising the starting material 58 with DMF and 
increasing the reaction times and temperature. Despite this 126 was successfully 
synthesised via route B (Scheme 2.19). 
 
Scheme 2.19: Synthesis of 126 via route B. Reagents and Conditions: iodixanol (1 eq.), TsOH (0.5 
eq.), 2,2-dimethoxypropane (6 eq.), DMF, r.t., 24h, 33%. 
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The product 126 however showed no solubility in ethyl cyanoacrylate 37. Therefore 
overall it can be concluded that iodixanol 58 is not as good a candidate for 
modification than iohexol 55. After much investigation it is clear that the acetate 
protected iohexol 110 is the only viable option for incorporation into cyanoacrylate 
adhesive for use in medical devices.  
 
2.2.4 Partition Coefficient 
 
So far all the solubilities have been judged by observing the maximum amount of 
contrast agent able to dissolve in ethyl cyanoacrylate monomer 37 by % weight; in 
order to quantify these values the partition coefficient for each contrast agent was 
calculated. The partition coefficient Pow is the ratio of concentrations of a compound 
in two immiscible phases, commonly octanol and water. Therefore Pow is a measure 
of the difference in solubility of the compound in the two liquids. In other words 
how hydrophobic or hydrophilic the compound is. The Pow was calculated using the 
‘shake flask method’ with octanol and water.193 Analytical grade n-octanol and 
double distilled water were used, and both were first mutually saturated at r.t. by 
shaking equal amounts of both liquids on a mechanical shaker for 24 h. This was 
poured into a separating funnel and allowed to settle, water was let out the bottom 
and octanol poured out of the top to prevent contamination once separated.  
 
To measure the Pow for each sample 2 mL of water and 2 mL of octanol were added 
to a vial and 0.02 g of sample added before the sealed tube was shaken by hand for 
10 minutes. After which the contents were allowed to settle for 1 h and then 
separated in the same way as the saturated liquids. The absorbance of each sample 
was measured in water and octanol at 240 nm. By using pre-determined calibration 
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graphs the concentration in each layer was calculated (See Appendix). Pow is 
determined by dividing the concentration in octanol by the concentration in water. 
Pow is dimensionless and is usually given in the form of log Pow, a high Pow is 
considered hydrophobic and a low Pow is hydrophilic. 
 
The shake flask method was applied to each of the protected contrast agents and then 
the absorbance measured for both the octanol and water layers so that the Pow could 
be calculated, (Table 2.2).  
Entry Sample Octanol Water Pow Log Pow 
A Conc. A Conc. 
 iohexol adducts       
1 acetate 110 2.95 0.046 1.29 0.003 15.3 1.19 
2 pentyl 111 2.75 0.032 2.09 0.013 2.5 0.39 
3 acetonide 116 (CuSO4) 2.76 0.032 2.28 0.016 2.0 0.30 
4 acetonide 116 (TsOH) 2.65 0.028 2.13 0.014 2.0 0.30 
5 6 ring 119 (CuSO4) 2.96 0.046 2.82 0.021 2.2 0.34 
6 6 ring 119 (TsOH) 2.80 0.034 2.15 0.014 2.4 0.39 
7 5 ring 124 (TsOH) 2.76 0.032 2.25 0.015 2.1 0.33 
        
 iodixanol adducts       
8 acetate 125 2.15 0.008 2.52 0.004 1.9 0.27 
9 acetonide 126 (TsOH) 2.11 0.008 2.57 0.004 1.8 0.26 
        
 diatrizoic acid adducts       
10 butyl ester 103 0.86 0.001 1.58 0.007 0.2 -0.81 
11 octyl ester 104 1.00 0.001 1.08 0.003 0.4 -0.42 
12 methyl ester 102 1.11 0.002 1.29 0.005 0.3 -0.51 
Table 2.2: Log Pow of protected contrast agents 102 – 126 
 
The only sample to give a high Pow and therefore to be more hydrophobic than the 
others is entry 1, the acetate protected iohexol 110. This follows the pattern of the 
solubility tests as 110 was the most soluble in ethyl cyanoacrylate. Entries 3 and 4 
show the acetonide protected iohexol 116 (CuSO4) and 116 (TsOH). These two 
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products, although appearing the same, gave differing results when tested for 
solubility in ethyl cyanoacrylate. However they each gave the same Pow showing 
them to both be hydrophilic. This result is pleasing in one respect and not in another.  
Firstly, the fact that both give the same Pow gives some credence to the theory that 
their differing solubility in ethyl cyanoacrylate is due to different morphologies.  
This difference would be negated once dissolved in the water used for the partition 
coefficient test. However, the fact that 116 (CuSO4) was soluble in ethyl 
cyanoacrylate but has a relatively low Pow value of 2.0 (lower than all the other ketal 
products that did not dissolve, entries 5-7) is worrying. This suggests that the 
octanol/ water Pow isn’t an exact model for how compounds will behave in ethyl 
cyanoacrylate. Pow is used to tell how hydrophilic or hydrophobic a compound is and 
therefore suggests whether it will be soluble in organic media or water. However 
octanol is very different to ethyl cyanoacrylate adhesive and so can only be used as a 
guide. 
 
The samples to give the lowest Pow and therefore to be very hydrophilic, were the 
diatrizoic acid analogues 102, 103 and 104, entries 10-12. These compounds showed 
no solubility in ethyl cyanoacrylate or several organic solvents. The two iodixanol 
adducts 125 and 126, entries 8 and 9, give the same low Pow showing them both to be 
hydrophilic. However although the acetonide product 126 (entry 9) showed no 
solubility in ethyl cyanoacrylate, the acetate compound 125 (entry 8) showed 5% 
solubility. This difference isn’t reflected in their Pow, though it is only a small 
difference and the octanol/water model can only be used as a guide.  
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2.2.5 X-ray analysis of 110 in ethyl cyanoacrylate 
 
Contrast agents diatrizoic acid 56, iohexol 55 and iodixanol 58 were successfully 
modified with a number of different protecting groups. The most soluble in ethyl 
cyanoacrylate was the acetate protected iohexol 110. This was the most viable 
candidate for incorporation into a cyanoacrylate medical product. However for it to 
be of use in the body, it needs to be able to be followed by X-ray.  Proof was needed 
to show that 110 was an efficient X-ray contrast agent within the adhesive structure. 
The acetate protected product 110 was dissolved in ethyl cyanoacrylate (10-18% 
w/w in 1% gradations). Mixtures containing over 15% w/w of 110 did not fully 
dissolve in these tests and contain un-dissolved product. X-ray images of the vials 
were then taken (Figure 2.36). 
 
Figure 2.36 X-ray images of acetate product 110 in cyanoacrylate 
 
The vials can be clearly seen on the X-ray, the darker the contents the more contrast 
the glue is displaying. The vials with 15% or more acetate product 110 show up 
10 – 14% 
15 – 18% 
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black in the X-ray, therefore 110 can be incorporating into the glue in sufficient 
amounts to give good contrast. 
 
2.3 Conclusion 
 
In conclusion, ethyl cyanoacrylate adhesive was proposed as an alternative to coiling 
for the treatment of brain aneurysms. In order to be able to dispense the adhesive in 
the correct location it needed to be visualised within the body. Hence the need to 
incorporate a contrast agent into the glue, however existing contrast agents do not 
dissolve in ethyl cyanoacrylate. Three existing imaging agents 55, 56 and 58 were 
modified with a range of hydroxyl protecting groups with different degrees of 
success. Solubility testing revealed that iohexol 55 was the best agent for 
modification, with three protected products 110, 111 and 116 showing significant 
solubility in ethyl cyanoacrylate. The best solubility was displayed by 110, this also 
had the biggest Pow. 110 was incorporated in ethyl cyanoacrylate monomer and this 
was allowed to polymerise.  After polymerisation the material was tested for contrast 
with X-rays and it was shown that it would show up in the body. The product 110 
gave good contrast and thus is a viable candidate to be used in the body for treatment 
of brain aneurysms.   
 
Diatrizoic acid 56 and iodixanol 58 were discounted as they were more problematic 
to protect and the products that were successfully synthesised did not show enough 
solubility, if any in ethyl cyanoacrylate. 
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3.0 - Anthracene Protected Route for Synthesis of Cyanoacrylates 
 
3.1 Introduction 
 
Alkyl cyanoacrylates 16 (Figure 3.1) have been utilised as adhesives for a number of 
years, across a wide range of industries.
194
 These compounds are highly adhesive and 
polymerise in the presence of a weak base such as water or alcohol due to the 
presence of two strong electron withdrawing groups. 
 
Figure 3.1: Alkyl cyanoacrylate 16 
 
Alkyl cyanoacrylates 16 have been developed for use as biological adhesives, and 
are currently used in preference to stitches for superficial external lacerations.
61
 
However, cyanoacrylate skin glues have their disadvantages; cyanoacrylates degrade 
to release formaldehyde, and this can lead to irritation and inflammation of adjacent 
tissues. Previous studies have shown that poly(ethyl cyanoacrylate) P(ECA), 
degrades to give formaldehyde faster than poly(octyl cyanoacrylate) P(OCA) and 
poly(2-octyl cyanoacrylate) P(2-OCA).
48
 Thus it has been suggested that the ester 
group of the cyanoacrylate 16 can directly affect the rate of degradation by steric 
hindrance at the ester. By changing the R group it may be possible to slow the rate of 
degradation further and therefore decrease the amount of formaldehyde released in 
vivo.  In this chapter this concept will be discussed.  
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3.1.1 Synthesis of cyanoacrylates 
 
There are a number of known routes for the synthesis of cyanoacrylate monomers, as 
described previously.
195
 Anthracene 46a has been used in previous syntheses as a 
protecting group, trapping the reactive cyanoacrylate monomer 16. Anthracene 46a 
undergoes a cycloaddition with the cyanoacrylate 16 to give a stable Diels-Alder 
adduct 45. The anthracene protecting group can be easily removed from 45 via a 
retro-Diels-Alder reaction to release the cyanoacrylate monomer 16, (Scheme 3.1).  
 
Scheme 3.1: Diels-Alder cycloaddition of anthracene 46a 
 
3.1.2 Diels-Alder reactions of anthracene 46a 
 
Anthracene 46a is a polycyclic aromatic hydrocarbon and was first isolated from 
coal tar in 1833. It has since been utilised for a diverse range of applications 
including preparation of alizarin dyes to electroluminescent devices.
195
 There has 
been a large amount of chemistry developed for the functionalisation and 
modification of anthracene’s aromatic ring system, in particular cycloadditions. The 
stereochemistry of the reaction involves exclusive cis addition of the dienophile to 
the anthracene 46a and retention of the dienophile stereochemistry in the product.
196
 
This retention of stereochemistry postulates a concerted mechanism, as for a two 
step mechanism to occur with retention of stereochemistry, the second step would 
have to be significantly faster than the rotation about the C-C σ bond formed in the 
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intermediate. The concerted mechanism involves forming two σ bonds 
simultaneously either by direct addition, or via an intermediate charge-transfer 
complex.
197
 It has been observed by many studies that a transient colour is produced 
and disappears as the Diels-Alder reaction of anthracene 46a proceeds. This has been 
attributed to the formation of a charge-transfer complex and therefore supports a 
concerted mechanism.
198
 Several studies of Diels-Alder reactions of anthracene 46a 
have investigated the solvent effect on the reaction rate.
199–201 
In some cases electron 
accepting solvents have been shown to increase the rate of reaction by stabilising the 
electron rich transition state.
201,202
 Aromatic solvents have been shown to produce an 
increase in reactivity with dienophiles that are capable of very strong charge-transfer 
interactions.
199 
However in general the influence of solvent on rate of reaction is 
relatively small. The rate of the Diels-Alder reaction of anthracene 46a appears 
instead to be governed more by temperature and substituent effects in the 
dienophile.
203,204 
 Lower temperatures and excess of dienophile can increase forward 
reactions rate, while higher temperatures favour the retro Diels-Alder, (Scheme 
3.2).
205
  
 
Scheme 3.2: Equilibrium reaction between anthracene 46a and ethyl cyanoacrylate 37 
 
9-10-Dimethyl anthracene has been shown to lead to a greater rate enhancement in 
the reaction with maleic anhydride than anthracene 46a itself,
206
 while electron 
withdrawing substituents on the dienophile can also effect the rate by lowering the 
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LUMO and  changing its ability to accept π electrons.207 The types of dienophiles 
used in Diels-Alder reactions of anthracene 46a fall into four classes; (i) α, β-
unsaturated carbonyls, (ii) alkenes attached to a heteroatom or halogen, (iii) alkenes 
and alkynes and (iv) heterodienophiles.  
 
The first reported cycloaddition of anthracene 46a was a fusion reaction (Scheme 
3.3) between anthracene 46a and maleic anhydride 47 in 1931,
208
 later it was shown 
that the same adduct 48a could be achieved by heating a solution of the two reactants 
in xylene.
209
 Reaction of anthracene 46a with various maleic anhydride type 
dienophiles is one of the most studied reactions of anthracene.
210–214
  
 
Scheme 3.3: Fusion reaction between anthracene 46a and maleic anhydride 47 
 
The first Diels-Alder reaction of anthracene with a monosubsituted alkene (Scheme 
3.4) was carried out with 1-nitroethene. The reaction was used in the preparation of 
1,1-disubstituted nitroalkenes 130 which were released after the decomposition of 
the modified adduct 129.
215–217
 The high reactivity of the nitro groups enabled the 
use of relatively mild conditions for these reactions; toluene, 110 
o
C, 3 h.
218
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Scheme 3.4: Preparation of new highly substituted nitroalkenes 130
195
 
 
This is an example of how the Diels-Alder reaction of anthracene 46a can be used to 
functionalise reactive alkenes by ‘trapping’ the reactive functionality as stable 
cycloadducts. Subsequent release of the 130, after modification can be carried out 
using a retro-Diels-Alder reaction.
219
 Anthracene 46a has been employed in a similar 
manner as a protecting group in the synthesis of natural products, in particular as 
protecting groups for benzoquinone, N-methyl maleimide and methyl acrylate.
211,220
 
This approach will be used to prepare a range of novel cyanoacrylates for testing as 
adhesives and measure the degree of formaldehyde release during degradation as a 
function of structure. 
 
3.2 Development of anthracene protected route using ethyl acrylate 131 
 
It was decided to prepare a range of novel cyanoacrylates differing in the ester group 
using an anthracene Diels-Alder protection/ chemical transformation/ retro-Diels-
Alder deprotection strategy. The chemistry had to be amenable to a large scale 
process (small amounts monomers/ polymers initially would be sufficient for the 
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study but ultimately it needs to be amenable to a multi Kg batch process) and 
consequently, it was decided to keep chromatography to a minimum.  Before 
embarking on chemistry with the highly reactive cyanoacrylates the protocols were 
optimised by examining the reaction of the easier to handle ethyl acrylate 131. Once 
all steps were established the procedure could be applied to cyanoacrylates. Heating 
ethyl acrylate 131 with anthracene 46a in refluxing xylene for 24 h furnished the 
protected anthracene adduct 132, (Scheme 3.5). 
 
Scheme 3.5: Synthesis of anthracene adduct 132. Reagents and Conditions: anthracene 46a (1 eq.), 
ethyl acrylate 131 (1.1 eq.), MEHQ (0.1 eq.), xylene, reflux, 24h, 96%. 
 
The crude 400 MHz 
1
H NMR showed 10% un-reacted anthracene 46a. Attempts to 
remove the excess anthracene by recrystallization using a variety of solvents 
(hexane, petrol, petrol/ EtOAc etc.) did not lead to pure 132. As the left over 
anthracene 46a was likely to be un-reactive in the further steps, the decision was 
taken to react 132 on crude. The next step undertaken was to hydrolyse the ester 132 
to the corresponding carboxylic acid 133 in order to allow further functionalisation. 
The literature conditions
221
 of a single equivalent of lithium hydroxide at r.t. gave no 
reaction, even after several days. Potassium carbonate in methanol and water was 
also tested as an alternative method however after four days heating at 65 ˚C there 
was still less than 50% conversion to 133. Finally heating at reflux in THF: H2O 
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with four equivalents of lithium hydroxide for 24 h proved successful, giving acid 
133 in 68 % yield (Scheme 3.6). 
 
Scheme 3.6: Ester hydrolysis to give carboxylic acid 132. Reagents and Conditions: 132 (1 eq.), 
LiOH (4 eq.), THF: H2O, 5: 4, reflux, 24 h, 68%. 
 
The carboxylic acid 133 was then reacted with thionyl chloride at reflux for 6 h to 
give the crude acyl chloride 134 which was reacted in-situ with various alcohols in 
ether with pyridine as base to give a range of esters 135a-e in 12-81% yield.  
(Scheme 3.7). These alcohols were chosen as they were readily available and 
represented various steric sizes.   
 
Scheme 3.7: Esterification of carboxylic acid 133. Reagents and Conditions: i) 133 (1 eq.), excess 
thionyl chloride, reflux, 6 h, ii) ROH (1.1 eq.), pyridine (1.1 eq.), Et2O, r.t., 24 h, 12 – 81%. 
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The final step of the anthracene protected route is to remove the anthracene via a 
retro-Diels-Alder reaction and thus yield the new acrylate monomer. Two possible 
methods were identified for this reaction; firstly heating the anthracene adduct in the 
presence of maleic anhydride 47.
39 
This was tried on the anthracene adduct 132 as 
there was a large amount available, this was the crude sample that contained 10% 
un-reacted starting material 46a (Scheme 3.8). The reaction was heated in xylene 
with an excess of maleic anhydride 47 (3 equivalents) in the presence of 
hydroquinone and phosphorous pentoxide and followed by 400 MHz 
1
H NMR over 
4 days.
 
 
Scheme 3.8: Retro-Diels-Alder reaction – maleic anhydride method. Reagents and Conditions: 
132 (1 eq.), maleic anhydride 47 (3 eq.), hydroquinone (0.5 eq.), phosphorus pentoxide (0.5 eq.), 
xylene, reflux, 4 days. 
 
During this time it was observed that the peaks for the un-reacted anthracene 46a 
were disappearing from the NMR but the peaks for the adduct 132 remained. This 
suggests the maleic anhydride 47 was reacting with the un-reacted anthracene 46a 
but not with any anthracene liberated from the retro-Diels-Alder reaction (Figure 
3.2).  
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Figure 3.2: NMR monitoring of retro-Diels-Alder via maleic anhydride method 
 
This suggested that refluxing xylene was not a high enough temperature to initiate an 
efficient retro-Diels-Alder process of 132. The second method involved heating 
anthracene adduct 132 under vacuum to temperatures of 200 
o
C and above
222
 
(Scheme 3.9). This method has the advantage that the starting material 46a is 
regenerated meaning the overall process may be suitable for continuous flow 
techniques.  
 
Scheme 3.9: Retro-Diels-Alder reaction – heating method. Reagents and Conditions: 132 (1 eq.), 
heat under vacuum 200 
o
C+ 
Starting Material 132  
After 4 days 
Anthracene/ maleic 
anhydride adduct 58 Hb 
Hb 
Ha 
Ha 
Anthracene 
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Several methods were examined including conventional vacuum distillation and 
Kugelrohr apparatus, but although this latter method showed signs of success it was 
also problematic. Due to the volatility of the acrylate monomer 131 liquid nitrogen 
was required to trap the product, but even this was not efficient and in general it was 
only possible to trap small quantities of ethyl acrylate 131. 
 
No acrylate monomer 131 was observed from the maleic anhydride method and only 
trace amounts were seen from the direct heating method. Problems with both 
methods were encountered due to the high volatility of ethyl acrylate 131 and the 
high temperature that it was formed at making efficient condensation difficult with 
the standard apparatus in the lab. However, cyanoacrylates themselves are less 
volatile than acrylates and so this last step should be less problematic with them.  
Having optimised the first four steps on ethyl acrylate 131 attentions turned to the 
desired cyanoacrylate monomers.  
 
3.2.1 Anthracene protected route optimisation with cyanoacrylate 
 
The previously established anthracene protected route can now be applied to the 
synthesis of novel cyanoacrylates. Methyl cyanoacrylate 136 was selected as the 
starting point due to its low cost and large scale availability.  Heating a slight excess 
of methyl cyanoacrylate 136 (1.1 equivalents) with anthracene 46a at reflux in 
xylene produced the Diels-Alder adduct 137. However on a large scale (500 g) 
removing the xylene in vacuo proved extremely difficult and time consuming. In 
order to remove the xylene sufficiently it was necessary to concentrate in vacuo 137, 
wash with hexane, filter and dry in a vacuum oven at 50 
o
C (10 mbar). However, this 
would not be viable on a large scale, thus xylene was substituted for toluene due to 
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its similar properties but lower boiling point, 110 
o
C, and this proved much easier to 
remove (Scheme 3.10). The lower temperature was still sufficient for efficient Diels-
Alder reaction providing 137 in 92% yield after 24 hours at 110 ˚C. 
 
Scheme 3.10: Synthesis of anthracene adduct 137. Reagents and Conditions: anthracene 46a (1 
eq.), methyl cyanoacrylate 136 (1.1 eq.), MEHQ (0.1 eq.), toluene, reflux, 24 h, 92% crude.  
 
As with ethyl acrylate 131 the reaction gave the anthracene adduct 137 in high yield 
but once again the crude material contained some un-reacted anthracene 46a. 
However, with methyl cyanoacrylate 136 there was only approximately 5% 
anthracene 46a remaining (by 400 MHz 
1
H NMR) compared to the 10% with ethyl 
acrylate 131. Thus the Diels-Alder / retro-Diels-Alder equilibrium favours the adduct 
137 more for cyanoacrylate 136 than 132 with ethyl acrylate 131. As before the 
synthesis was continued without removing the remaining anthracene 46a. In an 
attempt to make the synthesis more industrially attractive, lowering the temperature 
of the Diels-Alder reaction was briefly investigated. The reaction between 
anthracene 46a and methyl cyanoacrylate 136 was carried out at both r.t. and 40 
o
C 
in d8-toluene and followed by 
1
H NMR. At r.t. there was still 40% un-reacted 
anthracene 46a after 7 days (Figure 3.3). While at 40 
o
C the reaction reached 95% 
completion in 3 days (Figure 3.4) compared to 24 h for the same result in refluxing 
toluene. 
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Figure 3.3: 
1
H NMR of reaction between anthracene 46a and methyl cyanoacrylate 136 at r.t.  
 
Figure 3.4: 
1
H NMR of reaction between anthracene 46a and methyl cyanoacrylate 136 at 40 
o
C 
40 
o
C 
0 h 
1 day 
3 days 
r.t. 
46a 
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With the desired adduct 137 in hand (780 g) next the hydrolysis reaction to give the 
carboxylic acid 49 was investigated. Using the protocol determined in the reaction of 
the ethyl acrylate derivative 131 gave the desired carboxylic acid 49 in 68% yield. 
However an alternative method,
39
 KOH in refluxing ethanol, was found to give the 
desired product in 98% crude yield and with much shorter reaction times. This is 
much more suitable for an industrial process due to its shortened reaction time, 
increase in yield and simple filtration work-up.  
 
3.2.2 Synthesis of anthracene esters 
 
The carboxylic acid 49 was then reacted with various different alcohols to give a 
range of anthracene protected esters 138a-d, 139a-f, and 140a-c. It was necessary to 
synthesise a series of anthracene esters in order to produce a series of cyanoacrylate 
monomers for direct comparison of formaldehyde release from their polymers. The 
first series of anthracene esters was the C4 isomers 138a-d chosen to assess the effect 
of steric congestion on the formation of formaldehyde, (Figure 3.5). 
 
Figure 3.5: Anthracene esters 138a-d - C4 isomer series 
 
In addition, a range of phenolic esters 139a-f were synthesised from p-substituted 
phenols (Figure 3.6). This series was chosen to incorporate both electron 
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withdrawing (Cl, NO2, CF3) and electron donating groups (CH3, OMe) to probe the 
electronic effect on formaldehyde production. 
 
Figure 3.6: Anthracene esters 139a-f – p-substituted phenol series 
 
Polymer adhesives can also theoretically decompose via hydrolysis of the ester 
groups to liberate poly(cyanoacrylic acid), although this is likely to be slow at 
physiological pH with alkyl ester derivatives 138a-d it will be easier with phenyl 
ester derivatives 139a-f. Also prepared was a range of simple sterically hindered 
esters that could liberate antiseptic molecules 140a-c (e.g. 2,4,6-trichlorophenol and 
(-)-menthol), (Figure 3.7) upon hydrolysis. The 2,6-dimethoxy-6-methyl phenol 
derivative 140c was also prepared as an electron rich version of 140a.   
 
Figure 3.7: Anthracene esters 140a-c– tri-substituted phenols and antiseptic compounds 
  
The esters were prepared as before. Hence, refluxing acid 49 with thionyl chloride 
for 6 h followed by the removal of excess thionyl chloride on a rotary evaporator 
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gave the crude acid chloride 50. Addition of the appropriate alcohol or phenol to this 
acid chloride in chloroform furnished the desired adducts 138-140 in yields ranging 
from 6-65%, (Table 3.1), (Scheme 3.11). 
 
Scheme 3.11: Esterification of carboxylic acid 49. Reagents and Conditions: i) 49 (1 eq.), SOCl2, 
reflux, 6h, ii) p-nitro phenol (1.5 eq.), pyridine (1.1 eq.), chloroform, reflux, 36 h, 65%.  
 
Anthracene ester Reaction time (days) % yield 
138a 1.5 6 
138b 1.5 25 
138c 1.5 50 
138d 7 23 
139a 1.5 38 
139b 1.5 48 
139c 2 42 
139d 3 37 
139e 1.5 65 
139f 1.5 50 
140a 4 28 
140b 1.5 38
a
 
140c 4 31 
Table 3.1: Reaction times and % yields for synthesis of anthracene esters 138-140 
a
compound as a mixture of two inseparable diastereisomers (1:1) 
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3.2.3 Direct trans-esterification method 
 
While it was possible to prepare the desired esters using the 4 step protocol outlined, 
it would be industrially more attractive to transform the initial ester 137 to the 
desired esters 138a by a one-step trans-esterification process rather than via the 
carboxylic acid 49. This would shorten the route significantly. Initially the reaction 
between methyl ester 137 and n-butanol was investigated, using p-toluenesulfonic 
acid as an acid catalyst and an excess of n-butanol as solvent to drive the equilibrium 
towards the desired adduct 138a. The reaction was undertaken using a distillation 
head to remove the methanol produced and thus push the equilibrium towards 
product 138a (Scheme 3.12). 
 
Scheme 3.12: Direct trans-esterification of 137. Reagents and Conditions: 137 (1 eq.), TsOH (0.5 
eq.), n-butanol (excess), reflux, 2 days 43%. 
 
Figure 3.8: 
1
H NMR of crude n-butyl anthracene adduct 138a produced via a trans-
esterification approach 
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Although the method yielded the desired product 138a, it was not possible to get the 
reaction to go to completion even after 2 days (35% starting material 137 remained 
as determined by 400 MHz 
1
H NMR, Figure 3.8). In addition, while this example 
used n-butanol as both the reagent and solvent to help in developing a favourable 
equilibrium, for the other desired alcohols (many of which were solids) this would 
not be possible.  
 
3.3 Retro-Diels-Alder 
 
The first three steps of the anthracene protected route determined from the initial 
work with ethyl acrylate 131 transferred easily to the cyanoacrylates with only slight 
modifications. The final step is the retro-Diels-Alder to remove the anthracene 46a 
protecting group and liberate the highly reactive novel cyanoacrylates 138-140. The 
n-butyl protected ester 138a was used to optimise this step as the butyl cyanoacrylate 
monomer 29 liberated is a known compound and therefore its physical properties 
such as boiling point are already in the literature allowing easy identification.
223
 
Once the final step had been successfully optimised this route would then be used to 
generate the complete series of cyanoacrylate monomers 141-143. 
 
The two methods used previously for the ethyl acrylate adduct 131 were re-
investigated for cyanoacrylate adduct 138a. Firstly the use of high temperatures and 
vacuum to activate the retro-Diels-Alder reaction (Scheme 3.13). Extreme 
temperatures were achieved by heating with a hot air pistol. At 138 
o
C (3 mbar) a 
colourless liquid distilled which was confirmed by 400 MHz 
1
H-NMR to be the 
desired n-butyl cyanoacrylate 29, thus the retro-Diels-Alder step can be carried out 
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using only heat and vacuum. This would be beneficial for an industrial process as it 
has potential for use in a continuous flow reactor, with the anthracene starting 
material being regenerated and recycled.      
 
Scheme 3.13: Retro Diels-Alder reaction – heating method. Reagents and Conditions: 138a (1 
eq.), heat under vacuum 200 
o
C +, 23%. 
 
The second approach heats the anthracene adduct in the presence of maleic 
anhydride 47. When this method was attempted with the ethyl acrylate adduct 131 
none of the desired product was observed. For this reason the reaction was firstly 
carried out in d6-benzene at 80 ˚C in order to monitor the reaction by 
1
H NMR. Butyl 
anthracene adduct 138a was refluxed in the presence of maleic anhydride 47 for four 
days, however it appeared that no reaction had occurred by 
1
H-NMR. The reaction 
was repeated in xylene at 140 ˚C for 2 days in order to determine whether a higher 
reaction temperature was required for the substitution reaction to occur (Scheme 
3.14). After 48 h the reaction was removed from the heat and benzene was added to 
precipitate out the anthracene maleic anhydride adduct 48a, this was filtered off 
leaving butyl cyanoacrylate 29 in solution. The main impurity was small amounts of 
the anthracene maleic anhydride adduct 48a that didn’t precipitate out, this can be 
removed by distillation to give 29 as a colourless liquid (Figure 3.9). 
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Scheme 3.14: Retro Diels-Alder reaction – maleic anhydride method. Reagents and Conditions: 
138a (1 eq.), maleic anhydride 47 (3 eq.), hydroquinone (0.5 eq.), phosphorus pentoxide (0.5 eq.), 
xylene, reflux, 48 h, 10%. 
 
Figure 3.9: 
1
H NMR of n-butyl cyanoacrylate 29 
 
In this case while the anthracene starting material 46a was not recycled and the 
reaction time was longer than the vacuum method it required less harsh conditions 
e.g. lower temperatures, and the majority of by-product 48a was precipitated out 
from the desired cyanoacrylate monomer. Thus it was decided to carry out the retro-
Diels-Alder reaction using the maleic anhydride protocol on all anthracene esters 
138-140 yielding a variety of cyanoacrylate monomers 141-143 (Figure 3.10) in 
yields ranging from 18-63%.   
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Figure 3.10: Cyanoacrylate monomers 141-143 
 
3.4 Polymer degradation  
 
As previously stated, cyanoacrylate polymers 24 can degrade to liberate 
formaldehyde. Mechanistically this has been proposed to occur via nucleophilic 
displacement of a monomer group with hydroxide followed by base catalysed retro-
Kneoevenagel reaction to give 25 and 21 (Scheme 3.15). It is likely that two factors 
can control the rate of this process. Firstly, the steric environment around the 
reacting carbon atom will affect the ability of hydroxide to mediate the first step and 
secondly the stability of the released anion 21 (pKa of malonic ester derivative) will 
be important in both steps.  
 
Scheme 3.15: Degradation of cyanoacrylate polymer 24 
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The acetyl acetone (acac) method first published by Nash in 1953
224
 is a widely 
applied standard procedure for the analysis of formaldehyde. The method is based on 
the Hansch reaction which involves the cyclisation of 2,4-pentanedione (acac) 144, 
ammonium acetate 145 and formaldehyde 28 at 60 
o
C (Scheme 3.16). The resulting 
product is the highly fluorescent dihydropyridine 3,5-diacetyl-1,4-dihydrolutidine 
146 which can be detected by UV-vis spectroscopy at 412 nm.
225
  
 
Scheme 3.16: Reaction of formaldehyde 28 with 2,4-pentanedione 144 
 
Release of formaldehyde from poly(ethyl cyanoacrylate) P(ECA), poly(octyl 
cyanoacrylate) P(OCA) and poly(2-octyl cyanoacrylate) P(2-OCA) have been 
studied previously using the acac method. It has been reported that higher alkyl poly-
cyanoacrylates exhibited less tissue toxicity because they degrade and release 
formaldehyde slowly.
226
 Degradation studies performed at 85 
o
C under accelerated 
conditions showed P(ECA) released significantly higher levels of formaldehyde than 
P(OCA) and P(2-OCA); 90 μg/mL over 7 days compared to 50 μg/mL (Figure 
3.11).
227
 P(OCA) and P(2-OCA) gave very similar results suggesting little difference 
between the secondary and the primary ester. The production of formaldehyde is 
accompanied by a decrease in the average molecular weight of the polymer. This 
was shown by the change in average molecular weight of P(ECA), from 1427 to 990 
when the polymer was dissolved in 95% acetonitrile, 5% water solution and heated 
to 80 
o
C for 24 h.   
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Figure 3.11: Release profile of formaldehyde from P(ECA), P(2-OCA) and P(OCA)
227
 
 
3.4.1 Detection of formaldehyde in the decomposition of novel cyanoacrylate 
polymers P141-P143 
  
The monomers 141-143 produced in section 3.3 were polymerised by the addition of 
water (1-2 drops) to give polymers P141a-d, P142a-f and P143a-c. These polymers 
were suspended in water for 28 days at room temperature and the formaldehyde 
liberated measured every 7 days.  The resulting polymers were added to pentane-2,4-
dione reagent 144 (2 eq.), PBS extract solution (0.1 eq.) and PBS solution (0.9 eq.) 
in deionised water (0.05 M). The solution was heated to 60 
o
C for 10 min and then 
cooled in ice for 2 min. The UV absorption at 412 nm was recorded within 20 min of 
removal from the ice. This was carried out after 7, 14, 21 and 28 days from 
polymerisation. The amount of formaldehyde released was calculated using the pre-
determined calibration graph (see appendix).  
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The first series of polymers to be compared were the C4 isomers P141a-d differing 
in their steric hindrance around the ester functionality. All four materials released 
between 50 – 56 µg/mL over the course of the four weeks (Graph 3.1). This was 
intermediate between the ethyl, P(ECA) 90 µg/mL and the octyl P(OCA) 50  µg/mL. 
There were however slight differences between the four polymers, the highest 
amounts of formaldehyde were released by n-Bu and i-Bu cyanoacrylate polymers 
P141a (56 µg/mL) and P141b (55 µg/mL). The lowest amount of formaldehyde and 
hence the slowest to degrade was the t-Bu polymer P141d (50 µg/mL). The order of 
stability (P141d > P141c > P141b > P141a) indicates that the steric environment 
around the ester is important in determining the rate of degradation and that the more 
hindered isomers P141c-d liberate formaldehyde more slowly (although the 
difference between all four materials P141a-d was relatively small). There appears 
to be a change in rate for all the substrates between week 1 and 2 but the low number 
of data points makes this uncertain. 
 
Graph 3.1: Formaldehyde released from polymers P141a-d over 4 weeks 
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In order to monitor the electronic effect on the rate of degradation, a range of para-
substituted phenol polymers 142a-f were compared where the steric parameters were 
similar but the electronic effect on the stability of the malonitrile anion 21 produced 
was significantly different. As before there was relatively little difference between 
the amount of formaldehyde released (44 - 55 µg/mL) but there was an observable 
trend showing electron withdrawing groups provided the best stability towards 
degradation, (Graph 3.2). 
 
Graph 3.2: Formaldehyde released from polymers P142a-f over 4 weeks 
 
The degradation rate (P142f < P142a ~ P142d < P142b < P142c or NO2 < CF3 < H 
~ Cl < Me < OMe) generally parallels the acidity of the malonitrile leaving groups in 
water and the Hammett  para parameters.
228
 The slowest degradation was observed 
by p-NO2 (44 µg/mL) P142e and p-CF3 (48 µg/mL) P142f polymers, two highly 
electronegative groups. The highest levels of formaldehyde were released by the 
electron donating p-OMe P142c (55 µg/mL) and p-Me P142b (52 µg/mL) polymers. 
However p-Cl (50 µg/mL) P142d and phenol (49 µg/mL) P142a gave very similar 
results, showing marginal differences in degradation rates. The order or degradation 
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rate is opposite to that expected based upon the leaving group ability of the 
malonitrile groups. As the polymer degrades the polymer chain is ‘unzipped’ 
generating an anion. The ability of the R group to stabilise this anion through 
delocalisation should affect the rate of degradation. As before there appears to be a 
difference in degradation rate occurring between 1-2 weeks with the electron 
withdrawing derivatives undergoing this change more obviously. This may indicate a 
change in mechanism.  Hydrolysis of the ester groups on the polymers to carboxylic 
acids are more likely to occur with the electron poor phenol esters P142e-f than 
electron rich derivatives P142b-c. Once hydrolysis has taken place to give a 
cyanoacrylic acid group degradation to give formaldehyde is less likely to take place 
at this position on the polymer chain. In addition phenols are known to react with 
formaldehyde to produce phenol formaldehyde adhesives (PF resins) such as 
Bakelite. Liberated phenol could scavenge any formaldehyde produced and this 
might show up in a significant difference in rate of formaldehyde liberation over 
time depending upon the relative rates of hydrolysis verses formaldehyde generation.  
This may be one reason to explain the trend that formaldehyde formation decreases 
with the increasing leaving group ability of the phenol.   
 
Graph 3.3: Formaldehyde released from polymers P142a-f verse Hammett -parameter 
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The final series of polymers P143a-c were those that included R groups with 
medicinal properties (Graph 3.4). The three polymers gave results between 45-55 
µg/mL, this is within the same range as the above phenol series P142a-f.  
 
Graph 3.4: Formaldehyde released from polymers 143a-c over 4 weeks 
 
The slowest degradation was observed for the 2,4,6-trichlorophenol cyanoacrylate 
polymer P143a (45 µg/mL). This is similar to the p-nitrophenol analogue P142e (44 
µg/mL) and slower than the related p-chlorophenol derivative P142d (50 µg/mL). 
This is again confirming the trend that more electron withdrawing substituents lead 
to a decrease in the loss of formaldehyde, (pKa of p-nitrophenol = 7.16, 2,4,6-
trichlorophenol = 6.23, phenol = 9.98,  p-chlorophenol = 9.38 and p -methoxyphenol 
= 10.21).
229
 Comparison with the 2,6-dimethoxy-6-methyl phenol derivative P143c 
containing three electron donating groups confirms this but interestingly for the 
phenol derivatives the electronic effect was more pronounced than any steric effect.  
The rate of formation of formaldehyde from the menthol derivative P143b (50 
µg/mL) parallels that of the t-Bu P141d (50 µg/mL) and s-Bu P141c (52 µg/mL) 
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derivatives. This is not surprising as steric congestion at the - carbon of the ester 
alkoxy group is similar in P143a and P141c-d, as is their pKa’s (t-BuOH = 18, 
Menthol = 19.5).
230
   
 
3.5 Conclusion 
 
A synthetic route using anthracene as a protecting group has been applied to the 
synthesis of acrylate and cyanoacrylate monomers. The proposed route was 
successfully used for the production of novel cyanoacrylate monomers 141a-d, 
142a-f, 143a-c differing in the steric and electronic nature of the ester substituents. 
These monomers were allowed to polymerise in the presence of hydroxyl ions and 
the degradation of the resulting polymers P141a-d, P142a-f, P143a-c was monitored 
using a formaldehyde assay.  
 
Formaldehyde monitoring showed the slowest degradation was observed for the p-
NO2 P142e, p-CF3 P142f and the 2,4,6-trichlorophenol derived P143a polymers 
containing strongly electron withdrawing groups. While polymers with strongly 
electron donating groups e.g. p-methoxy P142c and 2,6-dimethoxy-4-methylphenol 
P143c showed the opposite effect. Interestingly for phenol derivatives the electronic 
effect was more pronounced than any steric effect and was the reverse to that 
expected for the accepted mechanism of formaldehyde formation by retro-
Knoevenagel reaction. Instead the data hints that for esters with good leaving groups 
(e.g. pKa of phenols between 6.2-7.2), competitive hydrolysis may occur over time 
which suppresses formaldehyde build-up by either decreasing the rate of retro-
Knoevenagel reaction or scavenging liberated formaldehyde in situ. For alkyl ester 
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substituents P141a-d with poorer leaving group ability (pka 16-19) then steric 
parameters become dominant, presumably due to decomposition by the accepted 
retro-Knoevenagel pathway. 
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4.0 Substituted Anthracene Investigations: Finding a better anthracene 
derivative for a viable industrial cyanoacrylate process.  
 
4.1 Introduction 
 
Previous investigations have shown the anthracene 46a (R = H) protected route for 
the synthesis of a range of cyanoacrylates 16 was a viable process (Scheme 4.1). 
However the forward Diels-Alder
208
 (46→127) step requires long reaction times 
(depending upon the temperature) and the retro-Diels-Alder step (45→16) is slow, 
low yielding and also requires high temperatures. For any commercial industrial 
process these steps need to be optimised and temperatures lowered as much as 
possible to save on energy costs. For this route to be improved changes need to be 
made in both the first step and the final step.  
 
Scheme 4.1: Route to cyanoacrylates 
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Cycloaddition/retro-cycloaddition sequences are equilibria. For [4+2] cycloadditions 
this equilibrium normally favours the Diels-Alder adduct because of 
thermodynamics, (lose two C=C  bonds and gain two C-C  bonds).
231
 Typically 
therefore retro-Diels-Alder reactions are carried out at high temperatures. Retro-
reactions have been performed at low temperatures but only when one of the retro-
products is either highly volatile or can be trapped out by another species (thereby 
removing it from the equilibrium). Many strategies have been used to facilitate retro-
Diels-Alder reactions at low temperatures, for example the use of a base to 
strategically deprotonate one of the retro-products can bias the equilibrium,
232
 
(Scheme 4.2). The strategy used here employs an excess of maleic anhydride to trap 
out the anthracene product. Anthracene benefits from favourable re-aromatisation 
during the retro-reaction and also gives the insoluble maleic anhydride/anthracene 
adduct 52 which biases the equilibrium.   
 
Scheme 4.2: Low temperature base mediated retro-Diels-Alder reaction 
 
4.1.1 The rates of Diels-Alder and retro-Diels-Alder reactions 
 
The rates of both forward and backward reactions can be controlled electronically by 
changing the structure of the diene or dienophile component. In cycloadditions 
orbitals need to be available with the correct symmetry in order for the reaction to 
proceed. During ‘normal’ Diels-Alder reactions the HOMO of the diene (e.g. 
anthracene) combines with LUMO of the dienophile (e.g. ethyl cyanoacrylate) 
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(Scheme 4.3). In order for the reaction to occur there must be a bonding interaction 
at each end and the rate of the reaction will be controlled by the HOMO/LUMO 
energy separation. Electron withdrawing substituents on the dienophile lower the 
LUMO and electron donating substituents on the diene raise the HOMO providing a 
lower energy gap between the reacting orbital’s and a faster reaction as a 
consequence. For example, the Diels-Alder reaction between anthracene 46a and 
maleic anhydride 47 readily occurs because the symmetry is correct and there is a 
good match between the energy of the anthracene HOMO and the maleic anhydride 
LUMO (due to two electron withdrawing groups on the dienophile).
233
   
 
Scheme 4.3: Molecular orbitals of anthracene 46a reacting with maleic anhydride 47 and ethyl 
cyanoacrylate 48a 
 
In reverse electron demand Diels-Alder reactions the opposite is true, it is the 
HOMO of the dienophile that is closer in energy to the LUMO of the diene. In these 
cases electron donating groups on the dienophile will increase the rate. Hence, 
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reaction of the iminium ion diene 148 with dienophiles 149a-c shows increasing 
rates with increasing electron donation of the substituents (Scheme 4.4). 
Scheme 4.4: Diels-Alder reaction between pyrido[1,2-b]isoquinolinium and dienophile 149a-c
234 
 
Few reports have emerged dealing with substituents effects in retro-Diels-Alder 
reactions.
222
 Those have indicated that while electron donating substituents generally 
increase the rate of the backward reaction, electron withdrawing substituents can 
have the same effect. This was explained due to the movement towards a biradical 
mechanism. 
 
4.1.2 Approach to improving first step (46→127) 
 
The first step (46→127) could be improved by altering the electronic nature of the 
groups R
1
 and R
2
 on the anthracene 46a-l (Figure 4.1).
235
 It should be possible to 
alter the rate of both the initial Diels-Alder and the final retro-Diels-Alder reaction 
by tailoring this substituent (see section 4.1.4). Generally the forward reaction should 
be increased by electron donating groups at the 9-position.
195
 
 
Figure 4.1: 9, 10-substituted anthracene 
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4.1.3  Approach to improving the final step (45→16) 
 
While the effect of different substitution at C-9 or C-10 of the anthracene dienes on 
the rate of the first step (46→127) is relatively simple to predict, the effect on the 
rate of the final step (45→16) is less certain. That is because the final step involves 
two separate processes, the retro-Diels-Alder reaction itself followed by the trapping 
of the anthracene derivative 46a-m with maleic anhydride. Any change in substituent 
at the anthracene will change the rates of both these processes. As previously stated, 
other studies have shown that the rate of the retro-Diels Alder reaction can be 
accelerated by both electron withdrawing and donating substituents.
222
    
 
Both cyanoacrylate and maleic anhydride are reactive dienophiles and there will be a 
competition between them for the anthracene derivative. Another approach to 
increase the rate of the final step would be to replace maleic anhydride with a more 
reactive (lower energy LUMO) dienophile such as 1,1,2,2-tetracyanoethene. 
 
4.2 Aim 
 
In order to identify an anthracene derivative 46a-l that is better suited to an industrial 
synthesis of cyanoacrylate derivatives it was decided to study the effect of different 
substituents at the C-9 and C-10 position of anthracene upon the first step 
(conversion to give 127) and in the last step (conversion to give 16) of the process. 
Whether 1,1,2,2-tetracyanoethylene would be a better candidate as a anthracene 
trapping agent was also studied. If it was found that one substituent was optimal for 
the first step, but a different one for the last step it may be possible to interconvert 
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the anthracene substituents (151→152) midway in the overall synthetic strategy to 
take advantage of this (Scheme 4.5).  
Scheme 4.5: Potential modification of anthracene protected route 
 
4.3 Choice of anthracene derivatives 
 
A number of substituted 46a-m anthracenes were chosen which included a range of 
electron withdrawing and electron donating groups at C-9 and C-10 for comparison 
against the current model; anthracene 46a (Figure 4.2).  
 Figure 4.2: Substituted anthracenes 46a-m 
 
Mono-substituted 9-anthracenes 46b-j and fluorinated anthracene 46m would lead to 
two possible regioisomeric products (127b-jT, 127b-jK and 127mT, 127mK 
respectively). However, any mixture of Diels-Alder adduct isomers would ultimately 
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be destroyed in the retro step meaning this was not necessarily a problem. The two 
9,10-disubstituted products 46k and 46l would avoid this complication giving 127k-l 
only (assuming both R groups were the same).   
 
4.4 Synthesis of substituted anthracenes 
 
Anthracenes 46a-b, f-i and k-m were commercially available and were used without 
further purification. The commercially available 9-anthracenecarboxaldehyde 46f 
was reduced with NaBH4 to give 9-hydroxymethylanthracene
236
 46c in 46% yield 
(Scheme 4.6). 
 
Scheme 4.6: Synthesis of 9-hydroxymethylanthracene 46c. Reagents and Conditions: 9-
anthracenecarboxaldehyde 46f (1 eq.), NaBH4 (2 eq.), THF, 0 
o
C then reflux, 16 h, 46%. 
 
A Buchwald-Hartwig
237
 coupling between methanol and 9-bromoanthracene 46i 
utilising palladium (II) acetate and X-Phos as ligand furnished 9-methoxyanthracene 
46d (Scheme 4.7). Careful chromatography was required to purify 46d but it was 
impossible to remove 20% residual anthracene 46a (from an incomplete coupling). 
 
Scheme 4.7: Synthesis of 9-methoxyanthracene 46d. Reagents and Conditions: 9-bromoanthracene 
46i (1 eq.), methanol (2 eq.), Cs2CO3 (1.5 eq.), Pd(OAc)2 (0.05 eq.), X-Phos (0.05 eq.), toluene, 90 
o
C, 
3 days, 15%. 
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It was possible to make 9-aminoanthracene 46e via a three step procedure from 
anthracene 46a. Firstly, anthracene 46a was treated with concentrated HNO3/HCl in 
glacial acetic acid to give 9-nitro-10-chloro-9,10-dihydroanthracene 153 as a yellow 
precipitate. This was converted in situ with 10% NaOH
238
 to give 9-nitroanthracene 
46j in 61% yield over the two steps (Scheme 4.8). 
 
Scheme 4.8: Synthesis of 9-nitroanthracene 46j. Reagents and Conditions: (i) anthracene 46a (1 
eq.), HNO3 (1.5 eq.), 1:1 CH3CO2H: HCl, (ii) NaOH 10%, 60-70 
o
C, 61% over two steps. 
 
Reduction of 9-nitroanthracene 46j with SnCl2/HCl in acetic acid, followed by 
reaction in situ with 5% NaOH produced 9-aminoanthracene 46e in 39% yield 
(Scheme 4.9).
239
 This molecule was found to be unstable and had to be stored in the 
dark in a freezer. It was used in experiments immediately before it could degrade. 
 
Scheme 4.9: Synthesis of 9-aminoanthracene 46e. Reagents and Conditions: 9-nitroanthracene 46j 
(1 eq.), CH3CO2H, SnCl2 (5 eq.), HCl, 30 min, 80 
o
C; 5% NaOH, 30 min, r.t. 39%. 
 
Figure 4.3: Mass spectroscopy of 9-aminoanthracene 46e 
[M+H]
+
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4.4.1 Comparison of rates for the forward Diels-Alder reaction 
 
With a range of substituted anthracenes 46a-m in hand it was possible to investigate 
their reactions with ethyl cyanoacrylate 37. In order to gather data into the relative 
rates of reaction for each of the anthracene derivatives the conversion by 
1
H NMR at 
a specific time point was measured as a direct comparison.  Anticipating that some 
reactions would be faster than the parent anthracene 46a and others slower, 
conditions which provided an intermediate conversion of 61% for anthracene itself 
were chosen (heating at 70 
o
C for 7 h in d8 toluene as solvent with an 1.1 eq. excess 
of ethyl cyanoacetate). All the reactions were carried out at the same concentration 
(0.25 M) and an internal standard (anisole) was added (50 mol%) to each reaction to 
allow accurate ratios of products to be determined by 
1
H NMR. The NMR standard 
anisole was subjected to reaction with ethyl cyanoacrylate 37 to check it was un-
reactive under the standard reaction conditions. The reaction could be followed by 
the loss of the characteristic aromatic peaks for each anthracene derivative and the 
increase in peaks between at 1.7 ppm and 3.0 ppm corresponding to the 
diastereotopic CH2 group in the bridge of the adducts. Figure 4.4 shows the 
corresponding regions for the 9,10-dimethyl anthracene 46k reaction as way of 
illustration. 
 
The majority of the reactions were successful in providing the desired adducts, 
however 9-aminoanthracene 46e failed to give 127e instead it appeared to 
decompose under the reaction conditions. Consequently, it was not possible to 
evaluate the 9-amino derivative 46e any further. The Diels-Alder reaction of 9-
methoxyanthracene 46d also caused issues. Due to the 20% contamination with 
anthracene 46a two Diels-Alder adducts were obtained in a 4:1 ratio. 
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Figure 4.4: 
1
H NMR of 9,10-dimethyl anthracene 46k and 9,10-dimethyl anthracene adduct 
127k 
Comp. Subs. Conversion to kinetic 
product K 
(7 h / 70˚C)a 
Reaction time 
(days) 
Yield of thermodynamic 
product T  
(time / 110˚C) 
46a H 61% 1 81%
b 
46b Me 100% 0.33 88%
c 
46c CH2OH 43% 2 48% 
46d OMe 80%
d 
2 85%
d
 
46e NH2 - - - 
46f CHO 38% 2 41% 
46g C(O)Me 43%
e 
2 10% 
46h CO2H 0% 3 10% 
46i Br 63%
f 
2 26% 
46j NO2 0% 3 9% 
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46k Me 100% 0.33 87%
b 
46l Br 25% 4 16%
b 
46m F 60%
g 
2 68%
g 
 
a
Ratio determined by 400 MHz 
1
H NMR, estimated error ± 3%. 
b
Only one product possible. 
c
5:1 ratio 
of thermodynamic T: kinetic products K. 
d
As a 4:1 inseparable mixture of 127dK and 127a, 
significant reaction to give 127dK occurs at room temperature. 
e
Both regioisomers were formed (ratio 
K:T = 2:1). 
f
Both regioisomers were formed (ratio K:T = 16:1) 
g
An inseparable mixture of four 
compounds in a 1:2:2:2 ratio was isolated (each regioisomer produces an exo and endo product). No 
further effort was undertaken to establish the identify of each isomer or separate the mixture.  
Table 4.1: % conversion of anthracene’s 46a-m for Diels-Alder step 
 
With the exception of 9-amino 46e the order of reactivity (Table 4.1) was found to 
be 46d>46k~46b>46i~46a~46m>46c~46f~46g>46l>46h~46j. As expected the 
electron donating substituents 46b, 46k increased the rate of the reaction (it was not 
possible to get accurate values for 46d, see later but significant formation of the 
desired adduct occurs at room temperature), while the electron withdrawing 
substituents slowed the reaction. The most electron withdrawing substituent 46j 
(NO2 Hammett -value = 0.78) exhibited the slowest rate. Intermediate rates were 
provided by 46f, 46g, 46c with intermediate -values (CHO Hammett -value = 
0.42, C(O)Me Hammett -value = 0.50, CH2OH Hammett -value not available) 
and the fastest rate of an electron withdrawing substituent by 46i with the lowest -
value as expected (Br, Hammett -value = 0.23).
240
  
 
The most convenient alternative substrates to anthracene for an industrial process 
therefore were both 9-methylanthracene 46b and 9,10-methylanthracene 46k which 
resulted in 100% conversion within the 7 h.  This is clear due to the disappearance of 
Chapter 4: Substituted Anthracene Investigations 
 
131 
 
the anthracene starting material peaks between 7.0 and 8.5 ppm. Such was the 
reactive nature of 46k that it was possible to prepare the adduct 127k in 78% yield 
after 4 h at only 40 ˚C.    
 
4.4.2 Kinetic verses Thermodynamic control 
 
Interestingly, the products obtained from 9-monosubstituted anthracenes 46a-j were 
dependent upon the reaction conditions. This can be illustrated by methyl substituted 
compound 46b (Figure 4.5). At the lower temperature (70 ˚C) the expected kinetic 
product 127bK was formed exclusively (the so called ‘ortho’ adduct), while at 
higher temperature the thermodynamic product 127bT (‘meta’ adduct) was formed 
predominantly (5:1 after 8 h). The 
1
H NMR of the thermodynamic product 127bT, 
exhibits the signal for H
a
 as a singlet at 4.77 ppm while for the kinetic product 
127bK it is a triplet at 3.84 ppm due to coupling with the bridgehead methylene 
group (Figure 4.6). This coupling was readily observable in the COSY spectrum 
(Figure 4.7).   
Figure 4.5: Thermodynamic and Kinetic products of 46b 
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Figure 4.6: 
1
H NMR of 9-methyl anthracene adduct 127b at 70 
o
C (kinetic product) and 110 
o
C 
(thermodynamic: kinetic product, 5:1) 
Figure 4.7: COSY of 9-methyl anthracene adduct 127b showing coupling between H
a
 and the 
methylene group in the thermodynamic and kinetic product  
H
a
T H
a
K 
CH2T 
CH2T 
CH2K 
CH2K 
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The formation of the thermodynamic product 127bT when the reaction was carried 
out at 110 ˚C suggests that the Diels-Alder reaction is reversible under these 
conditions.  The factors that control regiochemistry in Diels-Alder reactions are well 
known. For example, the reaction of methoxybutadiene 154 with acrolein 155 
favours the ‘ortho’ adduct 156 and electron donating substituents at the 9-position of 
anthracene 46b-j would be expected to do the same. The regioselectivity can be 
explained by analysing the energy gaps of the HOMO/LUMO molecular orbital 
combinations and the coefficients of the atomic orbitals on these HOMO’s and 
LUMO’s, (Figure 4.8). For 154 and 155 the most important interactions occur 
between the HOMO of the diene and the LUMO of the dienophile (8.5 eV difference 
in energy). The LUMO of the diene and HOMO of the dienophile energy gap is 
much higher (13.4 eV) and as such is less important in the analysis of 
regiochemistry. Best overlap occurs when orbitals of the similar size can interact. 
Thus for 154 and 155 the ‘ortho adduct’ is predicted and observed. Alternatively, the 
same regiochemical outcome can be predicted by a stepwise (non-concerted) 
mechanism. 
 
Figure 4.8: Interaction of molecular orbitals in Diels-Alder reactions 
Chapter 4: Substituted Anthracene Investigations 
 
134 
 
The reactions of 46b (Me), 46c (CH2OH), 46f (CHO),  after 7 h showed formation of 
the products 127bK, 127cK and 127fK respectively (kinetic) while 46d (OMe), 46g 
(C(O)Me), and 46i (Br) showed mixtures of the two products 127 K:T (127d = 4:1, 
127g = 2:1, 127i = 16:1) and 127h (CO2H) and 127j (NO2) showed no products. 
Compounds 46a, 46k and 46l only furnish one product (due to the symmetry of the 
molecule) while 46m formed an inseparable mixture of regioisomers (each showing 
an exo and endo product) giving rise to a 1:2:2:2 mixture of isomers. Heating all the 
9-monosubstituted substrates at 110 ˚C between 24-78 h furnished the 
thermodynamic products only 127b-jT. For each substrate the two products could be 
easily distinguished by both the chemical shifts of protons H
a
, H
b
, and H
c
 and their 
coupling patterns. For the products T, H
a
 was typically 1.0 ppm higher than in K, 
while the bridge diastereotopic methylene protons were widely separated (0.6-0.9 
ppm) in T compared to those in K (0.2-0.5 ppm) (Figure 4.9).   
Figure 4.9: Thermodynamic T versus kinetic K products 
 
Comp. Subs. 
1
H NMR  127b-jK 
ppm
a 
 of H
b-
H
c 
ppm
a 
1
H NMR  127b-jT 
ppm
a 
 of H
b-
H
c 
ppm
a 
46b Me H
b
 = 2.41, H
c
 = 2.09, 0.32 H
b
 = 2.60, H
c
 = 2.01, 0.59 
46c CH2OH H
b
 = 2.29, H
c
 = 2.00, 0.29 H
b
 = 2.71, H
c
 = 2.15, 0.56 
46d OMe H
b
 = 2.30, H
c
 = 2.06,
 
0.24 H
b
 = 2.96, H
c
 = 2.17, 0.79 
46f CHO H
b
 = 2.37, H
c
 = 2.21, 0.16 H
b
 = 2.94, H
c
 = 2.35, 0.59 
46g C(O)Me H
b
 = 2.35, H
c
 = 2.22,
 
0.13 H
b
 = 3.08, H
c
 = 2.33, 0.75 
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46h CO2H 
b b 
H
b
 = 3.14, H
c
 = 2.55, 0.59 
46i Br H
b
 = 2.26, H
c
 = 2.18,
 
0.08 H
b
 = 3.26, H
c
 = 2.55, 0.71 
46j NO2 
b b
 H
b
 = 3.40, H
c
 = 2.79, 0.61 
a
Measured by 400 MHz 
1
H NMR. 
b
No product detected. 
Table 4.2: Chemical shifts of H
b
 and H
c
 in 127b-jK and 127b-jT 
 
In frontier molecular orbital terms there are two effects of placing an electron 
withdrawing substituent on a diene when reacting with an electron poor dienophile. 
Firstly, the energy gap between the most important HOMO/LUMO interaction is 
larger (meaning slower reaction) but the difference between the energies of the two 
different HOMO/LUMO interactions is less than for a conventional diene/dienophile 
interaction. For diene 46h the gap is 9.5 eV and 10.4 eV respectively (compared with 
8.5 and 13.4 eV for 154 and 155). The closer difference in energy suggests that both 
interactions might become important in any analysis of regiochemistry of 46h. The 
second is that the polarisation of the orbital coefficients will be significantly altered. 
Combining both of these effects can lead to loss of regiochemistry. For strongly 
electron withdrawing substituents, ‘meta’ compounds can become the fastest formed, 
with both kinetic and thermodynamic control providing the same product (Figure 
4.10). 
 
Figure 4.10: Molecular orbital interactions of 46h 
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Thus, the results (Table 4.2) can be explained by a combination of these factors. For 
the highly electron withdrawing groups (46j, NO2) only ‘meta’ products are isolated 
after prolonged reaction times, for intermediate electron withdrawing groups (46g, 
C(O)Me or 46i, Br) mixtures of regioisomers are detected at 70 ˚C (less selective 
reactions) but ‘meta’ products are detected at higher temperatures. For electron 
donating substituents (46b, Me) the reactions are fast and even after 8 h significant 
formation of the ‘meta’ adducts is occurring.   
 
Special mention should be made of the reactions with 9-methoxyanthracene (46d) 
which was reacted 80% pure (contaminated with anthracene). The 
1
H NMR of the 
reaction at 70 ˚C shows two adducts, the expected kinetic adduct 127dK and the 
anthracene adduct 127a. After prolonged heating at 110 ˚C the thermodynamic 
adduct 127dT and anthracene adduct 127a were isolated, (Figure 4.11). However, it 
proved impossible to separate the adducts 127a and 127dT by chromatography and 
as such this derivative was not pursued any further as it was unlikely to lead to 
efficiencies in any industrial process. However, significant reaction occurs at room 
temperature after only 10 minutes (40% conversion of 46d) which indicates that the 
9-methoxy anthracene derivative 127d is the most reactive. 
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Figure 4.11: 
1
H NMR of 9-methoxy anthracene adduct 127d at 70 
o
C and 110 
o
C 
 
4.4.3 Diels-Alder reactions of 46k-m 
 
The reactions of 9-substituted anthracenes lead to complications as two Diels-Alder 
products could be isolated. The addition of an identical group at the 10-position 
would alleviate this problem. Consequently the reactions of 46k-l with ethyl 
cyanoacrylate were analysed at both 70 ˚C for 7 h and at 110 ˚C for 8 h (46k) and 4 
days (46l) respectively. The derivatives were chosen because 46b (9-Me) gave the 
best results of an electron donating group and 46i (9-Br) gave the best results of an 
electron withdrawing group. Unsurprisingly the reaction of 9,10-dibromoanthracene 
46l was significantly slower than for 9-bromoanthracene. Pleasingly, the 9,10-
dimethyl anthracene derivative 46k gave high yields of isolated product 127k at 70 
˚C and 110 ˚C in fact it was possible to run the forward Diels-Alder reaction in high 
yield (78%) at only 40˚C. 
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The only other substituted anthracene to be investigated was 2-fluoroanthracene 
46m. The fluorine substituent was not directly attached to one of the carbons of the 
‘diene’ central anthracene ring but would exhibit a secondary electronic effect. The 
reaction gave a complicated mixture of regioisomeric products (each as a mixture of 
exo and endo isomers 1:2:2:2). While the rate was similar to the parent anthracene it 
did not provide any advantages in attempting to improve the industrial synthesis of 
cyanoacrylates over other derivative studied. 
 
In summary, the 9,10-dimethylanthracene 46k was determined to be the best 
derivative to facilitate the Diels-Alder step of any industrial synthesis of ethyl 
cyanoacrylate derivatives. Its increased reactivity over the parent anthracene 46a 
allowed the forward reaction to be undertaken at 40 ˚C, and the symmetrical nature 
of the derivative precluded regioisomer complications. In addition it is commercially 
available. 
 
4.5 Retro-Diels-Alder reaction investigations 
 
The retro-Diels-Alder reaction is an important process that can be used to make 
reactive or strained molecules.
241
 It is governed by the Woodward-Hoffman rules
241–
244
 and has found numerous applications in materials chemistry and synthesis.
245–248
 
The reaction is normally carried out thermally at high temperatures (>150 ˚C), but 
photochemical conditions also have been  studied.
249
 Having investigated the 
forward Diels-Alder reactions, it was now wished to explore the reverse process. In 
the reaction of 9-substituted anthracenes two regioisomers were produced depending 
upon the reaction conditions. These two regioisomers may have different retro-Diels-
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Alder rates. While it was possible to furnish all the products 127b-jT by heating at 
110 ˚C in toluene, it was not possible to find conditions that lead to regioisomers 
127b-jK exclusively for all the substrates. Thus it was decided to compare the retro-
Diels-Alder reactions of the thermodynamic adducts 127b-jT only, acknowledging 
that this is a practically more difficult retro-process than if the reverse reaction of the 
kinetic products 127b-jK were compared. 
 
During the reaction the anthracene adducts 127a-m undergo a retro-Diels-Alder 
reaction to give ethyl cyanoacrylate 37 and the anthracene liberated under these 
conditions forms a Diels-Alder adduct 48a with maleic anhydride. The formation of 
48a affects the equilibrium of the reaction because the freed anthracene 46a-m is not 
then able to react again with ethyl cyanoacrylate 37. Therefore the equilibrium is 
pushed in favour of ethyl cyanoacrylate monomer 37 (Figure 4.12). 
 
Figure 4.12: Reaction between freed anthracene and maleic anhydride to give adduct 48a-l 
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The production of the maleic anhydride adduct can be seen in the 400 MHz 
1
H 
NMR; the two protons where the anthracene bridge and the maleic anhydride are 
joined come at approximately 3.5 ppm. When X=H the remaining proton/s on the 
bridge come around 4.8 ppm (Figure 4.13). 
Figure 4.13: 
1
H NMR of anthracene maleic anhydride adduct 48a  
 
4.5.1 Measurement of conversion in retro-Diels-Alder reaction by 
1
H NMR 
 
All the anthracene adducts 127a-m were combined with maleic anhydride (3 
equivalents), hydroquinone (to suppress radical polymerisation of cyanoacrylate 37) 
phosphorous pentoxide (to suppress water initiated polymerisation of cyanoacrylate 
37) and 1-methyl naphthalene (as an internal standard) and refluxed in xylene for 8 h 
at 140 ˚C in order to undergo a retro-Diels-Alder reaction. These conditions were 
chosen to mimic the industrial process where it is important to add the 
polymerisation inhibitors. Conditions were chosen so that the reaction of the 
anthracene adduct 127a did not go to completion but progressed approximately 60%. 
After the reaction, all the volatiles (including ethyl cyanoacrylate) were removed on 
a vacuum pump and the crude mixtures analysed by 
1
H NMR.  
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A typical 
1
H NMR spectrum of an experimental run is shown in Figure 4.14 for the 
reaction of the 9-formyl derivative 127f. It shows peaks for the starting material 
127f, the maleic anhydride adduct 48f and 9-formyl anthracene 46f. A certain level 
of 9-formyl anthracene 46f (from the retro-reaction without trapping) builds up in the 
reaction mixture because the ‘trapping’ reaction with maleic anhydride is slow (due 
to electronically mismatched partners). The methyl peak at 2.7 ppm is for the NMR 
standard 1-methyl naphthalene (50 mol% added to the reaction). The amount of 
starting material 127f remaining (61%) was calculated using the average of the 
clearly separated peaks at 10.84 (s), 4.89 (s), 2.94 (d) and 2.36 (d) ppm. The amount 
of maleic anhydride adduct 48f, (35%) and 9-formyl anthracene 46f (4%) was 
calculated in a similar manner; 48f [peaks at 10.88 (s), 4.83 (d), 4.03 (d), 3.58 (dd)]; 
46f [(11.54 (s), 9.00 (d), 8.72 (s)]. The conversion to ethyl cyanoacrylate 37 is 
therefore 39% (Figure 4.14).  
 
 
 
 
Figure 4.14: 
1
H NMR of retro-Diels-Alder reaction of 9-formyl anthracene adduct 127f 
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Using this approach it was possible to measure the conversion by determining the 
levels of starting material remaining. 
Comp. Subs. Conversion after 8 h
a 
127a H 75% 
127b Me 54% 
127c CH2OH -
b 
127f CHO 39% 
127g C(O)Me 52%
 
127h CO2H -
c 
127i Br 45%
 
127j NO2 0% 
127k Me 40% 
127l Br 70% 
127m F 56%
 
a 
Conversion determined by 400 MHz 
1
H NMR, estimated error ± 3%. 
b
 Not studied in detail due to 
competing acylation of free hydroxyl group with maleic anhydride. 
c 
Not studied in detail as possible 
reactions with both maleic anhydride to give mixed anyhdride and dehydration with P2O5 possible.  
Trace amounts < 3% of maleic anhydride adduct identified in crude NMR. 
Table 4.3: % conversion of retro-Diels-Alder reactions of 127a-m 
 
Hydroxymethylene derivative 127c was not studied in detail due to the inherent 
reactivity of the free hydroxyl towards maleic anhydride. Heating 127c with maleic 
anhydride under the retro-Diels-Alder reaction conditions led to a relatively messy 
1
H NMR spectrum. The acylated product 157 was tentatively identified from this 
crude spectrum, (Figure 4.15), but no further analysis was undertaken. No peaks 
corresponding to trapping of the retro-Diels-Alder product 48c could be detected in 
this crude NMR.  
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Figure 4.15: 
1
H NMR of retro-Diels-Alder reaction of 127c and proposed acylated product 157  
 
Reaction of the carboxylic acid derivative 127h was also not studied in detail for 
similar reasons. Reaction of maleic anhydride with the carboxylic acid functionality 
could furnish a mixed anhydride and the P2O5 added to the reaction mixture could 
also cause dehydration of 127h to give a symmetrical anhydride. This coupled with 
the low yield of 127h produced in the forward reaction meant that 46h was a poor 
candidate for further study.  
 
The factors which affect the rate of retro-Diels-Alder reactions are known to be 
complicated. In the related retro-Diels-Alder reactions of di-substituted adducts 
158a-e
222
 mildly electron withdrawing R-groups (R = C(O)Me, k = 3 x 10
5
 s
-1
) 
showed similar rates to mildly electron donating substituents (R = Me, k = 3 x 10
5
 s
-
1
), halogen substituents were slightly slower (R = Br, k = 1 x 10
5
 s
-1
) and strongly 
electron donating (R = OMe, k = 7 x 10
6
 s
-1
) and strongly electron withdrawing (R = 
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NO2, k = 3 x 10
3
 s
-1
) significantly faster and slower respectively. The effect of 
carboxylic acid and aldehyde functionality were not studied. They concluded that for 
mildly electron withdrawing groups the mechanism was moving towards a biradical 
process (rather than a concerted process). Other work
250
 has provided evidence of a 
steric acceleration in the retro-Diels-Alder reaction as steric release for the 
substituents R occurs on going from 127a to anthracene 46a which increases the rate 
with larger substituents. In addition, R substituents that are potentially conjugating 
(e.g. CHO, C(O)Me) would gain conjugation in the anthracene which would be 
lacking in the Diels-Alder adduct. Our results are in broad agreement with those of 
Czarnik
251
 on the retro-Diels-Alder of acrylate derivatives 158a-e (Scheme 4.10) 
(127b~127g>127f~127i>>>127j).  
 
Scheme 4.10: Retro-Diels-Alder reaction of 158a-e 
 
However, the reactions studied here are inherently more complicated because they 
are followed by another Diels-Alder reaction of the released anthracene derivatives 
with maleic anhydride to ultimately force the initial retro-Diels-Alder equilibrium in 
the desired direction (Scheme 4.11). Thus reagents which may undergo a faster retro-
Diels-Alder sequence (e.g. 127g, R = C(O)Me) may undergo a slower ‘trapping’ 
reaction with maleic anhydride. This was observed for a substrates 127f (R = CHO) 
and 127g (R = C(O)Me) as the corresponding free 9-substituted anthracene 
derivatives 46f and 46g could also be detected in the reaction mixtures after 8 h. The 
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best results were obtained with the parent anthracene 127a, 9,10-dibromoanthracene 
127k and 2-fluoroanthracene 127m adducts with intermediate results for the 9-
methyl 127b and 9,10-dimethyl anthracene 127k derivatives. The relatively fast rate 
of the 9,10-dibromo derivative 127l (faster than 9-bromo derivative 127i) may be 
due to the release of extra steric strain during the reaction.   
 
Scheme 4.11: Retro-Diels-Alder mechanism using maleic anhydride 
 
4.5.2   Changing dienophile to 1,1,2,2-cyanoethylene 
 
Changing the trapping agent from maleic anhydride to 1,1,2,2-tetracyanoethylene 
159 in the retro-Diels-Alder reaction of the anthracene 127a and 9,10-
dimethylanthracene 127k derivatives was briefly studied. The cycloaddition between 
159 and anthracene 127a is well documented. It is rapid and proceeds via an initial 
charge transfer complex due to the low lying LUMO of the dienophile component.
198
 
Kinetics and mechanistic studies also show that solvent effects are also 
important.
197,252
 First authentic samples of the two adducts 160a,k  were prepared 
using a literature procedure.
253 
 
Then both 127a and 127k were subjected to the same reaction conditions as before 
but replacing maleic anhydride with 1,1,2,2-cyanoethylene. Upon addition of the 
dienophile a colour change (white to orange) characteristic of the diene/ dienophile 
charge transfer complex occurred indicating trapping of anthracene adducts. 
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However surprisingly conversion was lower for both 127a (52% compared to 75%) 
and 127k (32% compared to 40%) compared to with maleic anhydride. At this time 
it is unclear why this should be the case and further investigation is needed to probe 
these effects more deeply. 
 
Figure 4.16: Retro-Diels-Alder reaction replacing maleic anhydride with 1,1,2,2-
tetracyanoethylene  
 
4.6 Conclusion  
 
In conclusion, the forward and reverse reactions of a range of 9-substituted 46a-j and 
9,10-disubstituted anthracenes 46k-l with ethyl cyanoacrylate 37 have been 
investigated. The rates of reactions and their initial regiochemistry could be 
predicted using a frontier molecular orbital approach. In general for 9-substituted 
derivatives, ‘ortho’ adducts 127a-jK, (kinetic products) were obtained after reaction 
at 70 ˚C for 7 h, reflecting the polarisation of coefficients in the diene component, 
but ‘meta’ adducts (thermodynamic products) obtained after 1-4 days at 110 ˚C, 
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indicating the reactions were reversible at this temperature. For some substrates with 
strongly electron withdrawing groups (46h, 46j) ‘meta’ adducts were the only 
products isolated whatever the conditions indicating that for these substrates the 
polarisation of coefficients in the diene was changed or that the HOMO (dienophile)/ 
LUMO (diene) interaction was now the dominant pathway. The most industrially 
useful substrates for the forward reaction were identified as 9,10-dimethyl 
anthracene 46k, 9-methyl anthracene 46b and anthracene itself 46a. Due to the lack 
of regioisomeric products and their commercial availability both 46k and 46a were 
identified as viable candidates for an industrial synthesis, with the remaining 
determining factor the cost of the starting materials verses the cost of the energy 
required to facilitate the reaction. 
 
In the retro-Diels-Alder reaction the relative conversions of substrates could not be 
predicted based upon electronic considerations alone. Both mildly electron donating 
and withdrawing groups showed similar reactivities. This was similar to other 
studies by Czarnik
222
 on retro-Diels-Alder reactions of anthracene acrylate 158a-e 
adducts. One possible explanation is that for the electron withdrawing adducts the 
reverse reaction is proceeding via a different mechanism (e.g. biradical, or one with 
significant build -up of charge separation 161). The relatively fast rate of the 9,10-
dibromo derivative 127l (faster than 9-bromo derivative 127i) may be due to the 
release of extra steric strain during the reaction compared to the 9-bromo analogue 
127i (Figure 4.17).   
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Figure 4.17: Effect of EWG on charge separation of 161 
 
Combining the efficiencies of both the forward Diels-Alder and the retro-Diels-Alder 
steps together under the conditions studied it becomes clear that the most likely 
candidates for an industrial process are 46a, 46b or 46k (Table 4.4).   
Comp. Subs. Efficiency of both 
steps combined
 
46a H 46% 
46b Me 54% 
46f CHO 15% 
46g C(O)Me 22%
 
46i Br 28%
 
46j NO2 0% 
46k Me 40% 
46l Br 17% 
46m F 34%
 
 
Table 4.4: Overall efficiency of anthracenes 46a-m 
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5.0 Experimental 
 
5.1 General Information and Procedures 
 
The starting materials used in the syntheses were obtained from commercial 
suppliers and were used without further purification. All melting points were 
measured using a Gallenkamp variable heater melting point apparatus and are 
uncorrected. NMR spectra were obtained at 298 K unless otherwise stated. 
1
H and 
13
C-NMR were recorded on Bruker DPX-300, DPX-400 and DRX-500 instruments 
and are referenced to tetramethylsilane (TMS) 0.00 ppm. Chemical Shifts (δH) are 
quoted in parts per million (ppm), coupling constant J is quoted to the nearest half 
hertz (Hz), data is reported as (δH, integration, multiplicity). Proton and carbon NMR 
assignments were routinely confirmed by 
1
H-
1
H (COSY), 
1
H-
13
C (HMQC) and 
1
H-
13
C (HMBC) experiments.  
 
Low resolution mass spectra were recorded on Bruker Esquire 2000 for electro spray 
(ES) conditions, high resolution mass spectra was recorded on a Bruker MicroTOF. 
Only molecular ions, fractions from molecular ions and other major peaks are 
reported as mass/charge (m/z) ratios. Infrared spectra were recorded as solid state on 
Perkin-Elmer Avatar 320 FTIR spectrometer. Absorption maxima (νmax) are recorded 
in wavenumbers (cm
-1
). UV/vis spectra were recorded on Perkin Elmer Lambda 25 
UV/vis spectrometer. Elemental analysis was performed by Warwick Analytical 
Services. TGA/ DSC were used to measure thermal properties of cyanoacrylate 
contrast mixtures using a Metler Toledo DSCI-Star.  
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Thin layer chromatography was performed on Merck silica gel 60 F-254 tlc sheets, 
the tlc plate was then visualized under a UV lamp and then stained with potassium 
permanganate. Flash column chromatography was carried out using Merck silica gel 
60, 35-75μm as the stationary phase according to the procedure of Still et al.254 
Petrol refers to petroleum ether (40-60 
o
C) unless otherwise stated. All water used 
was deionised, solvents were evaporated on Büchi Re111 Rotavaporator equipped 
with a Büchi 461 water bath. All glassware was pre-dried in an oven (80 
o
C), cooled 
in a dry atmosphere before use.  
 
5.2 Experimental procedures for substrates synthesised in Chapter 2 
 
5.2.1 Diatrizoic acid (56) substrates 
 
Methyl 3,5-diacetamido-2,4,6-triiodobenzoate (102) 
 
Thionyl chloride (15.0 mL, 207 mmol) was added to diatrizoic acid 56 (10.0 g, 16.3 
mmol) and heated to reflux for 5 h. Excess thionyl chloride was removed in vacuo. 
Methanol (25.0 mL, 617 mmol) and pyridine (1.45 mL, 17.9 mmol) were added and 
refluxed for 24 h. The methanol was removed in vacuo and the reaction taken up in 
EtOAc (50.0 mL) and water (50.0 mL). The product was subsequently extracted with 
EtOAc (3 x 50.0 mL) and the organic phase washed with 2M aq. HCl (100 mL) and 
sat. aq. NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo. This resulted 
in crude product 102 (0.83 g) as an orange solid, which was purified by column 
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chromatography (19:1 petrol/ EtOAc) to furnish the title compound 102 (0.22 g, 0.33 
mmol, 2%) as a yellow/ orange solid. Rf (19:1 petrol/ EtOAc) 0.35; m.p.: 210 – 212 
o
C; vmax/cm
-1
: 3258 (NH), 2998 (CH), 1717 (C=O), 1655 (NH-C=O); δH (700 MHz, 
MeOD) 3.94 (3H, s, COOCH3), 2.15 (6H, s, NHCOCH3); δC (175 MHz, MeOD) 
170.3 (NHC=O), 169.7, 169.2 (C=O), 149.4, 147.2 (NHCCI), 142.7 (CO2CCI), 85.9 
(NHCCICNH), 77.6, 75.3 (CO2CCICNH), 52.2 (COOCH3), 23.0, 21.6 (NHCOCH3); 
m/z (ES
+
) 650.8 [M+Na]
+
, found: 650.7750 [M+Na]
+
 (C12H11I3N2NaO4 requires 
650.7751). 
 
Butyl 3,5-diaacetamido-2,4,6-triiodobenzoate (103) 
 
Thionyl chloride (10.0 mL, 138 mmol) was added to diatrizoic acid 56 (10.0 g, 16.0 
mmol) and heated to reflux for 8 h. Excess thionyl chloride was removed in vacuo, 
butan-1-ol (50.0 mL, 546 mmol) and pyridine (1.45 mL, 17.9 mmol) was added and 
the reaction was heated to reflux for 30 h. The mixture was removed from the heat, 
water (50.0 mL) was added and the product was extracted with Et2O (3 x 75.0 mL). 
The organic layers were washed with 2M aq. HCl (75.0 mL) and sat. aq. NaCl (75.0 
mL), dried (MgSO4) and concentrated in vacuo to give crude product 103 (28.8 g) as 
a brown liquid. The crude product was purified by flash column chromatography 
(19:1 EtOAc/ petrol), followed by re-crystallisation (hexane) to yield the title 
compound 103 (0.41 g, 0.64 mmol, 4%) as an off-white solid. Rf (19:1 EtOAc/ 
petrol) 0.45; m.p. 256-257 
o
C; vmax/cm
-1
 3320 (NH), 2968 (CH), 1718 (NH-C=O), 
1663 (O-C=O); δH (400 MHz, MeOD) 4.58 (2 H, s, 2 x NH), 4.37 (2H, t, J 6.5, 
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OCH2-CH2), 2.22 – 2.09 (6H, m, 2 x NH-CO-CH3), 1.84 – 1.69 (2H, m, OCH2-CH2), 
1.60 -1.44 (2H, m, CH2-CH2-CH3), 0.98 (3H, dd, J 8.0, 6.5, CH2-CH3); δC (100 
MHz, MeOD) 171.9, 171.5 (NHC=O), 169.7 (C=O), 149.9 (ArC-CO), 145.7, 145.6 
(ArC-NH), 107.2 (NHC-CI-CNH), 96.5, 96.3 (CO-C-CI), 67.6 (OCH2-CH2), 34.2 
(CH2-CH3), 31.5 (OCH2-CH2), 23.1 (2 x NH-CO-CH3), 20.4 (CH2-CH2-CH3), 14.0 
(CH2-CH3); m/z (ES
+
) 670.7 [M+H]
+
, 692.7 [M+Na]
+
, found: 692.8219 [M+Na]
+
 
(C15H17I3N2NaO4 requires 692.8220); found C: 26.8, H: 2.4, N: 4.1, C15H17I3N2O4 
requires C: 26.9, H: 2.6, N: 4.2.   
 
Octyl 3,5-diaacetamido-2,4,6-triiodobenzoate (104)  
 
Thionyl chloride (10.0 mL, 138 mmol) was added to diatrizoic acid 56 (10.0 g, 16.0 
mmol) and refluxed for 4 h. Excess thionyl chloride was removed in vacuo, octanol 
(30.0 mL, 191 mmol) and pyridine (1.45 mL, 17.9 mmol) were added and the 
mixture heated to reflux for 3 days. The reaction was removed from the heat, water 
(50.0 mL) was added and the product extracted with Et2O (3 x 100 mL). The 
combined organic phases were washed with 2M aq. HCl (100 mL) and sat. aq. NaCl 
(100 mL), dried (MgSO4) and concentrated in vacuo to yield the crude product 104 
(18.28 g) as a brown liquid. This was purified by flash column chromatography 
(19:1 DCM/ methanol) followed by re-crystallisation (hexane) to furnish the title 
compound 104 (0.28 g, 0.32 mmol, 2%) as an off-white solid. Rf (19:1 DCM/ 
methanol) 0.39; m.p. 269 – 270 oC; vmax/cm
-1
 3210, 3166 (NH), 2923 (CH), 1731 
(NH-C=O), 1666 (O-C=O); δH (400 MHz, MeOD) 4.59 (2H, s, 2 x NH), 4.36 (2H, t, 
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J 6.5, OCH2-CH2), 2.20 – 2.16 (6H, m, 2 x NH-CO-CH3), 1.53 –1.28 (12H, m, 6 x 
CH2), 0.92 – 0.88 (3H, m, CH2-CH3); δC (100 MHz, MeOD) 171.9, 171.5 (NHC=O), 
169.7 (C=O), 149.8 (ArC-CO), 145.7, 145.6 (ArC-NH), 107.2 (NH-C-CI), 96.5, 96.3 
(CO-C-CI), 67.9 (OCH2-CH2), 33.0, 30.4, 30.3, 29.4, 27.3, 23.7 (6 x CH2), 23.1 (2 x 
NH-CO-CH3), 14.5 (CH2-CH3); m/z (ES
+
) 748.9 [M+Na]
+
, found 748.8848 [M+Na]
+
 
(C19H25I3N2NaO4 requires 748.8846); found C: 31.5, H: 3.4, N: 3.9, C19H25I3N2O4 
requires C: 31.4, H: 3.5, N: 3.9. 
 
5.2.2 Iohexol (55) substrates 
 
N
1
,N
3
-Bis(2,3-diacetoxy)propylcarbamonyl)-5-(N-(2,3-
diacetoxy)propylacetamido)-2,4,6-triiodoisophthalamide (110) [py]) 
 
Iohexol 55 (10.0 g, 12.0 mmol) and acetic anhydride (9.00 mL, 96.0 mmol) were 
combined in pyridine (150 mL), warmed to 50 
o
C and left stirred for 48 h. Once the 
reaction had cooled water (100 mL) was added, the product was extracted with 
EtOAc (4 x 100 mL), washed with water (2 x 100 mL), 2M aq. HCl (2 x 100 mL) 
and sat. aq. NaHCO3 (100 mL). The organic phase was dried (MgSO4) and 
concentrated in vacuo to give the crude acetate 110 [py] (10.3 g) as an off-white 
solid. The crude product was purified by column chromatography (EtOAc) to furnish 
the title compound 110 [py] (7.90 g, 7.32 mmol, 61%) as a white solid. Rf (EtOAc) 
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0.57; m.p. 92 – 93 oC; vmax/cm
-1
 2996 (NH), 1731 (C=O), 1650 (N-C=O), 1543 (NH-
C=O); δH (400 MHz, CDCl3) 6.85 (1H, m, NH), 6.51 (1H, m, NH), 5.40 – 5.19 (3H, 
m, CH2-CH-CH2), 4.49 – 4.33 (4H, m, OCH2-CH and NHCH2-CH), 4.33 – 4.16 (4H, 
m, OCH2-CH and NHCH2-CH), 3.98 - 3.87 (2H, m, NCH2-CH), 3.77 - 3.60 (2H, m, 
OCH2-CH), 2.10 (12H, s, CO2-CH3), 2.09 (3H, s, N-CO-CH3), 1.91 (6H, s, CO2-
CH3); δC (100 MHz, CDCl3) 170.7, 170.6, 170.5, 170.4, 170.3, 170.2, 169.6, 169.3, 
169.1 (C=O), 151.3, 151.1, 150.8 (ArC), 99.1 (CO-C-CI), 89.7, 89.6 (CN-CI), 70.2, 
70.0, 69.9 (CH2-CH-CH2), 63.3, 63.0 (O-CH2-CH), 46.2 (N-CH2-CH), 40.1, 39.9 
(NH-CH2-CH), 22.8 (N-CO-CH3), 21.4, 21.2, 21.1, 21.0, 20.8, 20.6 (CO2-CH3); m/z 
(ES
+
) 1095.9 [M+Na]
+
, found: 1095.9341 [M+Na]
+
 (C31H38I3N3NaO15 requires 
1095.9335); found C: 34.3, H: 3.5, N: 3.9, C31H38I3N3O15 requires C: 34.7, H: 3.6, N: 
3.9. 
 
N
1
,N
3
-Bis(2,3-diacetoxy)propylcarbamonyl)-5-(N-(2,3-
diacetoxy)propylacetamido)-2,4,6-triiodoisophthalamide (110 [I2]) 
 
Iohexol 55 (7.50 g, 9.13 mmol) and iodine (0.23 g, 0.91 mmol) were combined in 
acetic anhydride (6.90 mL, 73.0 mmol) and left to stir at r.t. for 5 days. Water (10.0 
mL) and sat. aq. Na2SO3 (20.0 mL) were then added and the product subsequently 
extracted with EtOAc (3 x 50.0 mL). The combined organic layers were washed with 
sat. aq. Na2S2O3 (100 mL) and then sat. aq. NaHCO3 (100 mL), dried (MgSO4) and 
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concentrated in vacuo to yield crude acetate 110 [I2] (9.57 g) as a yellow solid. This 
was purified by column chromatography (EtOAc) to furnish the title compound 110 
[I2] (3.90 g, 3.65 mmol, 40%) as a white solid. Rf  (EtOAc) 0.39; m.p. 87-88 
o
C; 
vmax/cm
-1
 3280 (NH), 2910 (CH), 1729 and 1655 (C=O), 1541 (NH-C=O); δH (400 
MHz, CDCl3) 6.86 – 6.76 (1H, m, NH), 6.51 – 6.36 (1H, m, NH), 5.33 - 5.16 (3H, 
m, CH2-CH-CH2), 4.38 – 4.26 (3H, m, OCH2-CH), 4.23 – 3.91 (3H, m, OCH2-CH), 
3.87 – 3.68 (2H, m, NHCH2-CH), 3.64 – 3.44 (4H, m, NHCH2-CH and NCH2CH), 
2.02 – 2.00 (12H, m, CO2-CH3), 1.97 (3H, s, N-CO-CH3), 1.89 – 1.80 (6H, m, CO2-
CH3); δC (100 MHz, CDCl3) 170.8, 170.7, 170.6, 170.5, 170.3, 170.2, 169.7, 169.4, 
169.2 (C=O), 151.1, 150.8, 150.7 (Ar-C), 99.1 (CO-C-CI), 89.8, 89.6 (CN-CI), 70.1, 
69.9, 68.4 (CH2-CH-CH2), 63.7, 63.0 (OCH2-CH), 46.2, 46.1 (OCH2-CH and N-
CH2-CH), 40.1, 39.9 (NH-CH2-CH), 22.9 (NCO-CH3), 21.2, 21.1, 21.0, 20.8, 20.6, 
20.5 (CO2-CH3); m/z (ES
+
) 1095.7 [M+Na]
+
, found: 1095.9336 [M+Na]
+
 
(C31H38I3N3NaO15 requires 1095.9335); found C: 34.3, H: 3.5, N: 3.9, C31H38I3N3O15 
requires C: 34.7, H: 3.6, N: 3.9. 
 
N
1
,N
3
-Bis(2,3-dipentanoyloxy)propyl)-5-(N-(2,3-
dipentanoyloxy)propylacetamido)-2,4,6-triiodoisophthalamide (111) 
 
Iohexol 55 (10.0 g, 12.2 mmol) and iodine (0.31 g, 1.22 mmol) were combined in 
valeric anhydride (19.2 mL, 97.4 mmol) and left to stir at r.t. for 6 days. Water (20.0 
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mL) was added and the product subsequently extracted with EtOAc (3 x 30.0 mL). 
The combined organic phase was washed with sat. aq. Na2S2O3 (50.0 mL), dried 
(MgSO4) and concentrated in vacuo to yield crude product 111 (23.5 g). This was 
purified by column chromatography (1:1 petrol/ EtOAc) to give the title compound 
111 (2.20 g, 1.71 mmol, 14%) as a yellow oil. Rf (1:1 petrol/ EtOAc) 0.73; vmax/cm
-1
: 
3283 (N-H), 2957 (CH), 1736 (C=O), 1542 (NH-C=O); δH (400 MHz, CDCl3) 7.35 – 
7.12 (1H, m, NH), 6.93 – 6.83 (1H, m, NH), 5.22 – 5.05 (3H, m, 3 x CH2-CH-CH2), 
4.34 – 4.28 (2H, m, OCH2-CH), 4.25 – 4.18 (1H, m, NCH2-CH),  4.17 – 4.04 (4H, 
m, OCH2-CH), 3.88 – 3.76 (1H, m, NCH2-CH), 3.76 – 3.32 (4H, m, NH-CH2-CH), 
2.25 – 1.93 (12H, m, CO2-CH2), 1.73 – 1.66 (3H, m, N-CO-CH3), 1.51 – 1.37 (12H, 
m, 6 x CH2-CH2-CH2), 1.29 – 1.11 (12H, m, 6 x CH2-CH3), 0.77 (18H, tt, J 10.0, 
5.0, 6 x CH2-CH3); δC (100 MHz, CDCl3) 174.2, 174.1, 173.3, 173.1, 173.0, 172.7, 
169.7, 169.5, 169.1 (9 x C=O), 151.0, 150.5, 146.1 (3 x ArC), 99.3 (CCO-CI-CCO), 
89.9, 89.6 (CN-CI-CCO), 69.8, 69.7, 68.0 (3 x CH2-CH-CH2), 63.6, 63.0, 62.8 
(OCH2-CH), 46.3, 46.2 (NH-CH2-CH), 39.9 (N-CH2-CH), 33.9, 33.8, 33.7, 33.5, 
33.2, 33.1 (6 x CO2-CH2), 26.9, 26.8, 26.7, 26.5, 26.4, 26.2 (6 x CH2-CH2-CH2), 
22.8 (N-CO-CH3), 22.4, 22.3, 22.1, 22.0, 21.9, 21.8 (6 x CH2-CH3), 13.8, 13.7, 13.6, 
13.5, 13.4, 13.3 (6 x CH2-CH3); m/z (ES
+
) 1348.0 [M+Na]
+
, found: 1348.2160 
[M+Na]
+
 (C49H74I3N3NaO15 requires 1348.2152). 
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N
1
,N
3
-Bis((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5-(N-((2,2-dimethyl-1,3-
dioxolan-4-yl)methyl)acetamido)-2,4,6-triiodoisophthalamide (116 [CuSO4])  
 
Iohexol 55 (7.50 g, 9.13 mmol), anhydrous CuSO4 (2.91 g, 18.3 mmol) and TsOH 
(0.35 g, 1.83 mmol) were combined in acetone (100 mL) and heated to 50 
o
C for 3 
days. The solution was dried (MgSO4) and concentrated in vacuo to give the crude 
product 116 [CuSO4] (8.20 g) as a brown solid. This was purified by column 
chromatography (EtOAc) to give the title compound 116 [CuSO4] (5.50 g, 5.84 
mmol, 64%) as a white solid. Rf (EtOAc) 0.66; m.p. 264-265 
o
C; vmax/cm
-1
 3268 
(NH), 2983 (CH), 1686 (C=O), 1550 (NH-C=O); δH (400 MHz, CDCl3) 6.63 – 5.99 
(2H, m, NH), 4.47 – 4.26 (3H, m, CH), 4.20 – 4.01 (4H, m, NCH2-CH, OCH2-CH), 
3.80 – 3.60 (5H, m, NHCH2-CH, OCH2-CH), 3.46 – 3.30 (2H, m, NHCH2-CH), 3.22 
– 3.06 (1H, m, NCH2-CH), 1.82 (3H, s, NCO-CH3), 1.38 (6H, s, CO2(CH3)2), 1.28 
(9H, s, CO2(CH3)2), 1.22 (3H, s, CO2(CH3)2); δC (100 MHz, CDCl3) 170.3 (N-C=O), 
169.5, 169.4 (NH-C=O), 151.5, 151.2 (Ar-C-C=O), 148.9 (Ar-C-N), 109.7, 109.4, 
109.3 (CO2(CH3)2), 98.5 (CCO-CI), 89.8, 89.5 (CN-CI), 74.3, 73.8 (CH2-CH-CH2), 
68.9, 67.1 (OCH2-CH), 52.7 (NCH2-CH), 42.4, 42.2 (NH-CH2-CH), 27.1, 26.9, 25.5, 
25.3 (CO2(CH3)2), 22.9 (N-CO-CH3); m/z (ES
+
) 963.8 [M+Na]
+
, found 963.9641 
[M+Na]
+
 (C28H38I3N3NaO9 requires 963.9640); found C: 35.5, H: 4.0, N: 4.2, 
C28H38I3N3O9 requires C: 35.7, H: 4.1, N: 4.5. 
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N
1
,N
3
-Bis((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5-(N-((2,2-dimethyl-1,3-
dioxolan-4-yl)methyl)acetamido)-2,4,6-triiodoisophthalamide (116 [TsOH]) 
 
Iohexol 55 (7.50 g, 9.13 mmol) and TsOH (0.17 g, 0.91 mmol) were combined in 
DMF (75.0 mL), 2,2-dimethoxypropane (4.50 mL, 36.5 mmol) was added and the 
reaction left to stir at r.t. for 24 h. Water (50.0 mL) was added and the product 
extracted in EtOAc (3 x 100 mL). The combined organic layers were washed 2M aq. 
HCl (100 mL) and NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to 
give the crude product 116 [TsOH] (10.1 g) as a yellow solid. This was purified by 
column chromatography (EtOAc) to yield the title compound 116 [TsOH] (7.31 g, 
7.76 mmol, 85%) as a white solid. Rf (EtOAc) 0.58; m.p. 271-273 
o
C; vmax/cm
-1
 3265 
(NH), 2983 (CH), 1638 (C=O), 1546 (NH-C); δH (400 MHz, CDCl3) 6.71 – 6.34 
(2H, m, NH), 4.39 – 4.18 (3H, m, CH2-CH-CH2), 4.09 – 4.02 (1H, m, NCH2-CH), 
4.01 - 3.93 (2H, m, O-CH2-CH), 3.76 – 3.49 (6H, m, NHCH2-CH, OCH2-CH), 3.39 
– 3.21 (2H, m, NHCH2-CH), 3.16 - 2.98 (1H, m, NCH2-CH), 1.74 (3H, s, N-CO-
CH3), 1.30 (6H, s, CO2(CH3)2), 1.21 (9H, s, CO2(CH3)2), 1.13 (3H, s, CO2(CH3)2); 
δC (100 MHz, CDCl3) 170.3 (N-C=O), 169.4 (NH-C=O), 151.5, 151.2 (Ar-C-C=O), 
148.8 (Ar-C-N), 109.7, 109.3 (CO2(CH3)2), 98.4 (CO-CI), 89.9, 89.5 (CN-CI), 74.2, 
73.8 (CH2-CH-CH2), 69.0, 67.2 (OCH2-CH), 52.7 (NCH2-CH), 42.4 (NHCH2-CH), 
27.1, 26.9, 25.5, 25.3 (CO2(CH3)2), 23.0 (N-CO-CH3); m/z (ES
+
) 963.6 [M+Na]
+
, 
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found: 963.9644 [M+Na]
+
 (C28H38I3N3NaO9 requires 963.9640); found C: 35.3, H: 
4.0, N: 4.3, C28H38I3N3O9 requires C: 35.7, H: 4.1, N: 4.5. 
 
1,1-Dimethoxycyclopentane (123) 
 
Cyclopentanone (15.0 g, 0.18 mol), trimethyl orthoformate (39.1 mL, 0.36 mol) and 
zinc chloride (2.40 g, 0.02 mol) were combined in anhydrous methanol (75.0 mL) 
and heated to reflux for 4 days. The resulting crude mixture was distilled under 
vacuum to yield the title compound 123 (29-32 
o
C, 9.45g, 0.07 mol, 41%) as a 
colourless liquid. Rf (9:1 petrol/ EtOAc) 0.45; b.p. 29-32 
o
C (8 mbar), lit.
255
 b.p. 50 
o
C (27 mbar); vmax/cm
-1
 2950 (CH), 1450 (OCH3); δH (400 MHz, CDCl3) 3.13 (6H, 
s, OCH3), 1.72 – 1.65 (4H, m, C(OCH3)-CH2), 1.62 – 1.55 (4H, m, CH2-CH2); δC 
(100 MHz, CDCl3) 111.3 (C(OCH3)2), 49.2 (2 x OCH3), 34.3 (C(OCH3)-CH2), 23.3 
(CH2-CH2); m/z (ES
+
) 153.1 [M+Na]
+
, found: 153.088 [M+Na]
+
 (C7H14NaO2 
requires 153.0888). 
 
N
1
,N
3
-Bis(1,4-dioxaspiro[4.4]nonan-2-ylmethyl)-5-(N-(1,4-dioxaspiro[4.4]nonan-
2-ylmethyl)acetamido)-2,4,6-triiodoisophthalamide (124) 
 
Chapter 5: Experimental 
 
160 
 
Iohexol 55 (7.50 g, 9.13 mmol), dimethyl cyclopentanone ketal (4.75 g, 36.5 mmol) 
and TsOH (0.35 g, 1.83 mmol) were combined in DMF (30.0 mL) and stirred at r.t. 
for 30 h. Water (50.0 mL) was added and the product extracted with EtOAc (3 x 50.0 
mL). The combined organic layers were washed with 2M aq. HCl (100 mL) and sat. 
aq. NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to give the crude 
product 124 (6.22 g) as an off-white solid. This was purified by flash column 
chromatography (1:2 petrol/ EtOAc) to yield the title compound 124 (3.50 g, 3.47 
mmol, 38%) as a white solid. Rf (1:2 petrol / EtOAc) 0.36; m.p. 266-267 
o
C; 
vmax/cm
-1
 3250 (NH), 2934 (CH), 1638 (C=O), 1553 (NH-C=O); δH (400 MHz, 
CDCl3) 6.67 – 6.03 (2H, m, 2 x NH), 4.43 – 4.20 (3H, m, 3 x CH2-CH-CH2), 4.17 – 
4.06 (1H, m, NCH2-CH), 4.05 - 3.93 (3H, m, OCH2-CH), 3.84 – 3.55 (5H, m, 
NHCH2-CH, OCH2-CH), 3.34 – 3.30 (2H, m, NHCH2-CH), 3.24 – 3.08 (1H, m, 
NCH2-CH), 1.82 (3H, s, N-CO-CH3), 1.78 – 1.66 (12H, m, O2C-CH2-CH2),  1.62 – 
1.50 (12H, m, CH2-CH2); δC (100 MHz, CDCl3) 170.3 (N-C=O), 169.5, 169.3 (NH-
C=O) 151.5, 151.2 (Ar-C-C=O), 148.8 (Ar-C-N), 119.6 (O2C-(CH2)2), 119.2 (O2C-
(CH2)2), 100.6 (CO-CI-CO), 98.5, 98.4 (CN-CI), 73.8, 73.4 (CH2-CH-CH2), 68.8, 
67.1 (OCH2-CH), 52.6 (NCH2-CH), 42.5, 42.4 (NH-CH2-CH), 36.7, 36.6, 36.2, 36.0 
(O2C-CH2), 23.7, 23.6, 23.3, 23.3 (CH2-CH2), 23.0 (N-CO-CH3); m/z (ES
+
) 1041.8 
[M+Na]
+
, found: 1042.0104 [M+Na]
+
 (C34H44I3N3NaO9 requires 1042.0109); found 
C: 40.1, H: 4.4, N: 4.3, C34H44I3N3O9 requires C: 40.1, H: 4.4, N: 4.1. 
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N
1
,N
3
-Bis(1,4-dioxaspiro[4.5]decan-2-ylmethyl)-5-(N-(1,4-dioxaspiro[4.5]decan-
2-ylmethyl)acetamido)-2,4,6-triiodoisophthalamide (119) 
 
Iohexol 55 (7.00 g, 8.52 mmol), anhydrous CuSO4 (2.72 g, 17.05 mmol) and TsOH 
(0.32 g, 1.70 mmol) were combined in cyclohexanone (30.0 mL), stirred and heated 
to 85 
o
C for 6 days. The solution was diluted with EtOAc (30.0 mL), filtered, dried 
(MgSO4) and concentrated in vacuo to give crude product 119 (12.3 g) as brown oil. 
This was purified by column chromatography (19:1 petrol/ EtOAc) to furnish the 
title compound 119 (1.03 g, 1.02 mmol, 12%) as an off-white solid. Rf (19:1 petrol/ 
EtOAc) 0.52; m.p. 157 – 158 oC; vmax/cm
-1
 3274 (NH), 2930 (CH), 1648 (C=O), 
1541 (NH-C=O); δH (400 MHz, CDCl3) 6.50 – 6.30 (2H, m, NH), 4.52 – 4.32 (3H, 
m, CH2-CH-CH2), 4.25 – 3.99 (3H, m, OCH2-CH and NCH2-CH), 3.84 – 3.71 (6H, 
m, OCH2-CH and NHCH2-CH), 3.51 – 3.37 (2H, m, NHCH2-CH), 3.21 (1H, t, J 
12.0, NCH2-CH), 1.93 – 1.74 (3H, m, N-CO-CH3), 1.67 – 1.46 (24H, m, CH2 of 
cyclohexane ring), 1.38 (6H, s, CH2 of cyclohexane ring); δC (100 MHz, CDCl3) 
173.5 (N-C=O), 169.4, 169.2 (NH-C=O), 151.5, 151.2 (Ar-C-C=O), 148.9 (Ar-C-N), 
110.4, 110.1, 109.1 (O2C-(CH2)2), 100.9 (CO-CI-CO), 98.5, 98.4 (CO-CI-CN), 73.6, 
73.4 (CH2-CH-CH2), 68.4, 66.7 (OCH2-CH), 52.7 (NCH2-CH), 42.7, 42.5 (NHCH2-
CH), 36.7, 36.6, 35.0, 34.9, 34.7, 34.4, 25.1, 24.0, 23.8 (CH2 of cyclohexane ring), 
23.0 (N-CO-CH3); m/z (ES
+
) 1084.1 [M+Na]
+
, found 1084.0573 [M+Na]
+
 
(C37H50I3N3NaO9 requires 1084.0579). 
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1,1-Dimethoxycyclohexane (121)  
 
Cyclohexanone (10.0 g, 102 mmol), trimethyl orthoformate (22.3 mL, 204 mmol) 
and zinc chloride (1.39 g, 10.2 mmol) were combined in anhydrous methanol (50.0 
mL) and heated to reflux for 4 days. The resulting crude mixture was distilled under 
vacuum to give the title compound 121 (44-46 
o
C, 10.7 g, 74.5 mmol, 73%) as a 
colourless liquid. Rf (4:1 Petrol/ EtOAc) 0.63, b.p. 44-46 
o
C (8 mbar), Lit.
256
 b.p. 66 
o
C (26 mbar); vmax/cm
-1
: 2936 (CH), 1445 (COCH3); δH (400 MHz, CDCl3) 3.10 
(6H, s, 2 x C-O-CH3), 1.60 – 1.52 (4H, m, C(OCH3)2-CH2), 1.43 (4H, dt, J 11.5, 6.0, 
C(OCH3)2-CH2-CH2), 1.35 – 1.30 (2H, m, C-CH2-CH2-CH2); δC (100 MHz, CDCl3) 
99.6 (C(OCH3)2), 47.3 (2 x C-O-CH3), 32.7 (C(OCH3)2-CH2), 25.6 (C-CH2-CH2-
CH2), 22.8 (C(OCH3)2-CH2-CH2); m/z (ES
+
) 167.1 [M+Na]
+
, found: 167.1043 
[M+Na]
+
 (requires C8H16NaO2 167.1048). 
 
N
1
,N
3
-Bis(1,4-dioxaspiro[4.5]decan-2-ylmethyl)-5-(N-(1,4-dioxaspiro[4.5]decan-
2-ylmethyl)acetamido)-2,4,6-triiodoisophthalamide (119)  
 
Iohexol 55 (7.50 g, 9.13 mmol) and TsOH (1.74 g, 1.83 mmol) and cyclohexanone 
dimethyl ketal (5.60 mL, 36.5 mmol) were combined in DMF (30.0 mL) and stirred 
at r.t. for 24 h. Water (50.0 mL) was added and the product extracted in EtOAc (3 x 
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100 mL). The combined organic layers were washed with 2M aq. HCl (100 mL) and 
sat. aq. NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to give crude 
product 119 (9.29 g) as a white solid. This was purified by column chromatography 
(EtOAc) to yield the title compound 119 (6.71g, 6.30 mmol, 69%) as a white solid. 
Rf (EtOAc) 0.72; m.p. 154-156 
o
C; vmax/cm
-1
 3283 (NH), 2931 (CH), 1743 (C=O), 
1542 (NH-C=O); δH (400 MHz, CDCl3) 6.46 - 5.76 (2H, m, NH), 4.45 – 4.37 (1H, 
m, CH2-CH-CH2), 4.37 – 4.29 (2H, m, CH2-CH-CH2), 4.20 – 4.09 (1H, m, NCH2-
CH), 4.08 – 3.92 (3H, m, OCH2-CH), 3.80 – 3.63 (5H, m, OCH2-CH and NH-CH2-
CH), 3.45 – 3.30 (2H, m, NHCH2-CH), 3.22 – 3.09 (1H, m, NCH2-CH), 1.85 – 1.81 
(3H, m, N-CO-CH3),  1.61 – 1.40 (24H, m, CH2 of cyclohexane ring), 1.33 (6H, bs, 
CH2 of cyclohexane ring); δC (100 MHz, CDCl3) 171.4 (N-C=O), 169.3, 169.1 (NH-
C=O), 151.4, 151.2 (Ar-C-C=O), 148.9 (Ar-C-N), 110.4, 110.2, 109.8 (O2C-(CH2)2), 
100.4 (CO-CI-CO), 98.5, 98.4 (CO-CI-CN), 73.7, 73.6 (CH2-CH-CH2), 68.4, 66.9, 
66.7 (OCH2-CH), 52.7 (NCH2-CH), 42.7, 42.0 (NHCH2-CH), 36.9, 36.8, 36.7, 36.6, 
36.2, 35.4, 35.0, 34.9, 34.7, 27.0, 25.0, 24.0, 23.9, 23.8, 23.0 (CH2 of cyclohexane 
ring), 23.0 (N-CO-CH3); m/z (ES
+
) 1083.8 [M+Na]
+
, found: 1084.0583 [M+Na]
+
 
(C37H50I3N3NaO9 requires 1084.0579); found C: 42.1, H: 4.8, N: 3.8, C37H50I3N3O9 
requires C: 41.9, H: 4.8, N: 4.0. 
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5.2.3 Iodixanol (58) substrates  
 
5,5'-(2-Acetoxypropane-1,3-diyl)bis(acetylazanediyl)bis(N
1
,N
3
-
bis((diacetoxypropylcarbamoyl)-2,4,6-triiodoisophthalamide) (125) 
 
Iodixanol 58 solution was concentrated in vacuo to remove water, resulting in a 
colourless solid that was crushed up to give a white powdered solid. The solid (5.65 
g, 3.64 mmol) was combined with iodine (0.09 g, 0.36 mmol) in acetic anhydride 
(4.13 mL, 43.7 mmol) and stirred at r.t. for 6 days. Water (20.0 mL) was added and 
the product extracted with EtOAc (3 x 50.0 mL). The organic phase was washed 
with sat. aq. Na2S2O3 (2 x 100 mL), dried (MgSO4) and concentrated in vacuo to 
yield the title compound 125 (5.34g, 2.77 mmol, 76%) as a yellow solid. Rf (EtOAc) 
0.14; m.p. 154-155 
o
C; vmax/cm
-1
 3282 (NH), 2935 (CH), 1729 (C=O), 1541 (NH-
C=O); δH (400 MHz, CDCl3) 8.21 – 7.49 (2H, m, NH), 6.52 – 6.12 (2H, m, NH), 
5.49 – 5.13 (5H, m, CH2-CH-CH2), 4.55 – 4.33 (4H, m, OCH2-CH), 4.33 – 4.14 (4H, 
m, OCH2-CH), 4.14 – 3.85 (4H, m, NCH2-CH), 3.85 – 3.19 (8H, m, NHCH2-CH), 
2.18 – 1.97 (33H, m, 11 x CO-CH3); δC (100 MHz, CDCl3) 174.8, 171.4, 171.2, 
171.0, 170.9, 170.8, 170.7, 170.6, 170.5, 170.4, 170.2, 170.1, 169.9, 169.6, 169.5 
(C=O), 151.6, 151.5, 151.3, 151.2, 150.8, 150.7 (ArC-CO and ArC-N), 94.7, 94.0, 
90.8, 90.6, 90.4, 90.0 (ArC-I), 70.3, 70.1, 70.0, 69.9, 68.2 (CH2-CH-CH2), 63.3, 
63.2, 63.1, 63.0 (OCH2-CH), 40.2, 40.1, 40.0, 39.9, 39.8, 39.7 (NCH2-CH and 
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NHCH2-CH), 23.0, 22.9, 22.8, 21.4, 21.3, 21.3, 21.2, 21.2, 21.1, 20.8, 20.7 (CO-
CH3); m/z (ES
+
) 1950.3 [M+Na]
+
, found: 1928.8156 [M+H]
+
 (C53H63I6N6O24 
requires 1928.8156); found C: 32.5, H: 3.1; N: 4.3, C53H62I6N6O24 requires C: 33.0, 
H: 3.2, N: 4.4. 
 
5,5'-(2-hydroxypropane-1,3-diyl)bis(acetylazanediyl)bis(N
1
,N
3
-bis((2,2-
dimethyl-1,3-dioxolan-4-yl)methyl)-2,4,6-triiodoisophthalamide) (126) 
 
Iodixanol 58 (10.0 g, 6.45 mmol), TsOH (0.62 g, 3.24 mmol) and 2,2-
dimethoxypropane (4.76 mL, 38.7 mmol) were combined in DMF (100 mL) and 
stirred at r.t. for 24 h. Water (100 mL) was added and the product extracted in 
EtOAc (3 x 100 mL). The combined organic layers were washed with 2M aq. HCl 
(100 mL) and sat. aq. NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo 
to furnish the crude product 126 (6.29 g) as a yellow oil. This was purified by 
column chromatography (9:1 DCM/ methanol) to yield the title compound 126 (3.63 
g, 2.13 mmol, 33%) as a yellow solid. Rf (9:1 DCM/ methanol) 0.67; m.p. 167-169 
o
C; vmax/cm
-1
 3267 (NH), 2979 (CH), 1735 (C=O), 1542 (NH-C=O); δH (400 MHz, 
MeOD) 4.61 – 4.36 (5H, m, CH2-CH-CH2), 4.28 – 4.13 (4H, m, OCH2-CH), 4.08 – 
3.87 (4H, m, OCH2-CH), 3.60 – 3.41 (8H, m, NH-CH2-CH), 3.34 (4H, dt, J 3.0, 1.5, 
NH-CH2-CH), 1.97 – 1.86 (6H, m, N-CO-CH3), 1.46 (12H, s, CO2(CH3)2), 1.37 
(12H, s, CO2(CH3)2); δC (100 MHz, MeOD) 172.6, 172.5, 172.4, 172.3, 172.2, 172.1 
(C=O), 153.0, 152.9, 152.8, 152.7, 152.6, 152.5 (ArC-C and ArC-N), 110.7 
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(CO2(CH3)2), 91.4, 91.3, 91.2, 91.1, 90.7, 90.4 (ArC-I), 75.3, 75.2, 75.1, 75.1, 75.0 
(CH2-CH-CH2), 69.3, 69.1, 69.0, 68.9 (OCH2-CH), 44.0, 43.9, 43.8, 43.7, 43.7, 43.6 
(NHCH2-CH and NCH2-CH), 27.5, 27.4, 25.8, 25.7 (CO2(CH3)2), 23.2, 23.1 (N-CO-
CH3); m/z (ES
+
) 1732.4 [M+Na]
+
, found: 1732.8272 [M+Na]
+
 (C47H60I6N6NaO15 
requires 1732.8282); found C: 32.9, H: 3.6, N: 4.9, C47H60I6N6O15 requires C: 33.0, 
H: 3.6, N: 4.9. 
 
5.3 Experimental procedures for substrates synthesised in Chapter 3 
 
5.3.1 Substrates from the development of anthracene protected route using 
ethyl acrylate 
  
Ethyl-9,10-dihydro-9,10-endo-ethanoanthracene-11-(ethyl)-carboxylate (132) 
 
Anthracene 46a (15.0 g, 84.2 mmol), ethyl acrylate (9.27 g, 92.6 mmol) 131 and 
MEHQ (0.52 g, 4.21 mmol) were combined in xylene (100 mL) and heated to 130 
o
C for 24 h. The reaction mixture was allowed to cool to room temperature and then 
concentrated in vacuo to yield the crude product 132 (22.6 g, 96%, containing 10% 
starting material by 
1
H NMR) as a pale yellow solid. The product was used without 
further purification. A small amount of the crude ester 132 (0.15 g) was purified by 
column chromatography (30:1 petrol/ EtOAc) to obtain the title compound 132 (0.10 
g, 0.84 mmol, 1%) as a white solid. Rf (30:1 petrol/ EtOAc) 0.56; m.p. 101-103 
o
C; 
Lit
222
 m.p. 98 - 99 
o
C; vmax/cm
-1
 2961 (C-H), 1726 (C=O); δH (300 MHz, CDCl3) 
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7.17-7.32 (4H, m, Ar-H), 7.02-7.12 (4H, m, Ar-H), 4.67 (1H, d, J 2.5, ArC-CH-CH), 
4.32 (1H, t, J 2.5, Ar-C-CH-CH2), 4.01 (2H, qq, J 11.0, 7.0, OCH2-CH3), 2.85 (1H, 
ddd, J 11.5, 5.0, 2.5, ArC-CH-CH-CO2), 2.16 (1H, ddd, J 12.5, 5.0, 2.5, CH-CH2-
CH), 1.96 (1H, ddd, J 12.5, 10.5, 2.5, CH-CH2-CH), 1.17 (3H, t, J 7.0, OCH2-CH3); 
δC (75 MHz, CDCl3) 172.9 (C=O), 143.4, 143.0, 141.9, 139.4 (Ar-C), 125.6, 125.5, 
125.1, 125.1, 124.2, 123.1, 122.8, 122.7 (Ar-CH), 60.1 (OCH2-CH3), 46.3 (ArC-CH-
CH), 43.4 (ArC-CH-CH-CO2), 43.2 (ArC-CH-CH2), 30.1 (CH-CH2-CH), 13.7 
(OCH2-CH3); m/z (ES
+
) 301.0 [M+Na]
+
, 279.0 [M+H]
+
, found 301.1203 [M+Na]
+
 
(C19H18NaO2 requires 301.1204). Found C: 81.9, H: 6.5, C19H18O2 requires C: 82.0, 
H 6.5. 
 
Ethyl 9,10-dihydro-9,10-endoanthracene-11-carboxylic acid (133) 
 
The ethyl ester 132 (3.00 g, 10.8 mmol) and lithium hydroxide (1.00 g, 43.1 mmol) 
were dissolved in THF/H2O, 5:4 (20.0 mL), heated to reflux and left stirring for 24 h. 
The reaction was removed from the heat and allowed to cool, water (30.0 mL) and 
DCM (30.0 mL) were added. The product was extracted with DCM (3 x 30.0 mL), 
the aqueous layer was acidified (2M aq. HCl) and then re-extracted with DCM (2 x 
30.0 mL). The combined organic layers were dried (MgSO4) and concentrated in 
vacuo to furnish the title compound 133 (1.83 g, 68%, containing 10% starting 
material by 
1
H NMR) as a pale yellow solid. The product was used without further 
purification. A small amount of the crude acid 133 (0.10 g) was purified by re-
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crystallisation, firstly in methanol followed by hexane to yield title compound 133 
(0.08 mg, 0.32 mmol, 3%) as a white solid. Rf (20:1 petrol/ EtOAc) 0.66; m.p. 185-
186 
o
C; Lit
222
 m.p. 189 - 192 
o
C; vmax/cm
-1
 3020 (O-H), 2910 (C-H), 1707 (C=O); δH 
(400 MHz, CDCl3) 7.24-7.32 (4H, m, Ar-H), 6.94-7.18 (4H, m, Ar-H), 4.67 (1H, d, J 
2.5, ArC-CH-CH), 4.34 (1H, t, J 2.5, ArC-CH-CH2), 2.90 (1H, ddd, J 10.0, 5.0, 2.5, 
ArC-CH-CH-CO2), 2.11 (1H, ddd, J 12.5, 5.0, 2.5, CH-CH2-CH), 2.00 (1H, ddd, J 
12.5, 10.0, 2.5, CH-CH2-CH); δC (100 MHz, CDCl3) 179.6 (C=O), 143.8, 143.7, 
142.4, 139.7 (ArC), 126.3, 126.3, 125.8, 125.8, 125.1, 123.7, 123.6, 123.2 (ArC-H), 
46.6 (ArC-CH-CH), 44.0 (ArC-CH-CH-CO2), 43.8 (ArC-CH-CH2), 30.6 (CH-CH2-
CH); m/z (ES
+
) 273.1 [M+Na]
+
, 251.1 [M+H]
+
, found: [M+Na]
+
 273.0886 
(C17H14NaO2 requires 273.0891). 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-(benzyloxyethyl)- 
carboxylate (135a) 
 
Carboxylic acid 133 (0.65 g, 2.60 mmol) was dissolved in thionyl chloride (3.00 mL, 
41.4 mmol), and refluxed for 30 min before allowing to cool to r.t. The reaction was 
concentrated in vacuo to remove the thionyl chloride. Et2O (1.00 mL), pyridine (0.25 
mL, 2.86 mmol), and 2-benzyloxy ethanol (0.45 mL, 2.86 mmol) were added to the 
resulting acid chloride and the reaction was heated to 30 
o
C for 24 h. The product 
was extracted with Et2O (2 x 10.0 mL), washed with 2M aq. HCl (2 x 10.0 mL) and 
sat. aq. NaHCO3 (2 x 10.0 mL), dried (MgSO4) and concentrated in vacuo to give 
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crude product 135a (0.71 g, 1.85 mmol, 71%) as an orange oil. The crude product 
was purified by column chromatography (10:1 hexane/ EtOAc) to obtain the title 
compound 135a (0.32 g, 0.88 mmol, 34%) as a yellow oil. Rf (10:1 hexane/ EtOAc) 
0.22; vmax/cm
-1
 2947 (C-H), 2865 (C-O), 1729 (C=O); δH (500 MHz, CDCl3) 7.22-
7.41 (8H, m, Ar-H), 6.97-7.21 (5H, m Ar-H), 4.70 (1H, d, J  2.5, ArC-CH-CH), 4.56 
(2H, s, OCH2-ArC), 4.34 (1H, t, J  2.5, ArC-CH-CH2), 4.21 (1H, ddd, J  12.0, 6.0, 
3.5, CO2CH2-CH2O), 4.13 (1H, ddd, J  12.0, 6.0, 3.5, CO2CH2-CH2O), 3.51-3.71 
(2H, m, CO2CH2-CH2O), 2.92 (1H, ddd, J 10.5, 4.5, 2.5, ArC-CH-CH-CO2), 2.18 
(1H, ddd, J  12.5, 4.5, 2.5, CH-CH2-CH), 1.99 (1H, ddd, J 12.5, 10.0, 2.5, CH-CH2-
CH); δC (100 MHz, CDCl3) 173.5 (C=O), 144.1, 143.7, 142.5, 140.0, 138.0 (ArC), 
129.8, 128.6, 127.9, 127.8, 126.3, 126.2, 125.8, 125.8, 124.9, 123.8, 123.5, 123.3, 
122.8 (ArC-H), 73.2 (OCH2-ArC), 68.1 (CO2CH2-CH2O), 63.9 (CO2CH2-CH2O), 
46.9 (ArC-CH-CH), 44.1 (ArC-CH-CH-CO2), 43.9 (ArC-CH-CH2), 30.8 (CH-CH2-
CH); m/z (ES
+
) 407.2 [M+Na]
+
, 385.1 [M+H]
+
 found: [M+Na]
+
 407.1618 
(C26H24NaO3 requires 407.1623). 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-(benzyl)-carboxylate (135b) 
 
Carboxylic acid 133 (0.50 g, 2.00 mmol) was dissolved in thionyl chloride (3.00 mL, 
41.4 mmol), stirred and refluxed for 30 min before allowing to cool to r.t. The 
reaction was concentrated in vacuo to remove the thionyl chloride. Diethyl ether 
(1.50 mL), pyridine (0.18 mL, 2.2 mmol), and benzyl alcohol (0.23 mL, 2.2 mmol) 
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were added to the resulting acid chloride and the reaction was heated to 30 
o
C for 24 
h. The product was extracted with Et2O (2 x 10.0 mL), washed with 2M aq. HCl (2 x 
10.0 mL) and sat. aq. NaHCO3 (2 x 10.0 mL), dried (MgSO4) and concentrated in 
vacuo to give crude product 135b (0.55 g, 81%) as an orange oil. The crude product 
was purified by column chromatography (hexane) to furnish the title compound 
135b (0.08 g, 0.26 mmol, 13%) as an off-white solid. Rf (hexane) 0.39; m.p. 76.2-
78.3 
o
C; vmax/cm
-1
 3021, 2985 (C-H), 1723 (C=O); δH (400 MHz, CDCl3) 7.22-7.36 
(8H, m, Ar-H), 6.99-7.11 (5H, m, Ar-H), 5.01 (2H, ABq, J 12.5, OCH2-ArC), 4.67 
(1H, d, J 2.0, ArC-CH-CH), 4.33 (1H, s, ArC-CH-CH2), 2.92 (1H, m, ArC-CH-CH-
CO2), 2.22 (1H, ddd, J 12.5, 3.0, 2.5, CH-CH2-CH), 1.99 (1H, m, CH-CH2-CH); δC 
(100 MHz, CDCl3) 173.5 (C=O), 144.0, 143.7, 142.4, 139.9, 135.9 (ArC), 128.6, 
128.5, 128.3, 128.1, 126.3, 126.2, 126.0, 125.8, 124.8, 124.6, 123.7, 123.5, 123.3 
(ArC-H), 66.6 (OCH2-ArC), 46.9 (ArC-CH-CH), 44.1 (ArC-CH-CH2), 43.8 (ArC-
CH-CH-CO2), 30.7 (CH-CH2-CH); m/z (ES
+
) 363.1 [M+Na]
+
, found: [M+Na]
+
 
363.1356 (C24H20NaO2 requires 363.1361). 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-(dodecyl)-carboxylate 
(135c)  
 
Carboxylic acid 133 (0.50 g, 2.00 mmol) was dissolved in thionyl chloride (3.00 mL, 
41.4 mmol), stirred and refluxed for 30 min before allowing to cool to r.t. The 
reaction was concentrated in vacuo to remove the thionyl chloride. Et2O (1.50 mL), 
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pyridine (0.18 mL, 2.2 mmol), and dodecanol (0.49 mL, 2.2 mmol) were added to 
the resulting acid chloride and the reaction was heated to 30 
o
C for 24 h. The product 
was extracted with Et2O (2 x 10.0 mL), washed with 2M aq. HCl (2 x 10.0 mL) and 
sat. aq. NaHCO3 (2 x 10.0 mL), dried (MgSO4) and concentrated in vacuo to give 
crude product 135c (0.52 g, 62%) as red/brown crystals. The crude product was 
purified by column chromatography (hexane), followed by re-crystallisation in 
hexane to obtain the title compound 135c (0.10 g, 0.24 mmol, 12%) as a pale yellow 
solid. Rf (hexane) 0.74; m.p. 68.1-69.7 
o
C; vmax/cm
-1
 2917, 2850 (C-H), 1731 (C=O); 
δH (400 MHz, CDCl3) 7.21-7.33 (4H, m, Ar-H), 7.04-7.12 (4H, m, Ar-H), 4.67 (1H, 
d, J 2.5, ArC-CH-CH), 4.33 (1H, t, J 2.5, ArC-CH-CH2), 3.90-4.01 (2H, m, OCH2-
CH2), 2.87 (1H, ddd, J 10.0, 4.5, 2.5, ArC-CH-CH-CO2), 2.17 (1H, ddd, J 12.5, 4.5, 
2.5, CH-CH2-CH), 1.98 (1H, ddd, J 12.5, 7.5, 2.5, CH-CH2-CH), 1.28 (22H, s, CH2 
chain), 0.88 (3H, t, J 6.5, CH2-CH3); δC (100 MHz, CDCl3) 173.6 (C=O), 144.0, 
143.7, 142.6, 140.0 (ArC), 126.2, 125.7, 125.6, 124.8, 123.7, 123.5, 123.3 (ArC-H), 
64.9 (OCH2-CH2), 46.9 (ArC-CH-CH), 44.2 (ArC-CH-CH-CO2), 43.9 (ArC-CH-
CH2), 31.9, 30.8, 29.9, 29.8, 29.7, 29.6, 29.4, 29.3, 28.7, 26.0 (CH-CH2-CH), 22.7 
(CH2-CH3); m/z (ES
+
) 441.1 [M+Na]
+
, 419.1 [M+H]
+
, found: [M+Na]
+
 441.2764 
(C29H38NaO2 requires 441.2770); found C: 83.1, H: 9.2, C29H38O2 requires C: 83.2, 
H: 9.2.  
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Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-(pentenyl)-carboxylate 
(135d) 
 
Carboxylic acid 133 (1.42 g, 5.68 mmol) was dissolved in thionyl chloride (4.0 mL, 
55.1 mmol), stirred and refluxed for 30 min before allowing cooling to r.t. The 
reaction was concentrated in vacuo to remove the thionyl chloride. Et2O (2.00 mL), 
pyridine (0.50 mL, 6.25 mmol), and 4-penten-1-ol (0.42 mL, 6.25 mmol) were added 
to the resulting acid chloride and the reaction was heated to 30 
o
C for 24 h. The 
product was extracted with Et2O (2 x 10.0 mL), washed with HCl (2 x 10.0 mL) and 
NaHCO3 (2 x 10.0 mL), dried (MgSO4) and concentrated in vacuo to give crude 
product 135d (0.70 g, 39%) as an orange oil. The crude product was purified three 
times by column chromatography (30:1, 20:1 hexane/ EtOAc, 10:1 hexane/ Et2O) to 
give the title compound 135d (0.03 g, 0.11 mmol, 2%) as a yellow oil. Rf (10:1 
hexane/ Et2O) 0.32; vmax/cm
-1
 2949 (C-H), 1730 (C=O), 1640 (C=C); δH (400 MHz, 
CDCl3) 7.22-7.33 (4H, m, 4 x Ar-H), 7.05-7.11 (4H, m, 4 x Ar-H), 5.73-5.83 (1H, m, 
CH2-CH=CH2), 4.98-5.07 (2H, m, CH=CH2), 4.67 (1H, d, J 2.0, ArC-CH-CH), 4.37 
(1H, s, ArC-CH-CH2), 3.98 (2H, m, q, J 10.5, 6.5, CH2-CH2-CH=CH2), 2.87 (1H, dt, 
J 10.0, 3.5, ArC-CH-CH-CO2), 2.13-2.19 (1H, m, CH-CH2-CH), 1.96-2.08 (3H, m, 
CH-CH2-CH and OCH2-CH2), 1.62-1.68 (2H, p, J 13.5, 7.0, OCH2-CH2-CH2); δC 
(100 MHz, CDCl3) 173.6 (C=O), 143.9, 143.7, 142.5, 140.0 (ArC), 137.5 (CH2-
CH=CH2), 126.3, 126.1, 125.8, 125.7, 124.8, 123.7, 123.5, 123.3 (ArC-H), 115.3 
(CH=CH2), 64.2 (CH2-CH2-CH=CH2), 47.0 (ArC-CH-CH), 44.2 (ArC-CH-CH-
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CO2), 43.9 (ArC-CH-CH2), 30.8 (CH-CH2-CH), 30.1 (OCH2-CH2), 27.9 (OCH2-
CH2); m/z (ES
+
) 341.1 [M+Na]
+
, 319.0 [M+H]
+
 found: [M+Na]
+
 341.1512 
(C22H22NaO2 requires 341.1517). 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-(cyclohexenyl)-carboxylate 
(135e) 
 
Carboxylic acid 133 (0.50 g, 2.00 mmol) was dissolved in thionyl chloride (3.00 mL, 
41.4 mmol), stirred and refluxed for 30 min before allowing to cool to r.t. The 
reaction was concentrated in vacuo to remove the thionyl chloride. Et2O (1.00 mL), 
pyridine (0.18 mL, 2.2 mmol), and cyclohexen-1-ol (0.22 mL, 2.2 mmol) were added 
to the resulting acid chloride and the reaction was heated to 30 
o
C for 24 h. The 
product was extracted with Et2O (2 x 10.0 mL), washed with 2M aq. HCl (2 x 10.0 
mL) and sat. aq. NaHCO3 (2 x 10.0 mL), dried (MgSO4) and concentrated in vacuo 
to give crude product 135e (0.42 g, 64%) as a yellow oil. The crude product was 
purified by column chromatography (10:1 hexane/ Et2O), to yield the title compound 
135e (0.10 g, 0.30 mmol, 15%) as an off-white solid. Rf (10:1 hexane/ Et2O) 0.29; 
m.p. 110-111 
o
C; vmax/cm
-1
 2905 (C-H), 1912 (C=C), 1732 (C=O); δH (400 MHz, 
CDCl3) 7.02-7.32 (4H, m, Ar-H), 7.04-7.12 (4H, m, Ar-H), 5.92-5.97 (1H, m, CH2-
CH=CH), 5.56-5.62 (1H, m, CH-CH=CH), 5.14 (1H, s, OCH-CH=CH), 4.68 (1H, d, 
J 1.0, ArC-CH-CH), 4.34 (1H, s, ArC-CH-CH2), 2.87 (1H, ddd, J 10.0, 4.5, 2.5, 
ArC-CH-CH-CO2), 1.92-2.22 (4H, m, CH-CH2-CH and CH=CH-CH2), 1.55-1.81 
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(4H, m, OCH-CH2-CH2 and OCH-CH2-CH2); δC (100 MHz, CDCl3) 173.1 (C=O), 
144.1, 143.7, 142.5, 139.9 (ArC), 132.7 (CH=CH-CH2), 132.6 (CH=CH-CH2), 
126.1, 125.8, 125.7, 125.6, 124.9, 124.7, 123.7, 123.4 (ArC-H), 68.3 (OCH-
CH=CH), 47.1 (ArC-CH-CH), 44.1 (ArC-CH-CH2), 43.9 (ArC-CH-CH-CO2), 30.6 
(CH-CH2-CH), 28.4 (CH=CH-CH2), 28.2 (OCH-CH2-CH2), 24.9 (OCH-CH2-CH2); 
m/z (ES
+
) 353.1 [M+Na]
+
, found: [M+Na]
+
 353.1512 (C23H22NaO2 requires 
353.1517).  
 
5.3.2 Anthracene protected esters from cyanoacrylate 
 
Ethyl-9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(methyl)-
carboxylate (137) 
 
Anthracene 46a (10.0 g, 60.0 mmol), methyl cyanoacrylate 136 (8.90 g, 80.0 mmol) 
and MEHQ (0.4g, 3.00 mmol) were combined in toluene (100 mL) stirred and heated 
to reflux for 24 h. Once cool the reaction was concentrated in vacuo to give the crude 
product 137 (15.9 g) as a yellow solid. This was purified by column chromatography 
(9:1 petrol/ EtOAc) to yield the title compound 137 (12.3 g, 42.6 mmol, 71%) as a 
pale yellow solid. Rf (9:1 petrol/ EtOAc) 0.43; m.p. 95-97 
o
C, lit
257
 m.p. 91-92 
o
C; 
vmax/cm
-1
 2975 (C-H), 2235(C≡N), 1751 (C=O); δH (400 MHz, CDCl3) 7.04-7.52 
(8H, m, Ar-H), 4.86 (1H, s, ArC-CH-CCN), 4.36 (1H, t, J 2.5, ArC-CH-CH2), 3.60 
(3H, s, OCH3), 2.74 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 2.14 (1H, dd, J 13.0, 2.5, 
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CH-CH2-CCN); δC (100 MHz, CDCl3) 167.4 (C=O), 143.1, 142.4, 138.1, 137.3 
(ArC), 127.7 127.5, 126.7, 126.5, 125.9, 124.9, 124.0, 123.7 (ArC-H), 119.9 (CN), 
54.0 (O-CH3), 51.8 (ArC-CH-CCN), 47.4 (CCN), 43.2 (ArC-CH-CH2), 38.2 (CH-
CH2-CCN); m/z (ES
+
) 312.0 [M+Na]
+
, found: [M+Na]
+
 312.0995 (C19H15NNaO2 
requires 312.1000). 
 
Ethyl 9,10-dihydro-9,10-endoanthracene-11-cyano-11-carboxylic acid (49) 
 
Methyl ester 137 (468 g, 1.62 mol) was combined in KOH solution (181.5 g in 750 
mL) and ethanol (750 mL), stirred and refluxed for 4.5 h. The reaction was allowed 
to cool; water (750 mL) was added followed by 2M aq. HCl acid until solid stopped 
crashing out of solution (approx. 1L). Suction filtration resulted in the crude 
carboxylic acid 49 (391 g) as a yellow solid. This was reacted on without 
purification, for analysis 1.50 g was purified by column chromatography (9:1 petrol/ 
EtOAc) to yield the title compound 49 (0.90 g, 3.24 mmol, 0.2% overall) as a white 
solid. Rf (9:1 petrol/ EtOAc) 0.03; m.p. 185-186 
o
C; vmax/cm
-1
 3050 b (OH), 1716 
(C=O); δH (400 MHz, CDCl3) 7.49-7.07 (8H, m, Ar-H), 4.85 (1H, s, ArC-CH-CCN), 
4.42 (1H, s, ArC-CH-CH2), 3.98 (1H, s, OH), 2.68 (1H, dd, J 13.0, 2.5, CH-CH2-
CCN), 2.20 (1H, dd, J 13.0, 2.5, CH-CH2-CCN); δC (100 MHz, CDCl3) 170.6 
(C=O), 142.8, 142.5, 138.3, 137.3 (ArC), 127.6, 127.5, 126.6, 126.4, 125.8, 125.4, 
123.7, 123.6 (ArC-H), 120.4 (CN), 51.6 (ArC-CH-CCN), 47.9 (CCN), 43.2 (ArC-
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CH-CH2), 38.1 (CH-CH2-CN); m/z (ES
+
) 298.0 [M+Na]
+
, found: 298.0838 [M+Na]
+
 
(C18H13NNaO2 requires 298.0844).  
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(butyl)-
carboxylate (138a) 
 
Carboxylic acid 49 (20.0 g, 0.07 mol) and thionyl chloride (20.0 mL) were combined 
in chloroform (30.0 mL) and heated to reflux for 6 h. Excess thionyl chloride was 
removed in vacuo, before butan-1-ol (10.1 mL, 0.11 mol), pyridine (6.40 mL, 0.08 
mol) and chloroform (100 mL) were added and heated to reflux for 36 h. The 
reaction was allowed to cool to r.t., water (100 mL) was added and the product 
extracted with Et2O (3 x 100 mL). The combined organic phase was washed with 
2M aq. HCl (100 mL) and sat. aq. NaHCO3 (100 mL), dried (MgSO4) and 
concentrated in vacuo to yield the crude product 138a as an orange solid (11.0 g). 
This was purified by flash column chromatography (19:1 petrol/ EtOAc), followed 
by re-crystallisation (petrol) to furnish the title compound 138a (1.52 g, 0.42 mmol, 
6%) as a yellow solid. Rf (9:1 petrol/EtOAc) 0.58; m.p. 81 – 82 
o
C; vmax/cm
-1
 2957 
(CH), 1743 (C=O); δH (400 MHz, CDCl3) 7.52 – 7.42 (2H, m, Ar-H), 7.35 – 7.25 
(2H, m, Ar-H), 7.24 – 7.07 (4H, m, Ar-H), 4.85 (1H, s, ArC-CH-CCN), 4.41 (1H, t, 
J 2.5, ArC-CH-CH2), 4.07 (2H, td, J 6.5, 1.0, OCH2-CH2), 2.80 (1H, dd, J 13.0, 2.5, 
CH-CH2-CCN), 2.19 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 1.66 – 1.56 (2H, m, 
OCH2-CH2-CH2), 1.46 – 1.32 (2H, m, CH2-CH2-CH3), 0.94 (3H, t, J 7.5, CH2-CH3); 
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δC (100 MHz, CDCl3) 166.9 (C=O), 143.0, 142.4, 138.0, 137.2 (ArC), 128.2, 127.6, 
126.6, 125.8, 125.4, 125.0, 123.9, 123.6 (ArC-H), 119.9 (CN), 67.1 (OCH2-CH2), 
51.8 (ArC-CH-CCN), 47.4 (CCN), 43.2 (ArC-CH-CH2), 38.0 (CH-CH2-CCN), 30.5 
(OCH2-CH2-CH2), 19.1 (CH2-CH2-CH3), 13.7 (CH2-CH3); m/z (ES
+
) 354.0 
[M+Na]
+
, found: 354.1467 [M+Na]
+
 (C22H21NNaO2 requires 354.1470); found C: 
80.1, H: 6.4, N: 4.1, C22H21NO2 requires C: 79.7, H: 6.4, N: 4.2. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(2-methylpropyl) 
carboxylate (138b) 
 
Carboxylic acid 49 (20.0 g, 0.07 mol) and thionyl chloride (20.0 mL, 276 mmol) 
were combined in chloroform (30.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, 2-methyl-1propanol (10.1 mL, 0.11 mol), pyridine 
(6.40 mL, 0.08 mol) and chloroform (100 mL) were added and heated to reflux for 
36 h. The reaction was allowed to cool to r.t., water (100 mL) was added and the 
product extracted with DCM (3 x 100 mL). The combined organic phase was washed 
with 2M aq. HCl and sat. aq. NaHCO3 (100 mL), dried (MgSO4) and concentrated in 
vacuo to yield the crude product 138b as a brown solid (19.7 g). This was purified 
by flash column chromatography (19:1 petrol/ EtOAc), followed by re-crystallisation 
(petrol) to furnish the title compound 138b (6.04 g, 0.02 mol, 25%) as a pale yellow 
solid. Rf (19:1 petrol/EtOAc) 0.36; m.p. 99 – 100 
o
C; vmax/cm
-1
 2962 (CH), 1746 
(C=O); δH (400 MHz, CDCl3) 7.53 – 7.42 (1H, m, Ar-H), 7.34 – 7.27 (2H, m, Ar-H), 
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7.24 – 7.07 (5H, m, Ar-H), 4.86 (1H, s, ArC-CH-CCN), 4.41 (1H, t, J 2.5, ArC-CH-
CH2), 3.84 (2H, dd, J 10.5, 6.5, OCH2-CH(CH3)2), 2.80 (1H, dd, J 13.0, 2.5, CH-
CH2-CCN), 2.20 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 1.95 (1H, dp, J 13.5, 6.5, 
OCH2-CH-(CH3)2), 0.95 (6H, dd, J 6.5, 4.5, CH-(CH3)2); δC (100 MHz, CDCl3) 
166.8 (C=O), 143.0, 142.4, 138.0, 137.2 (ArC), 128.2, 127.6, 126.6, 126.4, 125.9, 
125.0, 123.9, 123.6 (ArC-H), 119.9 (CN), 73.2 (OCH2-CH-(CH3)2), 51.9 (ArC-CH-
CCN), 47.5 (CCN), 43.2 (ArC-CH-CH2), 38.0 (CH-CH2-CCN), 27.7 (OCH2-CH-
(CH3)2), 19.1, 19.0 (OCH2-CH-(CH3)2); m/z (ES
+
) 354.0 [M+Na]
+
, found: 354.1465 
[M+Na]
+
 (C22H21NNaO2 requires 354.1470); found C: 80.0, H: 6.4, N: 4.2, 
C22H21NO2 requires C: 79.7, H: 6.4, N: 4.2. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(2-butyl)-
carboxylate (138c) 
 
Carboxylic acid 49 (20.0 g, 0.07 mol) and thionyl chloride (20.0 mL, 276 mmol) 
were combined in chloroform (30.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, butan-2-ol (10.1 mL, 0.11 mol), pyridine (6.40 mL, 
0.08 mol) and chloroform (100 mL) were added and heated to reflux for 36 h. The 
reaction was allowed to cool to r.t., water (100 mL) was added and the product 
extracted with Et2O (3 x 100 mL). The combined organic phase was washed with 
2M aq. HCl (100 mL) and NaHCO3 (100 mL), dried (MgSO4) and concentrated in 
vacuo to yield the crude product 138c as a brown oil (22.4 g). This was purified by 
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flash column chromatography twice (19:1 petrol/ EtOAc then 6:1 petrol/ EtOAc) to 
give the title compound 138c (12.0 g, 0.035 mol, 50%) as an orange oil. Rf (6:1 
petrol/ EtOAc) 0.37; vmax/cm
-1
 2971 (CH), 1741 (C=O); δH (400 MHz, CDCl3) 7.51 
– 7.45 (1H, m, Ar-H), 7.34 – 7.28 (2H, m, Ar-H), 7.22 – 7.17 (3H, m, Ar-H), 7.17 – 
7.07 (2H, m, Ar-H), 4.85 (1H, d, J 9.0, ArC-CH-CCN), 4.80 – 4.67 (1H, m, OCH-
CH3), 4.41 (1H, t, J 2.5, ArC-CH-CH2), 2.80 (1H, ddd, J 13.0, 8.0, 2.5, CH-CH2-
CCN), 2.18 (1H, ddd, J 13.0, 8.0, 2.5, CH-CH2-CCN), 1.72 – 1.49 (2H, m, OCH-
CH2-CH3), 1.19 (3H, ABq, J 6.5, OCH-CH3), 0.92 (3H, ABq, J 7.5, OCH-CH2-
CH3); δC (100 MHz, CDCl3) 166.4, 166.3 (C=O), 143.1, 143.0, 142.5, 142.4, 138.2, 
138.1, 137.1, 137.0 (ArC), 127.6, 127.6, 127.5, 126.6, 126.3, 126.2, 125.8, 125.2, 
123.9, 123.8, 123.6, 123.6 (ArC-H), 120.1, 120.0 (CN), 75.9, 75.8 (OCH-CH3), 51.8, 
51.7 (Ar-CH-CCN), 47.7, 47.3 (ArC-CH-CCN), 43.2 (ArC-CH-CH2), 38.0, 37.8 
(ArC-CH-CH2), 28.7, 28.6 (OCH-CH2-CH3), 19.6, 18.8 (OCH-CH3), 9.8, 9.6 (OCH-
CH2-CH3); m/z (ES
+
) 354.0 [M+Na]
+
, found: 354.1465 [M+Na]
+
 (C22H21NNaO2 
requires 354.1470). 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(tert-butyl)-
carboxylate (138d) 
 
Carboxylic acid 49 (20.0 g, 0.07 mol) and thionyl chloride (20.0 mL, 276 mmol) 
were combined in chloroform (30.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, tert-butanol (10.5 mL, 0.11 mol), pyridine (6.40 mL, 
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0.08 mol) and chloroform (100 mL) were added and heated to reflux for 7 days. The 
reaction was allowed to cool to r.t., water (100 mL) was added and the product 
extracted with Et2O (3 x 100 mL). The combined organic phase was washed with 
2M aq. HCl (100 mL) and sat. aq. NaHCO3 (100 mL), dried (MgSO4) and 
concentrated in vacuo to give the crude product 138d as a yellow solid (13.60 g). 
This was purified by flash column chromatography (9:1 petrol/ EtOAc), followed by 
re-crystallisation (petrol) to furnish the title compound 138d (5.10 g, 0.02 mol, 23%) 
as an off-white solid. Rf (9:1 petrol/ EtOAc) 0.54; m.p. 165 – 166 
o
C; vmax/cm
-1
 2985 
(CH), 1745 (C=O); δH (400 MHz, CDCl3) 7.51 – 7.44 (1H, m, Ar-H), 7.33 – 7.28 
(2H, m, Ar-H), 7.24 – 7.13 (4H, m, Ar-H), 7.13 – 7.07 (1H, m, Ar-H), 4.81 (1H, s, 
ArC-CH-CCN), 4.40 (1H, t, J 2.5, ArC-CH-CH2), 2.76 (1H, dd, J 13.0, 2.5, CH-
CH2-CCN), 2.14 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 1.40 (9H, s, C(CH3)3); δC (100 
MHz, CDCl3) 165.4 (C=O), 143.1, 142.4, 138.3, 137.2 (ArC), 127.6, 127.4, 126.5, 
126.1, 125.8, 125.3, 123.8, 123.5 (Ar-C-H), 120.3 (CN), 84.1 (OC(CH3)3), 51.9 
(ArC-CH-CCN), 48.0 (CCN), 43.2 (ArC-CH-CH2), 37.8 (CH-CH2-CCN), 27.7 
(C(CH3)3); m/z (ES
+
) 354.0 [M+Na]
+
, found: 354.1465 [M+Na]
+
 (C22H21NNaO2 
requires 354.1470); found C: 79.9, H: 6.4; N: 4.2, C22H21NO2 requires C: 79.7, H: 
6.4, N: 4.2. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(phenyl)-
carboxylate (139a) 
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Carboxylic acid 49 (2.00 g, 7.26 mmol) was combined with thionyl chloride (5.00 
mL, 68.9 mmol) in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, chloroform (20.0 mL), phenol (1.03 g, 10.9 mmol) 
and pyridine (0.65 mL, 7.99 mmol) was added and the reaction refluxed for 36 h. 
Water (50.0 mL) was added and the product was extracted with Et2O (3 x 50.0 mL). 
The organic phase was washed with 2M aq. HCl (100 mL) and sat. aq. NaHCO3 
(100 mL), dried (MgSO4) and concentrated in vacuo to give the crude product 139a 
(2.51 g) as a yellow solid. This was purified by column chromatography (9:1 petrol/ 
EtOAc), followed by recrystalisation (hexane) to yield the title compound 139a (1.00 
g, 2.76 mmol, 38%) as a white solid. Rf (9:1 petrol/ EtOAc) 0.33; m.p. 172 – 173 
o
C; 
vmax/cm
-1 
2320 (CN), 1774 (C=O); δH (400 MHz, CDCl3) 7.57 – 7.51 (1H, m, Ar-H), 
7.40 – 7.32 (5H, m, Ar-H), 7.27 – 7.14 (5H, m, Ar-H), 7.00 – 6.94 (2H, m, Ar-H), 
5.09 (1H, s, ArC-CH-CCN), 4.47 (1H, t, J 2.5, ArC-CH-CH2), 2.91 (1H, dd, J 13.0, 
2.5, CH-CH2-CCN), 2.29 (1H, dd, J 13.0, 2.5, CH-CH2-CCN); δC (100 MHz, 
CDCl3) 165.6 (C=O), 150.4 (O-ArC), 143.0, 142.4, 137.7, 137.0 (ArC), 129.6, 
127.9, 127.7, 126.8, 126.6, 126.5, 126.0, 125.2, 124.2, 123.7, 121.0, 120.6, 119.4 
(ArC-H), 115.3 (CCN), 51.9 (ArC-CH-CCN), 47.6 (CN), 43.2 (ArC-CH-CH2), 38.1 
(CH-CH2-CCN); m/z (ES
+
) 374.1 [M+Na]
+
, found 374.1148 [M+Na]
+
 
(C24H17NNaO2 requires 374.1157); Found C: 81.9, H: 4.9, N: 3.9, C24H17NO2 
requires C: 82.0, H: 4.9, N: 4.0. 
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Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(4-methylphenyl)-
carboxylate (139b) 
 
Carboxylic acid 49 (2.00 g, 7.26 mmol) was combined with thionyl chloride (10.0 
mL, 138 mmol) in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, chloroform (20.0 mL), pyridine (0.65 mL, 7.99 
mmol) and p-cresol (1.18 g, 10.9 mmol) were added and heated to reflux for 36 h. 
Water (50 mL) was added and the product extracted with Et2O (3 x 50.0 mL). The 
combined organic layers were washed with 2M aq. HCl (100 mL) and sat. aq. 
NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to give crude product 
139b as yellow/ orange solid (3.28 g). This was purified by column chromatography 
(9:1 petrol/ EtOAc) to yield the title compound 139b (1.25 g, 3.48 mmol, 48%) as a 
yellow solid. Rf (9:1 petrol/ EtOAc) 0.20; m.p. 169 – 170 
o
C; vmax/cm
-1
 2940 (CH), 
1768 (C=O); δH (400 MHz, CDCl3) 7.56 – 7.50 (1H, m, Ar-H), 7.37 – 7.32 (3H, m, 
Ar-H), 7.26 – 7.12 (6H, m, Ar-H), 6.87 – 6.82 (2H, m, Ar-H), 5.08 (1H, s, ArC-CH-
CCN), 4.47 (1H, t, J 2.5, ArC-CH-CH2), 2.91 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 
2.32 (3H, s, ArC-CH3), 2.28 (1H, dd, J 13.0, 2.5, CH-CH2-CCN); δC (100 MHz, 
CDCl3) 165.7 (C=O), 148.3, 143.1, 142.4, 137.7, 137.0, 136.3 (6 x ArC), 130.1 (2 x 
ArC-H), 127.9, 127.7, 126.7, 126.5, 126.0, 125.2, 124.2, 123.6 (8 x ArC-H), 120.6 (2 
x ArC-H), 119.4 (CN), 51.9 (ArC-CH-CCN), 47.5 (CCN), 43.2 (ArC-CH-CH2), 38.1 
(CH-CH2-CCN), 20.9 (ArC-CH3); m/z (ES
+
) 388.1 [M+Na]
+
, found: 388.1308 
(C25H19NNaO2 requires 388.1313). 
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Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(4-
methoxyphenyl)-carboxylate (139c) 
 
Carboxylic acid 49 (2.00 g, 7.26 mmol) was combined with thionyl chloride (5.00 
mL, 68.9 mmol) in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, chloroform (20.0 mL), pyridine (0.65 mL, 7.99 
mmol) and 4-methoxyphenol (1.35 g, 10.9 mmol) was added and the reaction heated 
to reflux for 48 h. Water (50.0 mL) was added and the product extracted with Et2O 
(3 x 50.0 mL). The organic phase was washed with 2M aq. HCl (100 mL) and sat. 
aq. NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to give crude 
product 139c (4.60 g) as an orange solid. This was purified by column 
chromatography (9:1 petrol/ EtOAc) to yield the title compound 139c (1.16 g, 3.05 
mmol, 42%) a yellow solid. Rf (9:1 petrol/ EtOAc) 0.14; m.p. 156 – 158 
o
C; vmax/cm
-
1
 2964 (CH), 1748 (C=O); δH (400 MHz, CDCl3) 7.56 – 7.50 (1H, m, Ar-H), 7.34 
(3H, dd, J 8.0, 3.5, Ar-H), 7.26 – 7.13 (4H, m, Ar-H), 6.91 – 6.82 (4H, m, Ar-H), 
5.08 (1H, s, ArC-CH-CCN), 4.46 (1H, t, J 2.5, ArC-CH-CH2), 3.76 (3H, s, OCH3), 
2.90 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 2.28 (1H, dd, J 13.0, 2.5, CH-CH2-CCN); 
δC (100 MHz, CDCl3) 165.9 (C=O), 157.8 (ArC-OCH3), 143.9, 143.1, 142.4, 137.7, 
137.0 (5 x ArC), 127.9, 127.7, 126.8, 126.5, 126.0, 125.2, 124.2, 123.6 (8 x ArC-H), 
121.7 (CO2-ArC-ArCH), 119.4 (CCN), 114.6 (ArCH-COCH3), 55.6 (OCH3), 51.9 
(ArC-CH-CCN), 47.5 (CN), 43.2 (ArC-CH-CH2), 38.1 (CH-CH2-CCN); m/z (ES
+
) 
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404.1 [M+Na]
+
, found: 404.1262 [M+Na]
+
 (C25H19NNaO3 requires 404.1263); found 
C: 78.3, H: 5.0, N: 3.6, C25H19NO3 requires C: 78.7, H: 5.0, N: 3.7. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(4-chlorophenyl)-
carboxylate (139d) 
 
Carboxylic acid 49 (2.00g, 7.26 mmol) and thionyl chloride (5.00 mL, 68.9 mmol) 
were combined in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, the resultant acid chloride was combined with 4-
chlorophenol (1.40 g, 10.9 mmol) and pyridine (0.65 mL, 7.99 mmol) in chloroform 
(20.0 mL) and heated to reflux for 3 days. The reaction was quenched with water 
(20.0 mL) and the product was extracted with Et2O (3 x 30.0 mL). The combined 
organic layers were washed with 2M aq. HCl (50.0 mL) and sat. aq. NaHCO3 (50.0 
mL), dried (MgSO4) and concentrated in vacuo to yield the crude product 139d (2.26 
g) as brown oil. This was purified by flash column chromatography (14:1 petrol/ 
EtOAc) to give the title compound 139d (1.02 g, 2.69 mmol, 37%) as a white solid. 
Rf (14:1 petrol/ EtOAc) 0.81; m.p. 148-150 
o
C; vmax/cm
-1 
2960 (CH), 2243 (CN), 
1741 (C=O); δH (400 MHz, CDCl3) 7.55 - 7.51 (1H, m, Ar-H), 7.37 - 7.30 (5H, m, 
Ar-H), 7.26 - 7.15 (4H, m, Ar-H), 6.93 - 6.89 (2H, m, Ar-H), 5.06 (1H, s, ArC-CH-
CCN), 4.48 (1H, t, J 2.5, ArC-CH-CH2), 2.91 (1H, dd, J 10.5, 3.0, CH-CH2-CCN), 
2.31 (1H, dd, J 10.5, 3.0, CH-CH2-CCN); ); δC (100 MHz, CDCl3) 165.4 (C=O), 
148.8 (ArC-Cl), 143.0, 142.3, 137.5, 136.9 (4 x ArC), 132.1 (ArC-O), 129.7 (O-C-
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(CH)2), 128.0, 127.8, 126.8, 126.6, 126.0, 125.4, 124.3, 123.7 (8 x ArCH), 122.4 
(Cl-C-(CH)2), 119.2 (CN), 51.9 (ArC-CH-CCN), 47.5 (CH-C-CN), 43.1 (ArC-CH-
CH2), 38.1 (CH-CH2-CCN); m/z (ES
+
) 407.9 [M+Na]
+
, found 408.0762 
(C24H16ClNNaO2 requires 408.0767); found C: 74.6, H: 4.2, N: 3.7, C24H16ClNO2 
requires C: 74.7, H: 4.8, N: 3.6. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(4-nitrophenyl)-
carboxylate (139e) 
 
Carboxylic acid 49 (2.00 g, 7.26 mmol) was combined with thionyl chloride (5.00 
mL, 68.9 mmol) in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, chloroform (20.0 mL), 4-nitrophenol (1.52 g, 10.9 
mmol) and pyridine (0.65 mL, 7.99 mmol) was added and the reaction refluxed for 
36 h. Water (50.0 mL) was added and the product was extracted with Et2O (3 x 50.0 
mL). The organic phase was washed with 2M aq. HCl (100 mL) and sat. aq. 
NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to give the crude 
product 139e (5.06 g) as a yellow solid. This was purified by recrystallisation 
(petrol/ EtOAc) to furnish the title compound 139e (1.87 g, 4.72 mmol, 65%) as an 
off-white solid. Rf (9:1 petrol/ EtOAc) 0.12; m.p. 124 – 125 
o
C; vmax/cm
-1
 1770 
(C=O), 1523 (NO2); δH (400 MHz, CDCl3) 8.23 – 8.12 (2H, m, Ar-H), 7.56 – 7.48 
(1H, m, Ar-H), 7.38 - 7.27 (3H, m, Ar-H), 7.27 – 7.13 (4H, m, Ar-H), 7.13 - 7.05 
(2H, m, Ar-H), 5.09 (1H, s, ArC-CH-CCN), 4.49 (1H, t, J 2.5, ArC-CH-CH2), 2.88 
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(1H, dd, J 13.0, 2.5, CH-CH2-CCN), 2.29 (1H, dd, J 13.0, 2.5, CH-CH2-CCN); δC 
(100 MHz, CDCl3) 165.0 (C=O), 154.7, 145.9, 143.0, 142.3, 137.3, 136.8 (ArC), 
128.2, 128.0, 126.9, 126.7, 126.1, 125.5, 125.4, 125.0, 124.4, 123.8, 122.1, 122.0 
(ArC-H), 119.0 (CN), 52.0 (ArC-CH-CCN), 47.7 (CCN), 43.1 (ArC-CH-CH2), 38.2 
(CH-CH2-CCN); m/z (ES
+
) 419.1 [M+Na]
+
, found 419.1004 [M+Na]
+
 
(C24H16N2NaO4 requires 419.1008); found C: 72.2, H: 4.0, N: 7.1, C24H16N2O4 
requires C: 72.7, H: 4.1, N: 7.1. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(4-trifluoromethyl 
phenyl)-carboxylate (139f) 
 
Carboxylic acid 49 (2.00 g, 7.26 mmol) was combined with thionyl chloride (5.00 
mL, 68.9 mmol) in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, chloroform (20.0 mL), 4-(trifluoromethyl) phenol 
(1.77 g, 10.9 mmol) and pyridine (0.65 mL, 7.99 mmol) was added and the reaction 
refluxed for 36 h. Water (50.0 mL) was added and the product was extracted with 
Et2O (3 x 50.0 mL). The organic phase was washed with 2M aq. HCl (100 mL) and 
sat. aq. NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to give the 
crude product 139f (2.28 g) as a brown oil. This was purified by column 
chromatography (9:1 petrol/ EtOAc) to furnish the title compound 139f (1.52 g, 3.63 
mmol, 50%) as an orange solid. Rf (9:1 petrol/ EtOAc) 0.48; m.p. 99 – 100 
o
C; 
vmax/cm
-1
 2934 (CH), 2110 (CN), 1756 (C=O); δH (400 MHz, CDCl3) 7.64 (2H, d, J 
8.5, Ar-H), 7.58 – 7.44 (2H, m, Ar-H), 7.35 (3H, m, Ar-H), 7.29 – 7.15 (3H, m, Ar-
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H), 7.09 (2H, d, J 8.5, Ar-H), 5.08 (1H, s, ArC-CH-CCN), 4.50 (1H, t, J 2.5, ArC-
CH-CH2), 2.91 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 2.31 (1H, dd, J 13.0, 2.5, CH-
CH2-CCN); δC (100 MHz, CDCl3) 165.2 (C=O), 152.7, 142.9, 142.3, 137.4, 136.8, 
128.8 (6 x ArC), 128.1, 127.9, 127.2, 127.1, 127.0, 126.9, 126.6, 126.0, 125.0, 124.3, 
123.7, 121.6 (12 x ArC-H), 119.0 (CN), 51.9 (ArC-CH-CCN), 47.6 (CH-C-CN), 
43.1 (ArC-CH-CH2), 38.1 (CH-CH2-CCN); δF (376 MHz, CDCl3) -62.4 (CF3); m/z 
(ES
+
) 442.1 [M+Na]
+
, found 442.1025 [M+Na]
+
 (C25H16F3NNaO2 requires 
442.1031); Found C: 71.3, H: 3.8, N: 3.3, C25H16F3NO2 requires C: 71.6, H: 3.9, N: 
3.3. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(2,4,6-
chlorophenyl)-carboxylate (140a) 
 
Carboxylic acid 49 (2.00g, 7.26 mmol) and thionyl chloride (5.00 mL, 68.9 mmol) 
were combined in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, the resultant acid chloride was combined with 2,4,6-
trichlorophenol (2.15 g, 10.9 mmol) and pyridine (0.65 mL, 7.99 mmol) in 
chloroform (20.0 mL) and heated to reflux for 4 days. The reaction was quenched 
with water (20.0 mL) and the product was extracted with Et2O (3 x 30.0 mL). The 
combined organic layers were washed with 2M aq. HCl (50 mL) and sat. aq. 
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NaHCO3 (50.0 mL), dried (MgSO4) and concentrated in vacuo to yield the crude 
product 140a (2.79 g) as orange oil. This was re-crystallised (hexane) to give the title 
compound 140a (0.95 g, 0.94 mmol, 13%) as a pale yellow solid. Rf (4:1 petrol/ 
EtOAc) 0.47; m.p. 166-167 
o
C; vmax/cm
-1
 2895 (CH), 2127 (CN), 1772 (CO); δH 
(400 MHz, CDCl3) 7.57 – 7.51 (1H, m, Ar-H), 7.41 – 7.35 (2H, m, Ar-H), 7.33 – 
7.30 (1H, m, Ar-H), 7.28 – 7.22 (2H, m, Ar-H), 7.20 – 7.08 (2H, m, Ar-H), 5.10 (1H, 
s, ArC-CH-CCN), 4.49 (1H, t, J 2.5, ArC-CH-CH2), 2.86 (1H, dd, J 13.0, 2.5, CH-
CH2-CCN), 2.49 (1H, dd, J 13.0, 2.5, CH-CH2-CCN); δC (100 MHz, CDCl3) 163.9 
(C=O), 142.6, 142.4, 142.3, 141.9, 138.1, 136.5, 132.8, 129.3 (8 x ArC), 128.8, 
128.7, 127.8, 127.7, 126.9, 126.5, 126.4, 125.9, 123.9, 123.6 (10 x ArC-H), 118.7 
(CN), 51.2 (ArC-CH-CCN), 47.5 (CH-C-CN), 43.1 (ArC-CH-CH2), 39.4 (CH-CH2-
CCN); m/z (ES
+
) 476.0 [M+Na]
+
, found 475.9984 (C24H14Cl3NNaO2 requires 
475.9988); found C: 63.2, H: 3.1, N: 3.1, C24H14Cl3NO2 requires C: 63.4, H: 3.1, N: 
3.1. 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-((-)-methyl)-
carboxylate (140b) 
 
Carboxylic acid 49 (2.00 g, 7.26 mmol) was combined with thionyl chloride (5.00 
mL, 68.9 mmol) in chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, chloroform (20.0 mL), (-)-menthol (1.70 g, 10.9 
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mmol) and pyridine (0.65 mL, 7.99 mmol) was added and the reaction refluxed for 
36 h. Water (50.0 mL) was added and the product was extracted with Et2O (3 x 50.0 
mL). The organic phase was washed with 2M aq. HCl (100 mL) and sat. aq. 
NaHCO3 (100 mL), dried (MgSO4) and concentrated in vacuo to give the crude 
product 140b (2.92 g) as an orange oil. This was purified by column chromatography 
(9:1 petrol/ EtOAc) to yield title compound 140b (1.13 g, 2.76 mmol, 38%) as a pale 
yellow oil (a mixture of two inseparable diastereoisomers in a 1:1 ratio, labelled as A 
and B). Rf (9:1 petrol/ EtOAc) 0.36; vmax/cm
-1
 2954, 2195 (CN), 2868 (CH), 1736 
(C=O); δH (400 MHz, CDCl3) 7.55 – 7.43 (2H, m, Ar-H), 7.37 – 7.26 (4H, m, Ar-H), 
7.24 – 7.13 (8H, m, Ar-H), 7.13 – 7.05 (2H, m, Ar-H), 4.87 (1H, s, A or B ArC-CH-
CCN), 4.82 (1H, s, A or B ArC-CH-CCN), 4.59 (2H, qd, J 11.0, 4.5, A and B O-CH-
CH2), 4.43 – 4.39 (2H, m, A and B ArC-CH-CH2), 2.80 (2H, dt, J 13.0, 2.5, A and B 
CH-CH2ax/eq-CCN), 2.20 (2H, td, J 13.0, 2.5, A and B CH-CH2ax/eq-CCN), 2.09 – 
1.98 (2H, m, A and B CH2-CH-CH3), 1.87 – 1.81 (2H, m, A or B OCH-CH-CH2), 
1.80 – 1.73 (1H, m, A or B OCH-CH-CH2), 1.73 – 1.61 (4H, m, A or B OCH-CH-
CH2 and A or B OCH-CH2-CH), 1.57 – 1.47 (2H, m, A or B OCH-CH2-CH), 1.47 – 
1.32 (2H, m, A and B CH-CH-(CH3)2), 1.16 – 1.04 (1H, m, A or B O-CH-CH), 1.04 
– 0.98 (4H, m, A and B CH3-CH-CH2-CH2), 0.98 – 0.82 (12H, m, A and B CH-CH-
(CH3)2), 0.76 (3H, d, J 7.0, A or B CH2-CH-CH3), 0.65 (3H, d, J 7.0, A or B CH2-
CH-CH3); δC (100 MHz, CDCl3) 166.5, 166.2 (A and B C=O), 143.1, 142.9, 142.5, 
142.5, 138.4, 138.1, 137.0, 137.0 (A and B ArC), 127.6, 127.5, 127.4, 126.6, 126.6, 
126.2, 126.2, 125.8, 125.7, 125.4, 125.3, 123.8, 123.7, 123.6, 123.6 (A and B Ar-
CH), 120.1, 119.9 (A and B CN), 77.8, 77.6 (A and B O-CH-CH2), 51.6, 51.6 (A and 
B ArC-CH-CCN), 48.0, 47.2 (A and B CH-C-CN), 47.0, 46.7 (A and B OCH-CH-
CH2), 43.2 (A and B ArC-CH-CH2), 40.8, 39.9 (CH2-CH2-CH-CH3), 38.2, 37.9 (A 
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and B CH-CH2-CCN), 34.1, 34.0 (A and B OCH-CH-CH2-CH2), 31.4, 31.4 (A and B 
CH-CH(CH3)2), 26.0, 25.7 (A and B CH2-CH-CH3), 23.0, 22.9 (A and B OCH-CH2-
CH), 22.0, 21.9, 21.0, 20.9 (A and B CH(CH3)2), 15.9, 15.9 (A and B CH2-CH-CH3); 
m/z (ES
+
) 436.2 [M+Na]
+
, found: 436.2247 [M+Na]
+
 (C28H31NNaO2 requires 
436.2252). 
 
Ethyl 9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(4-methyl-2,6-
dimethoxy-phenyl)carboxylate (140c) 
 
Carboxylic acid 49 (2.00 g, 7.26 mmol) and thionyl chloride (5.00 mL, 68.9 mmol) 
were combined in Chloroform (20.0 mL) and heated to reflux for 6 h. Excess thionyl 
chloride was removed in vacuo, 4-methyl-2,6-dimethoxy phenol (1.83 g, 10.9 
mmol), pyridine (0.65 mL, 7.99 mmol) and chloroform (20.0 mL) were added and 
the reaction heated to reflux for 4 days. Water (20.0 mL) was added and the product 
extracted with Et2O (3 x 30 mL). The combined organic layers were washed with 
2M aq. HCl (50.0 mL) and NaHCO3 (50.0 mL), dried (MgSO4) and concentrated in 
vacuo to give crude product 140c (2.58 g) as an orange solid. This was purified by 
flash column chromatography (petrol/ EtOAc 1:1) to furnish the title compound 140c 
(0.96 g, 2.25 mmol, 31%) as an off-white solid. Rf (1:1 petrol/ EtOAc) 0.56; m.p. 
170 – 171 oC; vmax/cm
-1
 2340 (CN), 1770 (C=O); δH (400 MHz, CDCl3) 7.56 – 7.49 
(1H, m, Ar-H), 7.42 (1H, d, J 7.0, Ar-H), 7.37 – 7.32 (1H, m, Ar-H), 7.28 (1H, d, J 
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7.0, Ar-H), 7.25 – 7.19 (2H, m, Ar-H), 7.17 – 7.08 (2H, m, Ar-H), 6.37 (2H, s, 2x 
(OCH3)C-CH-C(CH3)), 5.15 (1H, s, ArC-CH-CCN), 4.44 (1H, t, J 2.5, ArC-CH-
CH2), 3.75 (6H, s, 2x ArC-OCH3), 2.86 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 2.35 
(1H, dd, J 13.0, 2.5, CH-CH2-CCN), 2.30 (3H, s, ArC-CH3); δC (100 MHz, CDCl3) 
165.1 (C=O), 151.6 (ArC-OCH3), 142.9, 142.7 (2x ArC), 138.6 (ArC-CH3), 137.1, 
137.0 (2x ArC), 129.6, 127.5, 127.4, 126.6, 126.4, 126.0, 125.9, 123.7, 123.4, 121.0 
(10x ArC-H), 119.6 (CCN), 105.6 (CH3C-CH-COCH3), 56.3, 56.0 (2x ArC-OCH3), 
51.3 (ArC-CH-CCN), 47.4 (CN), 43.3 (ArC-CH-CH2), 38.7 (CH-CH2-CCN), 22.1 
(ArC-CH3); m/z (ES
+
) 448.2 [M+Na]
+
, 426.0 [M+H]
+
, found: 448.1523 [M+Na]
+
 
(C27H23NNaO4 requires 448.1525); C: 75.9, H: 5.5, N: 3.3, C27H23NO4 requires C: 
76.2, H: 5.5, N: 3.3.   
 
5.3.3 Cyanoacrylate monomers 
5.3.3.1 Heating method 
 
n-butyl 2-cyanoacrylate (141a) 
 
Butyl ester 138a (15.0 g, 45.0 mmol) was heated with a hot air pistol under vacuum 
distillation conditions. At a vapour temperature of 100 
o
C to 130 
o
C product was 
distilled into a cooled collection flask to give the crude cyanoacrylate 141a (2.53 g) 
as a colourless liquid. The crude mixture was purified by vacuum fractional 
distillation to yield the title compound 141a (1.60 g, 10.4 mmol, 23%) as a 
colourless liquid. b.p. 105-107 
o
C (8 mbar), Lit.
223
 b.p. 128-130 
o
C (2.66 mbar); δH 
(400 MHz, CDCl3) 7.05 (1H, s, C=CH2), 6.65 (1H, s, C=CH2), 4.28 (1H, t, J 6.5, 
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OCH2-CH2), 1.75 – 1.63 (1H, m, OCH2-CH2), 1.44 (1H, dq, J 14.5, 7.5, OCH2-CH2-
CH2), 0.96 (2H, t, J 7.5, CH2-CH3); δC (100 MHz, CDCl3) 160.5 (C=O), 143.1 
(C=CH2), 136.4 (C-CN), 114.3 (CN), 66.6 (OCH2-CH2), 30.1 (OCH2-CH2), 18.7 
(OCH2-CH2-CH2), 13.5 (CH2-CH3). 
 
5.3.3.2 Maleic anhydride method 
 
General procedure for retro-Diels-Alder reaction using maleic anhydride 47: 
Esters 138-140 (1 eq., 16.3 mmol), maleic anhydride 47 (3 eq., 48.9 mmol), 
hydroquinone (0.5 eq., 8.15 mmol) and phosphorus pentoxide (0.5 eq., 8.15 mmol) 
were combined in xylene (0.30 M) and heated to reflux for 48-72 h. The reaction 
was removed from the heat and allowed to cool, benzene was added to precipitate 
out the solid anthracene – maleic anhydride adduct 48a which was filtered off. The 
crude cyanoacrylates 141-143 were purified by vacuum fractional distillation. 
 
n-Butyl 2-cyanoacrylate (141a) 
 
The anthracene ester 138a was reacted for 48 h, the crude mixture was purified by 
vacuum fractional distillation to furnish the title compound 141a (1.25 g, 1.63 mmol, 
10%) as a colourless liquid. b.p. 103-106 
o
C (8 mbar), Lit.
223
 b.p. 128-130 
o
C (2.66 
mbar); δH (400 MHz, CDCl3) 7.06 (1H, d, J 2.0, C=CH2), 6.65 (1H, d, J 2.0 C=CH2), 
4.28 (2H, t, J 6.5, OCH2-CH2), 1.80 – 1.64 (2H, m, OCH2-CH2), 1.45 (2H, dq, J 
14.5, 7.5, OCH2-CH2-CH2), 0.96 (3H, t, J 7.5, CH2-CH3); δC (100 MHz, CDCl3) 
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160.9 (C=O), 143.1 (C=CH2), 136.1 (C-CN), 114.8 (CN), 66.61 (OCH2-CH2), 29.9 
(OCH2-CH2), 19.0 (OCH2-CH2-CH2), 13.7 (CH2-CH3). 
 
iso-Butyl 2-cyanoacrylate (141b) 
 
The anthracene ester 138b was reacted for 48 h, the crude solution was distilled 
under vacuum to give the title compound 141b (1.54 g, 9.45 mmol, 58 %) as a 
colourless liquid. b.p. 110 – 112 oC (8 mbar); δH (400 MHz, CDCl3) 7.07 (1H, d, J 
2.0, CH2=C), 6.65 (1H, d, J 2.0, CH2=C), 4.07 (2H, d, J 6.5, OCH2CH), 2.05 (1H, dt, 
J 13.5, 6.5, OCH2CH(CH3)2), 0.99 (6H, d, J 6.5, CH(CH3)2); δC (100 MHz, CDCl3) 
164.2 (C=O), 143.2 (CH2=C), 116.7 (CN), 114.4 (CH2=C), 72.7 (OCH2CH), 27.6 
(CH(CH3)2), 18.9 (CH(CH3)2). 
 
sec-Butyl 2-cyanoacrylate (141c) 
 
The anthracene ester 138c was reacted for 48 h, the crude solution was distilled 
under vacuum to give the title compound 141c (1.88 g, 10.27 mmol, 63%) as a 
colourless liquid. b.p. 108-112 
o
C (8 mbar); δH (400 MHz, CDCl3) 6.95 (1H, d, J 2.0, 
CH2=C), 6.54 (1H, d, J 2.0, CH2=C), 4.95 – 4.85 (1H, m, OCH(CH3)CH2), 1.69 – 
1.49 (2H, m, OCHCH2CH3), 1.23 (3H, d, J 6.5, OCHCH3), 0.86 (3H, t, J 7.5, 
CH2CH3); δC (100 MHz, CDCl3) 163.4 (C=O), 142.0 (CH2=C), 116.1 (CN), 113.6 
(CH2=C), 74.6 (OCH(CH3)CH2), 27.5 (OCHCH2), 18.2 (OCHCH3), 8.5 (CH2CH3). 
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tert-Butyl 2-cyanoacrylate (141d) 
 
The anthracene ester 138d was reacted for 48 h, the crude solution was distilled 
under vacuum to give the title compound
 
141d (1.10 g, 2.93 mmol, 18%) as a 
colourless liquid. b.p. (98 – 102 oC); δH (400 MHz, CDCl3) 7.09 (1H, d, J 2.0, 
CH2=C), 6.95 (1H, d, J 2.0, CH2=C), 2.35 (9H, s, (CH3)3); δC (100 MHz, CDCl3) 
163.1 (C=O), 136.7 (CH2=C), 116.0 (CN), 110.9 (CH2=C), 71.6 (OC(CH3)3), 27.8 
(C(CH3)3).
 
 
Phenyl 2-cyanoacrylate (142a) 
 
The anthracene ester 139a was reacted for 48 h, the crude solution was distilled 
under vacuum to give the title compound
 
142a (1.12 g, 7.17 mmol, 44%) as a 
colourless liquid. b.p. (130 – 134 oC); δH (400 MHz, CDCl3) 7.52 (2H, t, J 7.5, CO-
CH-CH-CH), 7.40 – 7.29 (3H, m, CO-CH-CH-CH), 7.06 (1H, d, J 2.0, CH2=C), 
6.74 (1H, d, J 2.0, CH2=C); δC (100 MHz, CDCl3) 162.0 (C=O), 149.5 (ArC-O), 
144.9 (C=CH2), 130.1, 125.2, 121.8 (ArC-H), 115.8, 110.8 (CN) and (CH2=C). 
 
p-Tolyl 2-cyanoacrylate (142b) 
 
The anthracene ester 139b was reacted for 48 h, the crude solution was distilled 
under vacuum to give the title compound
 
142b (1.20 g, 7.01 mmol, 43%) as a 
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colourless liquid. b.p. (128 - 134 
o
C); δH (400 MHz, CDCl3); 7.19 (2H, d, J 8.0, CH-
CH-C(CH3)), 7.04 (2H, d, J 8.0, CO-CH-CH), 7.01 (1H, d, J 2.0, CH2=C), 6.65 (1H, 
d, J 2.0, CH2=C), 2.32 (3H, s, CH3); δC (100 MHz, CDCl3) 160.8 (C=O), 147.8 
(ArC-O), 144.6 (CH2=C), 130.2, 120.7 (ArC-H), 116.5, 114.2 (CN, CH2=C). 
 
p-Methoxyphenyl 2-cyanoacrylate (142c) 
 
The anthracene ester 139c was reacted for 72 h, the crude solution was distilled 
under vacuum to give the title compound
 
142c (1.21 g, 8.64 mmol, 53%) as a 
colourless liquid. b.p. (124 - 128 
o
C); δH (400 MHz, CDCl3); 7.29 (2H, d, J 7.5, CO-
CH-CH), 7.18 (2H, d, J 7.5, C(OCH3)-CH-CH), 7.01 (1H, d, J 2.0, CH2=C), 6.68 
(1H, d, J 2.0, CH2=C), 3.78 (3H, s, OCH3); δC (100 MHz, CDCl3) 161.3 (C=O), 
156.4, 141.8 (ArC-O), 138.9 (CH2=C), 129.6, 122.4 (ArC-H), 114.8, 111.9 (CN, 
CH2=C), 55.6 (OCH3). 
 
p-Chlorophenyl 2-cyanoacrylate (142d) 
 
The anthracene ester 139d was reacted for 48 h, the crude solution was distilled 
under vacuum to give the title compound
 
142d (1.25 g, 6.03 mmol, 37%) as a 
colourless liquid. b.p. (128 - 132 
o
C); δH (400 MHz, CDCl3); 7.68 (2H, d, J 7.0, CH-
CH-CCl), 7.60 (2H, d, J 7.0, CO-CH-CH), 7.02 (1H, d, J 2.0, CH2=C), 6.68 (1H, d, J 
2.0, CH2=C); δC (100 MHz, CDCl3) 163.4 (C=O), 148.4 (ArC-O), 145.6 (CH2=C), 
131.1 (ArC-Cl), 128.0, 123.3 (ArC-H), 115.8, 113.8 (CN, CH2=C). 
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p-Nitrophenyl 2-cyanoacrylate (142e) 
 
The anthracene ester 139e was reacted for 72 h, the crude solution was distilled 
under vacuum to give the title compound
 
142e (1.15 g, 6.03 mmol, 37%) as a pale 
yellow liquid. b.p. (120 - 122 
o
C); δH (400 MHz, CDCl3); 8.27 (2H, d, J 7.5, CH-CH-
CNO2), 7.65 (2H, d, J 7.5, CH-CH-CO), 7.02 (1H, d, J 2.0, CH2=C), 6.64 (1H, d, J 
2.0, CH2=C); δC (100 MHz, CDCl3) 164.0 (C=O), 154.7 (ArC-O), 145.7 (ArC-NO2), 
136.8 (CH2=C), 125.5, 122.1 (ArC-H), 116.8, 112.3 (CN, CH2=C). 
 
p-(Trifluoromethyl)phenyl 2-cyanoacrylate (142f) 
 
The anthracene ester 139f was reacted for 72 h, the crude solution was distilled 
under vacuum to give the title compound
 
142f (1.24 g, 7.66 mmol, 47%) as a 
colourless liquid. b.p. (118 - 124 
o
C); δH (400 MHz, CDCl3); 7.75 (2H, d J 8.0, CH-
CH-C(CF3)), 7.31 (2H, d, J 8.0, CO-CH-CH), 7.02 (1H, d, J 2.0, CH2=C), 6.71 (1H, 
d, J 2.0, CH2=C); δC (100 MHz, CDCl3) 165.0 (C=O), 145.4, 143.2 (ArC-O, ArC-
CF3), 136.5 (CH2=C), 128.9, 121.7 (ArC-H), 115.5, 113.8 (CN, CH2=C). 
 
2,4,6-Trichlorophenyl 2-cyanoacrylate (143a) 
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The anthracene ester 140a was reacted for 48 h, the crude solution was distilled 
under vacuum to give the title compound
 
143a (1.10 g, 9.29 mmol, 57%) as a 
colourless liquid. b.p. (130 - 134 
o
C); δH (400 MHz, CDCl3); 7.52 (2H, s, C(Cl)-CH-
C(Cl)), 7.07 (1H, d, J 2.0, CH2=C), 6.75 (1H, d, J 2.0, CH2=C); δC (100 MHz, 
CDCl3) 164.0 (C=O), 142.5, 132.8, 130.3 (ArC-O, ArC-Cl), 129.8 (CH2=C), 128.8 
(ArC-H), 116.7, 112.8 (CN, CH2=C). 
 
5-iso-Propyl-2-methylcyclohexyl 2-cyanoacrylate (143b) 
 
The anthracene ester 140b was reacted for 72 h, the crude solution was distilled 
under vacuum to give the title compound
 
143b (1.12 g, 6.19 mmol, 38%) as a 
colourless liquid. b.p. (114 - 118 
o
C); δH (400 MHz, CDCl3); 7.03 (1H, d, J 2.0, 
CH2=C), 6.60 (1H, d, J 2.0, CH2=C), 2.09 – 1.99 (1H, m, CH2-CH-CH3), 1.93 – 1.80 
(1H, m, OCH-CH-CH2), 1.75 – 1.69 (2H, m, OCH-CH2-CH), 1.56 – 1.48 (2H, m, 
OCH-CH-CH2), 1.17 – 1.05 (1H, m, O-CH-CH), 1.04 – 0.98 (2H, m, CH3-CH-CH2-
CH2), 0.93 (6H, dd, J 11.0, 4.5, CH-CH(CH3)2), 0.78 (3H, d, J 7.0, CH2-CH-CH3); 
δC (100 MHz, CDCl3) 165.2 (C=O), 142.9 (CH2=C), 116.9, 111.8 (CN, CH2=C), 
77.6 (O-CH-CH2), 46.9 (OCH-CH-CH2), 40.4 (CH2-CH2-CH-CH3), 34.2, (OCH-
CH-CH2-CH2), 31.3 (CH-CH(CH3)2), 25.9 (CH2-CH-CH3), 22.9 (OCH-CH2-CH), 
21.6 (CH(CH3)2), 15.8 (CH2-CH-CH3). 
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2,6-Dimethoxy-4-methylphenyl 2-cyanoacrylate (143c) 
 
The anthracene ester 140c was reacted for 72 h, the crude solution was distilled 
under vacuum to give the title compound
 
143c (1.14 g, 5.71 mmol, 35%) as a 
colourless liquid. b.p. (130 - 134 
o
C); δH (400 MHz, CDCl3); 7.04 (1H, d, J 2.0, 
CH2=C), 6.94 (2H, s, CH-C(CH3)), 3.79 (6H, s, OCH3),  2.32 (3H, s, CH3); δC (100 
MHz, CDCl3) 163.1 (C=O), 151.2, 139.0, 137.1 (ArC-OCH3, ArC-CH3, ArC-O), 
138.9 (CH2=C), 116.6, 113.5 (CN, CH2=C), 105.4 (ArC-H), 56.2 (2x ArC-OCH3), 
22.0 (ArC-CH3). 
 
5.4 Experimental procedures for substrates synthesised in Chapter 4 
 
5.4.1 9-substituted anthracenes 46c,d,e,j 
 
9-Hydroxymethylanthracene (46c) 
 
9-Anthracenecarboxaldehyde 46f (0.50 g, 2.42 mmol) and sodium borohydride (0.22 
g, 5.82 mmol) were combined in THF at 0 
o
C, then refluxed o/n. The reaction was 
quenched with water (20.0 mL) and product was extracted with Et2O (3 x 30.0 mL). 
The combined organic layers were washed with sat. aq. NaHCO3 (50.0 mL), dried 
(MgSO4) and concentrated in vacuo to give crude product 46c (0.49 g) as a yellow 
solid. This was re-crystallised (hexane) to yield the title compound 46c (0.23 g, 1.11 
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mmol, 46%) as yellow needles. Rf (4:1 petrol/ EtOAc) 0.21; m.p. 162-164 
o
C; Lit
258
 
m.p. 162-163 
o
C; vmax/cm
-1
 3434 b (OH), 2945 (CH); δH (400 MHz, CDCl3) 8.42 
(1H, s, CH-C-CH-C-CH), 8.36 (2H, d, J 8.5, C-CH-CH), 7.99 (2H, d, J 8.5, C-CH-
CH), 7.56 – 7.50 (2H, m, CH-CH-CH-CH), 7.49 – 7.43 (2H, m, CH-CH-CH-CH), 
5.60 (2H, s, CH2OH), 1.84 (1H, s, CH2OH); δC (100 MHz, CDCl3) 131.0 (C-CH2-
OH), 131.6, 130.3 (C-CH-CH), 128.4 (CH-C-CH-C-CH), 129.2, 126.5, 125.1, 123.9 
(CH-CH-CH-CH), 57.4 (CH2OH); m/z (ES
+
) 230.8 [M+Na]
+
. 
 
9-Methoxy anthracene (46d) 
 
9-Bromoanthracene 46i (1.00 g, 3.89 mmol), methanol (0.32 mL, 7.78 mmol), 
Cs2CO3 (1.90 g, 5.84 mmol), Pd(OAc)2 (0.045g, 0.20 mmol) and X-Phos (0.10 g, 
0.20 mmol) were combined in toluene (20.0 mL) and heated to 90 
o
C for 3 days. The 
reaction was removed from the heat, water (10 mL) was added and the product 
extracted with DCM (3 x 15 mL). The combined organic layers were washed with 
sat. aq. NaHCO3 (30 mL), dried (MgSO4) and concentrated in vacuo to yield the 
crude product 46d (0.37 g) as a yellow solid. This was purified by flash column 
chromatography (9:1 petrol/ EtOAc) to give the title compound 46d (0.12 g, 0.58 
mmol, 15%) as a white solid. Rf (9:1 Petrol/EtOAc) 0.57; m.p. 90-92 
o
C; Lit
259
 m.p. 
92.3 – 93.3 oC; vmax/cm
-1
 2845 (CH), 1620 (CO); δH (400 MHz, CDCl3) 8.28 (2H, d, 
J 9.5, CH-CH-C-C(OMe)), 8.19 (1H, s, C-CH-C), 7.96 (2H, d, J 7.5, CH-CH-C-CH-
C), 7.49 – 7.41 (4H, m, CH-CH-CH-CH), 4.12 (3H, s, OCH3); δC (100 MHz, CDCl3) 
152.3 (C-OMe), 132.5, 131.7 (CH-C-CH-C-CH), 128.5, 128.2 (CH-C-CH-C-CH), 
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127.2, 126.3, 125.6, 125.4 (CH-CH-CH-CH), 124.5 (C-CH-C), 122.4, 122.3 (CH-C-
COMe-C-CH), 122.4, 122.3 (CH-C-COMe), 63.2 (OCH3); m/z (ES
+
) 209.1 [M+H]
+
. 
 
9-Aminoanthracene (46e) 
 
9-Nitro anthracene 46j (2.00 g, 8.96 mmol) was combined with glacial acetic acid 
(40.0 mL), stirred and heated to 80 
o
C for 30 minutes until all the solid had 
dissolved. SnCl2 (8.5 g, 44.8 mmol) in conc. HCl (30.0 mL) were added via 
dropping funnel. The reaction was allowed to cool to r.t., filtered and washed with 
conc. HCl (3 x 5.00 mL). The resulting yellow solid was put into a flask and covered 
with 5% NaOH. This was left for 15 minutes with occasional manual stirring, 
filtered and washed with water until neutral (approx. 200 mL). The resulting yellow 
solid was stored in the dark and dried in a desiccator for 4 days to give crude product 
46e (0.67 g, 3.49 mmol, 39%) as a yellow solid. The product was used without 
further purification due to stability problems. Rf (9:1 petrol/ EtOAc) 0.36; m.p. 129 – 
130 
o
C; Lit
260
 m.p. 145 – 146 oC; vmax/cm
-1
 1632 (NH2); δH (400 MHz, CDCl3) 8.61 
(1H, s, C-CH-C), 8.06 (2H, d, J 8.5, C-CH-CH), 7.93 (2H, d, J 8.5, C-CH-CH), 7.68 
– 7.60 (2H, m, C-CH-CH-CH), 7.58 – 7.51 (2H, m, C-CH-CH-CH); δC (100 MHz, 
CDCl3) 144.0 (C-NH2), 130.7 (CH-C-CH), 130.4 (C-CH-C), 128.4 (CH-C-CH), 
128.2 (C-CH-C-CH-CH), 127.1 (C-CH-C-CH-CH), 126.2 (C-CH-CH-CH), 126.0 
(C-CH-CH-CH), 125.2 (C-CH-CH-CH), 125.0 (C-CH-CH-CH), 122.6 (CH-C-
CNH2), 121.4 (CH-C-CNH2), 121.3 (C(NH2)-C-CH-CH), 121.1 (C(NH2)-C-CH-
CH); m/z (ES
+
) 194.1 [M+H]
+
, found: 194.0940 [M+H]
+
 (C14H12N requires 
194.0970). 
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9-Nitro anthracene (46j) 
 
Concentrated nitric acid (6.00 mL, 0.13 mol) was added drop-wise to a suspension of 
anthracene 46a (15.0 g, 0.08 mol) and glacial acetic acid (60.0 mL), keeping the 
temperature below 30 
o
C. This was stirred vigorously for 1 h, until all of the solid 
had dissolved giving a clear orange solution. A mixture of concentrated HCl and 
glacial acetic acid (1:1, 100 mL) was added slowly, resulting in a yellow precipitate. 
This was filtered and washed with water until the washings were neutral (approx. 
500 mL). The resulting yellow solid was treated with a warm solution (60-70 
o
C) of 
10% NaOH (250 mL). This was filtered and washed with water until the washings 
were neutral (approx. 500 mL), the resulting solid was air-dried. This was re-
crystallised in acetic acid to give the title compound 46j (11.5 g, 0.08 mmol, 61%) as 
a yellow solid. Rf (9:1 petrol/ EtOAc) 0.32; m.p. 148 – 150 
o
C; Lit
261
 m.p. 148-149 
o
C; vmax/cm
-1
 3059 (CH), 1624 (NO2); δH (400 MHz, CDCl3) 8.52 (1H, s, C-CH-C), 
8.00 (2H, d, J 8.5, NO2C-C-CH-CH), 7.92 (2H, dd, J 9.0, 1.0, C-CH-C-CH-CH), 
7.67 – 7.55 (2H, m, NO2C-C-CH-CH-CH), 7.55 – 7.44 (2H, m, C-CH-C-CH-CH); 
δC (100 MHz, CDCl3) 144.2 (C-NO2), 130.7 (CH-C-CH-C-CH), 130.4 (C-CH-C), 
128.9 (NO2C-C-CH-CH-CH), 128.4 (C-CH-C-CH), 126.2 (C-CH-C-CH-CH), 122.6 
(NO2C-C-CH), 121.3 (NO2C-C-CH-CH); m/z (ES
+
) 224.1 [M+H]
+
, 246.0 [M+Na]
+
, 
found: 246.0525 [M+Na]
+
 (C14H9NNaO2 requires 246.0531). 
 
 
 
Chapter 5: Experimental 
 
202 
 
5.4.2 Substituted anthracene adducts 127a-m 
 
Ethyl-9,10-dihydro-9,10-endo-ethanoanthracene-11-cyano-11-(ethyl)-
carboxylate (127a) 
 
Anthracene 46a (10.0 g, 60.0 mmol), ethyl cyanoacrylate 37 (10.0 g, 80.0 mmol) and 
MEHQ (0.40 g, 3.00 mmol) were combined in toluene (100 mL) and heated to reflux 
for 24 h. Once cool the reaction was concentrated in vacuo to give the crude product 
127a (16.5 g) as a pale yellow solid. This was purified by column chromatography 
(9:1 petrol/ EtOAc) to furnish the title compound 127a (14.8 g, 48.6 mmol, 81%) as 
a white solid. Rf (9:1 petrol/ EtOAc) 0.41; m.p. 120-122 
o
C, lit
257
 m.p. 118 
o
C; 
vmax/cm
-1
 2945 (C-H), 2120 (C-N), 1746 (C=O); δH (400 MHz, CDCl3) 7.50 – 7.03 
(8H, m, Ar-H), 4.87 (1H, s, ArC-CH-CCN), 4.39 (1H, t, J 2.5, ArC-CH-CH2), 4.11 
(2H, dq, J 11.0, 7.0, OCH2-CH3), 2.78 (1H, dd, J 13.0, 2.5, CH-CH2-CCN), 2.17 
(1H, dd, J 13.0, 2.5, CH-CH2-CCN), 1.23 (3H, t, J 7.0, OCH2-CH3); δC (100 MHz, 
CDCl3) 166.8 (C=O), 143.1, 142.4, 138.1, 137.2 (ArC), 127.6, 127.6, 126.7, 126.4, 
125.9, 125.2, 123.9, 123.6 (ArC-H), 119.9 (CN), 63.2 (OCH2-CH3), 51.8 (ArC-CH-
CCN), 47.4 (CCN), 43.2 (ArC-CH-CH2), 38.0 (CH-CH2-CCN), 14.1 (OCH2-CH3); 
m/z (ES
+
) 326.1 [M+Na]
+
, found: [M+Na]
+
 326.1151 (C20H17NNaO2 requires 
326.1157).  
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Ethyl-9-methyl, 10-hydro-9,10-endoanthracene-11-cyano-11-carboxylate (127b)  
 
9-Methyl anthracene 46b (0.05 g, 2.60 mmol), MEHQ (0.03 g, 0.26 mmol) and ethyl 
cyanoacrylate 37 (0.36 g, 2.86 mmol) were combined in toluene (5.00 mL) and 
heated to reflux for 8 h. The reaction was concentrated in vacuo to give crude 
product 127b (1.07 g) as a yellow solid. This was purified by flash column 
chromatography (9:1 petrol/ EtOAc) to furnish the title compound 127b (0.73 g, 2.29 
mmol, 88%) as a white solid, both 127bT and 127bK products were observed in a 
5:1 ratio in favour of 127bT. Rf (9:1 petrol/ EtOAc) 0.21; m.p. 134-136 
o
C; vmax/cm
-1
 
2964 (CH), 2215 (CN), 1741 (C=O); δH (400 MHz, CDCl3) 7.49 – 7.45 (1HT, m, Ar-
H), 7.32 – 7.26 (2HT, m, Ar-H), 7.25 – 7.10 (5HT, m, Ar-H), 7.49 - 7.10 (8HK, m, 
Ar-H), 4.84 (1HT, s, ArC-CH-CCN), 4.19 - 4.10 (2HT, m, OCH2CH3), 4.10 - 4.06 
(2HK, m, OCH2CH3), 3.84 (1HK, t, J 13.0, ArC-CH-CCN), 2.61 (1HK, dd, J 13.0, 
3.0, C(CH3)-CH2-CCN), 2.60 (1HT, d, J 13.0, C(CH3)CH2-CCN), 2.41 (1HK, dd, J 
13.0, 3.0, C(CH3)-CH2-CCN), 2.03 (3HK, s, C-CH3), 2.01 (1HT, d, J 13.0, 
C(CH3)CH2-CCN), 1.99 (3HT, s, C-CH3), 1.27 (3HT, t, J 7.0, OCH2CH3), 1.14 (3HK, 
t, J 7.0, OCH2CH3); δC (100 MHz, CDCl3) 166.8 (C=O), 145.2, 144.6, 138.5, 137.5 
(4 x Ar-C), 127.5, 127.4, 126.4, 126.1, 125.6, 124.9, 121.2, 121.0 (8 x Ar-CH), 
119.9 (CN), 63.2 (OCH2-CH3), 51.8 (ArC-CH-CCN), 48.4 (CCN), 44.3 
(C(CH3)CH2-CCN), 42.0 (C-CH3), 17.0 (C-CH3), 14.1 (OCH2-CH3); m/z (ES
+
) 339.9 
[M+Na]
+
, found 340.1308 (C21H19NNaO2 requires 340.1313). 
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Ethyl 9-hydroxymethyl 10-hydro-9,10-endoanthracene-11-cyano-11-carboxylate 
(127c) 
 
Anthracen-9-yl-methanol 46c (0.50 g, 2.40 mmol), MEHQ (0.03 g, 0.24 mmol) and 
ethyl cyanoacrylate 37 (0.33 g, 2.64 mmol) were combined in toluene (5.00 mL) and 
heated to reflux for 2 days. The reaction was concentrated in vacuo to yield crude 
product 127c (0.95 g) as a yellow solid. This was re-crystallised (hexane/ EtOAc) to 
give the title compound 127c (0.38 g, 1.15 mmol, 48%) as a pale yellow solid. Rf 
(1:1 Petrol/ EtOAc) 0.49; m.p. 179 – 181 oC; vmax/cm
-1
 3483 (OH), 2942 (C-H), 
2361 (N-H), 1751 (C=O); δH (400 MHz, CDCl3) 7.51 - 7.49 (1H, m, Ar-H), 7.44 - 
7.39 (2H, m, Ar-H), 7.28 - 7.20 (4H, m, Ar-H), 7.14 - 7.10 (1H, m, Ar-H), 4.84 (1H, 
s, ArC-CH-CCN), 4.74 (2H, d, J 2.5, CH2-OH), 4.16 (2H, m, O-CH2-CH3), 2.70 
(1H, d, J 2.5, C(CH2OH)CH2-CCN), 2.10 (1H, d, J 2.5, C(CH2OH)CH2-CCN), 1.80 
(1H, s, CH2OH), 1.27 (3H, t, J 1.5, O-CH2-CH3); δC (100 MHz, CDCl3) 166.8 
(C=O), 142.6, 142.1, 138.9, 137.9 (4 x ArC), 127.8, 127.5, 126.8, 126.3, 125.9, 
125.2, 122.0, 121.8 (8 x ArCH), 119.8 (CN), 63.3 (CH2-OH), 62.8 (O-CH2-CH3), 
52.0 (ArC-CH-CCN , 47.1 (C-CN), 39.6 (C(CH2OH)CH2-CCN), 14.4 (O-CH2-CH3); 
m/z (ES
+
) 356.1 [M+Na]
+
, found 356.1259 [M+Na]
+
 (C21H19NNaO3 requires 
356.1263). 
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Ethyl 9-methoxy10-hydro-9,10-endoanthracene-11-cyano-11-carboxylate (127d) 
 
9-Methoxyanthracene 46d (0.50 g, 2.40 mmol), ethyl cyanoacrylate 37 (0.33 g, 2.64 
mmol) and MEHQ (0.03g, 0.24 mmol) were combined with toluene (5.00 mL) and 
heated to reflux for 48 h. The reaction was removed from the heat and concentrated 
in vacuo to give crude product 127d (0.77 g) as an orange solid. This was purified by 
flash column chromatography (9:1 petrol/ EtOAc) to yield two adducts 127amaj and 
127dmin that couldn’t be separated, in a 4:1 ratio (0.68 g, 2.04 mmol, 85%). Rf (14:1 
petrol/ EtOAc) 0.31, m.p. 128-130 
o
C; vmax/cm
-1
 2959 (CH), 2231 (CN), 1747 
(C=O); δH (400 MHz, CDCl3) 7.33 - 7.26 (3Hmaj, m, Ar-H), 7.33 - 7.26 (3Hmaj, m, 
Ar-H), 7.26 – 7.04 (4Hmaj, m, Ar-H), 7.26 – 7.04 (4Hmin, m, Ar-H), 4.86 (1Hmaj, s, 
ArC-CH-CCN), 4.77 (1Hmin, s, ArC-CH-CCN), 4.41 (1Hmaj, t, J 2.5, ArC-CH-CH2), 
4.23 – 4.06 (2Hmaj and min, m, OCH2CH3), 3.74 (3Hmin, s, OCH3), 2.97 (1H, d, J 12.0, 
CH-CH2-CCN), 2.79 (1Hmaj, dd, J 13.0, 2.5, CH-CH2-CCN), 2.34 (1H, d, J 12.0, 
1Hmin, CH-CH2-CCN), 2.18 (1Hmaj, dd, J 13.0, 2.5, CH-CH2-CCN), 1.27 (3Hmin, t, J 
7.0, OCH2CH3), 1.25 (3Hmaj, t, J 7.0, OCH2CH3); δC (100 MHz, CDCl3) 166.8, 166.4 
(C=O), 143.3, 143.0, 142.7, 142.4, 138.0, 137.2, 136.8, 135.9 (ArC), 127.7, 127.6, 
127.5, 127.4, 127.3, 126.6, 126.4, 125.8, 125.6, 125.1, 124.7, 123.9, 123.6, 121.0, 
120.7, 119.9 (ArC-H), 116.0, 114.8 (CN), 63.5, 63.2 (OCH2-CH3), 53.6 (OCH3), 
51.8, 50.7 (ArC-CH-CCN), 47.5, 47.4 (CCN), 43.2 (ArC-CH-CH2), 38.0 (CH-CH2-
CCN), 14.1 (OCH2CH3); m/z (ES
+
) 356.1 [M+Na]
+
min, 326.1 [M+Na]
+
maj. 
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Ethyl 9-carboxaldehyde 10-hydro-9,10-endoanthracene-11-cyano-11-
carboxylate (127f) 
 
9-Anthracene carboxaldehyde 46f (0.50 g, 2.42 mmol), MEHQ (0.03 g, 0.24 mmol) 
and ethyl cyanoacrylate 37 (0.33 g, 2.67 mmol) were combined in toluene (5.00 mL) 
and heated to reflux for 2 days. The reaction was concentrated in vacuo to give crude 
product 127f (1.22 g) as a yellow solid. This was purified by column 
chromatography (9:1 petrol/ EtOAc) to furnish the title compound 127f (0.33 g, 0.99 
mmol, 41%) as a yellow solid. Rf (9:1 petrol/ EtOAc) 0.29; m.p. 143-145 
o
C; 
vmax/cm
-1
 2983 (CH), 2240 (CN), 1747 (C=O), 1723 (C=O); δH (400 MHz, CDCl3) 
10.85 (1H, s, CHO), 7.57 (1H, dd, J 6.5, 2.0, Ar-H), 7.36 – 7.27 (4H, m, Ar-H), 7.27 
– 7.14 (3H, m, Ar-H), 4.89 (1H, s, ArC-CH-CCN), 4.24 – 4.04 (2H, m, OCH2-CH3), 
2.94 (1H, d, J 13.5, C(CHO)-CH2-CCN), 2.36 (1H, d, J 13.5, C(CHO)-CH2-CCN), 
1.25 (3H, t, J 7.0, OCH2-CH3); δC (100 MHz, CDCl3) 201.0 (CHO), 166.2 (C=O), 
140.5, 139.9, 137.8, 136.9 (4 x ArC), 127.7, 127.7, 127.5, 127.2, 126.5, 125.8, 121.8, 
121.5 (8 x ArCH), 119.2 (CN), 63.5 (OCH2-CH3), 51.9 (ArC-CH-CCN), 47.4 (CH-
C-CN), 37.7 (C(CHO)-CH2-CCN), 14.0 (OCH2-CH3); m/z (ES
+
) 353.9 [M+Na]
+
, 
354.1106 [M+Na]
+
 found C21H17NNaO3 requires 354.1106.  
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Ethyl 9-acteyl -10-hydro-9,10-endoanthracene-11-cyano-11-carboxylate (127g) 
 
9-Actylanthracene 46g (0.50 g, 2.27 mmol) was combined with ethyl cyanoacrylate 
37 (0.31 g, 2.5 mmol) and MEHQ (0.02 g, 0.23 mmol) in toluene (5.00 mL) and 
heated to reflux for 2 days. The reaction was removed from the heat and 
concentrated in vacuo to give the crude product 127g (0.73 g) as a yellow oil. This 
was purified by flash column chromatography (4:1 petrol/ EtOAc) followed by re-
crystallisation (hexane) to furnish the title compound 127g (0.08 g, 0.23 mmol, 10%) 
as a white solid. Rf (4:1 petrol/ EtOAc) 0.27; m.p. 112 - 115 
o
C; vmax/cm
-1 
2246 
(CN), 1752, 1701 (C=O); δH (400 MHz, CDCl3) 7.58 – 7.52 (1H, m, Ar-H), 7.33 – 
7.16 (7 H, m, Ar-H), 4.87 (1H, s, ArC-CH-CCN), 4.19 – 4.09 (2H, m, OCH2CH3), 
3.00 (1H, d, J 13.0, C(COCH3)-CH2-CCN), 2.68 (3H, s, COCH3), 2.40 (1H, d, J 
13.0, C(COCH3)-CH2-CCN), 1.26 (3H, t, J 7.0, OCH2CH3); δC (100 MHz, CDCl3) 
206.8 (C=OCH3), 166.3 (C=O), 140.8, 140.1, 137.6, 136.7 (ArC), 127.8, 127.7, 
127.3, 127.0, 126.3, 125.5, 122.9, 122.5 (ArCH), 119.3 (CN), 63.4 (OCH2CH3), 60.2 
(ArC-C(COCH3)-CH2), 52.1 (ArC-CH-CCN), 48.1 (C-CN), 39.7 (C(COCH3)-CH2-
CCN), 30.9 (COCH3), 14.0 (OCH2CH3); m/z (ES
+
) 368.1 [M+Na]
+
, found 368.1259 
[M+Na]
+
 (C22H19NNaO3 requires 368.1263). 
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Ethyl 9-carboxylic acid 10-hydro-9,10-endoanthracene-11-cyano-11-carboxylate 
(127h) 
 
Anthracene-9-carboxylic acid 46h (0.50 g, 2.25 mmol), ethyl cyanoacrylate 37 (0.31 
g, 2.47 mmol) and MEHQ (0.03 g, 0.23 mmol) were combined in toluene (5 mL) 
and heated to reflux for 3 days. The reaction was concentrated in vacuo to give crude 
product 127h (0.37 g) as a yellow solid. This was purified by flash column 
chromatography to yield the title compound 127h (0.08 g, 0.23 mmol, 10%) as a 
yellow solid. Rf (4:1 petrol/ EtOAc) 0.42; m.p. 187-188 
o
C; vmax/cm
-1
 2983 b (OH), 
2245 (CN), 1749 and 1706 (C=O); δH (400 MHz, CDCl3) 7.60 – 7.55 (3H, m, Ar-H), 
7.36 – 7.30 (2H, m, Ar-H), 7.30 – 7.25 (2H, m, Ar-H), 7.24 – 7.18 (1H, m, Ar-H), 
4.91 (1H, s, ArC-CH-CCN), 4.25 – 4.08 (2H, m, OCH2CH3), 3.14 (1H, d, J 13.5, 
C(CO2H)-CH2-CCN), 2.55 (1H, d, J 13.5, C(CO2H)-CH2-CCN), 1.28 (3H, t, J 7.0, 
OCH2CH3); δC (100 MHz, CDCl3) 175.9 (CO2H), 166.3 (C=O), 140.3, 139.6, 137.1, 
136.2 (Ar-C), 127.9, 127.9, 127.5, 127.2, 126.1, 125.4, 123.0, 122.6 (Ar-CH), 119.2 
(CN), 63.5 (OCH2CH3), 55.0 (ArC-C-CO2H), 52.0 (ArC-CH-CCN), 47.6 (CCN), 
39.8 (C(CO2H)-CH2-CCN), 14.1 (OCH2CH3); m/z (ES
+
) 370.1 [M+Na]
+
, found 
370.1050 [M+Na]
+
 (C21H17NNaO4 requires 370.1055). 
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Ethyl-9-bromo 10-hydro-9,10-endoanthracene-11-cyano-11-carboxylate (127i) 
 
9-Bromoanthracene 46i (0.50g, 1.94 mmol), MEHQ (0.02 g, 0.19 mmol) and ethyl 
cyanoacrylate 37 (0.27 g, 2.14 mmol) were combined in toluene (5.00 mL) and 
heated to reflux for 2 days. The reaction was concentrated in vacuo to yield the crude 
product 127i (1.17 g) as brown oil. This was purified by flash column 
chromatography (9:1 petrol/ EtOAc) to give the title compound 127i (0.19 g, 0.51 
mmol, 26%) as a white solid. Rf (9:1 petrol/ EtOAc) 0.20; m.p. 142-145 
o
C; vmax/cm
-
1
 2985 (CH), 2110 (CN), 1747 (C=O); δH (400 MHz, CDCl3) 7.78 – 7.71 (2H, m, Ar-
H), 7.50 – 7.45 (1H, m, Ar-H), 7.32 – 7.26 (3H, m, Ar-H), 7.22 – 7.17 (2H, m, Ar-
H), 4.88 (1H, s, ArC-CH-CCN), 4.19 – 4.12 (2H, m, OCH2-CH3), 3.28 (1H, d, J 
13.0, CBr-CH2-CCN), 2.70 (1H, d, J 13.0, CBr-CH2-CCN), 1.26 (3H, t, J 7.1, 
OCH2-CH3); δC (100 MHz, CDCl3) 165.9 (C=O), 142.0, 141.4, 136.3, 135.4 (4 x 
ArC), 128.0, 128.0, 127.8, 127.5, 125.3, 124.6, 124.6, 124.4 (8 x Ar-CH), 118.8 
(CN), 63.6 (OCH2-CH3), 51.4 (ArC-CH-CCN), 49.0 (CCN), 48.5 (CBr-CH2-CCN), 
42.9 (CBr), 14.1 (OCH2-CH3); m/z (ES
+
) 404.0 [M+Na]
+
, found 404.0257 
(C20H16BrNNaO2 requires 404.0262).  
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Ethyl 9-nitro 10-hydro-9,10-endoanthracene-11-cyano-11-carboxylate (127j)  
 
9-Nitro anthracene 46j (0.50 g, 2.24 mmol), MEHQ (0.03 g, 0.22 mmol) and ethyl 
cyanoacrylate 37 (0.31 g, 2.46 mmol) were combined in toluene (5.00 mL) and 
heated to reflux for 3 days. The reaction was concentrated in vacuo to give crude 
product 127j (0.96 g) as a yellow solid. This was purified by column 
chromatography (6:1 petrol/ EtOAc) to yield the title compound 127j (0.07 g, 0.20 
mmol, 9%) as a white solid. Rf (6:1 petrol/ EtOAc) 0.31; m.p. 192-194 
o
C; vmax/cm
-1
 
2347 (CN), 1748 (C=O), 1544 (C-NO2); δH (400 MHz, CDCl3) 7.58 (1H, d, J 6.0, 
Ar-H), 7.40 – 7.32 (2H, m, Ar-H), 7.32 – 7.23 (5H, m, Ar-H), 4.93 (1H, s, ArC-CH-
CCN), 4.31 – 4.00 (2H, m, OCH2-CH3), 3.40 (1H, d, J 13.0, C(NO2)-CH2-CCN), 
2.79 (1H, d, J 13.0, C(NO2)-CH2-CCN), 1.27 (3H, t, J 7.0, OCH2-CH3); δC (100 
MHz, CDCl3) 165.4 (C=O), 137.8, 137.2, 135.4, 134.6 (4 x ArC), 128.5, 128.4, 
128.4, 128.2, 126.1, 125.2, 121.1, 120.7 (8 x Ar-CH), 118.3 (CN), 91.8 (C-NO2), 
63.9 (OCH2CH3), 51.6 (ArC-CH-CCN), 47.6 (CH-C-CN), 40.6 (C(NO2)-CH2-CCN), 
14.0 (OCH2CH3); m/z (ES
+
) 371.1 [M+Na]
+
, 371.1013 [M+Na]
+
 (C20H16N2NaO4 
requires 371.1008). 
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Ethyl 9,10-dimethyl -9,10-endoanthracene-11-cyano-11-carboxylate (127k) 
 
9,10-Dimethylanthracene 46k (0.40 g, 1.94 mmol) was combined with ethyl 
cyanoacrylate 37 (0.27 g, 2.13 mmol) and MEHQ (0.02 g, 0.19 mmol) in toluene 
(4.00 mL) and heated to reflux for 8 h. The reaction was removed from the heat and 
concentrated in vacuo to give the crude product 127k (0.62 g) as an orange solid. 
This was purified by flash column chromatography to yield the title compound 127k 
as a pale yellow solid (0.56 g, 1.69 mmol, 87%). Rf 9:1 petrol/ EtOAc 0.20; m.p. 
127-128 
o
C; vmax/cm
-1
 2974 (CH), 2256 (CN), 1720 (C=O); δH (400 MHz, CDCl3) 
7.49 – 7.42 (1H, m, Ar-H), 7.38 – 7.29 (2H, m, Ar-H), 7.27 – 7.14 (5H, m, Ar-H), 
4.17 – 4.01 (2H, m, OCH2CH3), 2.42 (1H, d, J 13.0, C(CH3)CH2C(CN)), 2.21 (1H, 
d, J 13.0, C(CH3)CH2CCN), 2.15 (3H, s, C(CH3)), 1.99 (3H, s, C(CH3)), 1.17 (3 H, t, 
J 7.0, OCH2CH3); δC (100 MHz, CDCl3) 167.5 (C=O), 145.3, 145.1, 141.6, 139.9 
(ArC), 127.1, 126.8, 126.3, 125.9, 122.8, 122.8, 120.9, 120.5 (8 x ArCH), 119.8 
(CN), 62.8 (OCH2CH3), 53.5 (C(CH3)CCN), 48.9 (C(CH3)), 48.1 (C(CH3)CH2CCN), 
41.2 (C(CH3)), 17.5, 14.9 (2 x C(CH3)), 14.0 (OCH2CH3); m/z (ES+) 354.1 
[M+Na]
+
, found 354.1465 [M+Na]
+
 (C22H21NNaO2 requires 354.1470). 
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Ethyl 9,10-dibromo-9,10-endoanthracene-11-cyano-11-carboxylate (127l) 
 
9,10-Dibromoanthracene 46l (0.50 g, 1.49 mmol) was combined with ethyl 
cyanoacrylate 37 (0.21 g, 1.64 mmol) and MEHQ (0.02g, 0.15 mmol) in toluene 
(5.00 mL) and heated to reflux. After 4 days no further reaction was observed, the 
reaction was removed from the heat and concentrated in vacuo to yield crude product 
127l (0.96 g) as a yellow solid. This was purified by flash column chromatography 
(4:1 petrol/ EtOAc) to give the title compound 127l (0.11 g, 0.24 mmol, 16%) as a 
yellow solid. Rf (4:1 petrol/ EtOAc) 0.45; m.p. 149 - 151 
o
C; vmax/cm
-1 
2176 (CN), 
1737 (C=O), 763 (C-Br); δH (400 MHz, CDCl3) 7.93 – 7.87 (1H, m, Ar-CH), 7.83 – 
7.70 (3H, m, Ar-CH), 7.40 – 7.36 (2H, m, Ar-CH), 7.36 – 7.28 (2H, m, Ar-CH), 4.17 
(2H, qq, J 10.5, 7.0, OCH2CH3), 3.05 (2H, s, BrC-CH2-CCN), 1.22 (3H, t, J 7.0, 
OCH2CH3); δC (100 MHz, CDCl3) 165.5 (C=O), 140.3, 139.8, 137.3, 135.5 (ArC), 
128.9, 128.5, 128.3, 127.8, 126.5, 126.0, 124.4, 123.7 (ArCH), 117.9 (CN), 63.7 
(OCH2CH3), 62.4 (CCN), 58.1 (CBr-CCN), 53.0 (CBr-CH2), 52.7 (BrC-CH2-CCN), 
13.9 (OCH2CH3); m/z (ES+) 481.9 [M+Na]
+
, found 481.9362 [M+Na]
+
 
(C20H15Br2NNaO2 requires  481.9367). 
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2-Fluoro ethyl 9,10-dihydro-9,10-endoanthracene-11-cyano-11-carboxylate 
(127m) 
 
2-Fluoroanthracene 46m (0.10 g, 0.51 mmol), MEHQ (0.01g, 0.05 mmol) and ethyl 
cyanoacrylate (0.07 g, 0.56 mmol) were combined in toluene (1.00 mL) and heated 
to reflux for 2 days. The reaction was concentrated in vacuo to yield crude product 
127m (0.20 g) as orange oil. This was purified by flash column chromatography (4:1 
petrol/ EtOAc) to give the title compound 127m (0.11 g, 0.35 mmol, 68%) as a 
colourless oil (an inseparable mixture of four compounds in a 1:2:2:2 ratio (exo and 
endo product for each regioisomer)). Rf (4:1 petrol/ EtOAc) 0.39; vmax/cm
-1
 2985 
(CH), 2242 (CN), 1745 (C=O); δH (400 MHz, CDCl3) 7.51 – 7.41 (1H, m, Ar-H), 
7.35 – 7.01 (5H, m, Ar-H), 6.96 – 6.73 (1H, m, Ar-H), 4.87 – 4.84 (1H, m, ArC-CH-
CCN), 4.44 – 4.38 (1H, m, ArC-CH-CH2), 4.23 – 4.08 (2H, m, OCH2-CH3), 2.84 – 
2.75 (1H, m, CH-CH2-CCN), 2.24 – 2.15 (1H, m, CH-CH2-CCN), 1.31 – 1.23 (3H, 
m, OCH2-CH3); δC (100 MHz, CDCl3) 163.2 (C=O), 160.8 (C-F), 144.6, 141.6, 
137.0, 132.9 (4 x ArC), 127.7, 126.9, 126.6, 125.8, 125.0, 124.0, 123.7 (7 x Ar-CH), 
119.6 (CN), 63.3 (OCH2-CH3), 51.1 (ArC-CH-CCN), 43.3 (ArC-CH-CH2), 37.7 
(CH-CH2-CCN), 14.1 (OCH2-CH3); δF (376 MHz, CDCl3) -114.5, -114.8, -116.1, -
116.4 (ArC-F); m/z (ES
+
) 344.1 [M+Na]
+
, found: 344.1059 [M+Na]
+
 
(C20H16FNNaO2 requires 344.1063).  
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9,10-Dihydro-9,10-ethanoanthracene-11,12-dicarboxylic acid anhydride (48a)  
 
Anthracene 46a (0.50 g, 2.81 mmol) and maleic anhydride 47 (1.10g, 8.43 mmol) 
were combined in xylene (10.0 mL) and heated to reflux for 24 h. The reaction was 
removed from the heat, benzene added to precipitate out the product 48a, the 
solution was filtered to give the title compound 48a (0.61 g, 2.19 mmol, 78%) as an 
off-white solid. Rf (14:1 petrol/ EtOAc) 0.47; m.p. 266-267 
o
C; lit
262
 m.p. 256 - 257 
o
C; vmax/cm
-1
 2972 (C-H), 1781 (C=O); δH (400 MHz, CDCl3) 7.43 – 7.29 (4H, m, 
Ar-H), 7.23 – 7.16 (4H, m, Ar-H), (2H, t, J 1.5, ArC-CH-CH), 3.52 (2H, t, J 1.5, 
CH-CH-CO); δC (100 MHz, CDCl3) 170.5 (C=O), 140.6, 138.1 (Ar-C), 127.8, 127.2, 
125.2, 124.4 (ArC-H), 48.0 (ArC-CH), 45.4 (CH-CO); m/z (ES
+
) 299.1 [M+Na]
+
, 
found: 299.0679 [M+Na]
+
 (C18H12NaO3 requires 299.0684). 
 
9,10-Dihydro-11,11,12,12-tetracyano-9,10-ethanoanthracene (160a) 
 
Anthracene 46a (25.0 mg, 0.14 mmol) and 1,1,2,2-tetracyanoethylene 159 (54.0 mg, 
0.42 mmol) were combined in xylene (0.60 mL) and stirred at r.t. for 4 h. The 
solution was filtered to give the title compound 160a (30.0 mg, 0.10 mmol, 70%) as 
a pale yellow solid. Rf (14:1 petrol/EtOAc) 0.53; m.p. 198-200 
o
C; vmax/cm
-1
 2952 
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(CH), 2231 (CN); δH (400 MHz, CDCl3) 7.63 - 7.55 (4H, m, Ar-H), 7.51 – 7.43 (4H, 
m, Ar-H), 5.08 (2H, s, CH-CCN); δC (100 MHz, CDCl3) 134.2, 131.9 (ArC), 130.0, 
126.8 (ArC-H), 110.7 (CN), 53.1 (CH-CCN), 45.2 (CCN); m/z (ES
+
) 329.1 
[M+Na]
+
, found: 329.0798 [M+Na]
+
 (C20H10N4Na requires 329.0803). 
 
9,10-Dimethyl-11,11,12,12-tetracyano-9,10-ethanoanthracene (160k) 
 
9,10-Dimethylanthracene 46k (20.0 mg, 0.06 mmol) and 1,1,2,2-tetracyanoethylene 
159 (23.0 mg, 0.18 mmol) were combined in xylene (0.30 mL) and stirred at r.t. for 
4 h. The solution was filtered to give the title compound 160k (15.0 mg, 0.05 mmol, 
75%) as a pale yellow solid. Rf (14:1 petrol/ EtOAc) 0.56; m.p. 207-208 
o
C vmax/cm
-1
 
2979 (CH), 2260 (CN); δH (400 MHz, CDCl3) 7.61 – 7.53 (4H, m, Ar-H), 7.52 – 
7.44 (4H, mm Ar-H), 2.45 (6H, s, 2 x CH3); δC (100 MHz, CDCl3) 136.9, 135.8 
(ArC), 129.1, 124.6 (ArC-H), 110.8 (CN), 53.4 (C-CN), 50.6 (ArC-C-CH3), 15.6 
(CH3); m/z (ES
+
) 357.1 [M+Na]
+
, found: 357.1111 [M+Na]
+
 (C22H14N4Na requires 
357.1116). 
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5.4.3 
1
H NMR monitoring experiments 
 
General method for Diels-Alder reaction between substituted anthracene and 
ethyl cyanoacrylate 
 
Anthracene 46a-m (25.0 mg, 1.0 eq.) and ethyl cyanoacrylate 37 (1.1 eq.) were 
combined in d8-toluene (0.25 M) with anisole (0.5 eq. 
1
H NMR standard). The 
reaction was heated in a young’s tap NMR Tube for 7 h at 70 oC. For anthracenes 
that are insoluble in toluene at r.t., the anthracene was pre-warmed in toluene 70 
o
C 
until fully dissolved before ethyl cyanoacrylate 37 was added.   
 
General method for retro-Diels-Alder reaction of substituted anthracene adduct 
with maleic anhydride 
 
Anthracene adduct 127a-m (25.0 mg, 1.0 eq.), maleic anhydride 47 (3.0 eq.), 
hydroquinone (0.5 eq.) and phosphrous pentoxide (0.5 eq.) were combined in xylene 
(0.25 M) with 1-methyl naphthalene (0.5 eq. 
1
H NMR standard). The reaction was 
refluxed for 8 h and then concentrated in vacuo to remove the xylene. 
 
General method for retro-Diels-Alder reaction of substituted anthracene adduct 
with 1,1,2,2-tetracyanoethylene 
 
Anthracene adduct 127a,k (25.0 mg) 1,1,2,2-tetracyanoethylene 159 (3.0 eq.), 
hydroquinone (0.5 eq.) and phosphrous pentoxide (0.5 eq.) were combined in xylene 
(0.25 M) with 1-methyl naphthalene (0.5 eq. 
1
H NMR standard). The reaction was 
refluxed for 8 h and then concentrated in vacuo to remove the xylene.
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Appendix 
A.1 Partition Coefficient Pow 
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A.2 Formaldehyde Assay 
 
 
Standards prepared at 25, 50, 75, 100, 125, 150 µg/mL levels of formaldehyde. The 
standards were prepared using pure para formaldehyde, decomposed in a sealed tube 
under heating (70-75 
o
C) in distilled water. Reaction with pentane-2,4-dione and 
ammonium acetate produced the highly coloured intermediate 3,5-diacetyl-1,4-
dihydrolutidine, maximum absorption 412 nm.   
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